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THESIS ABSTRACT  
 
Blood pressure (BP) is one of the most extensively researched topics. It is well 
established that elevated BP is the most prevalent treatable risk factor for 
cardiovascular disease. Despite our comprehensive knowledge of the importance of 
reducing mean levels of BP, we are less informed about the benefits of reducing 
other parameters of BP, specifically BP variability (BPV), which refers to the amount 
of variation over a period of time. Recent evidence has suggested that BPV may be 
an additional clinical target to mean level. However, its full prognostic significance 
and definition remains in doubt. BP does not remain stationary throughout the day 
but is constantly fluctuating and follows a circadian rhythm. Short-term BPV refers 
to fluctuations over this circadian rhythm. Ambulatory blood pressure monitoring 
(ABPM), which can be used to obtain estimates of BP usually every 30mins over a 
24h period, offers a powerful tool in the analysis of circadian patterns and short-
term BPV. Longitudinal circadian data with such a cyclical structure consisting of 
multiple repeated readings provides an opportunity to analysse BP in many 
different ways and an overview of possible approaches is outlined in this thesis. The 
main aims of this thesis were to explore and identify circadian BP patterns between 
individuals and groups, and extract meaningful measures that describe these 
patterns while appropriately accounting for the inherent cyclical structure of ABPM 
data. Specifically, the thesis includes a systematic review which identifies summary 
measures of BPV, such as standard deviation, that can easily be obtained from the 
observed data without the need for more advanced modelling. A meta-analysis 
exploring the correlation between short-term BPV and subclinical target organ 
damage (TOD), specifically left ventricular mass index, is included. The association 
between the identified summary measures and subclinical TOD is then explored in a 
group of middle aged adults. In an attempt to maximise the power of the repeated 
cyclical readings in ABPM and incorporate the data together in one model, different 
random-effects models were explored which allowed us to obtain estimates of both 
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within and between-individual variation of model parameters. A piece-wise linear 
mixed-effects model was considered as a simple but suitable approach to capture 
BP trajectory throughout the day. We attempt to relate factors such as the morning 
slope and within person variability (allowing this to be group-specific) to TOD 
(microalbuminuria). Finally, a two-component cosinor random-effects model is 
outlined where derivatives of the model fit presents a novel alternative method to 
locate and quantify the magnitude of slopes at critical points along the trajectory. 
This is used to obtain a measure of morning BP surge. We compare the random-
effects from this model to principle component scores obtained through functional 
principle component analysis. Our motivating data comes from the Mitchelstown 
Study, a population based study of Irish adults where a subsample underwent 24h 
ABPM. 
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1. INTRODUCTION  
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1.1 Introduction 
Hypertension  
Cardiovascular disease (CVD) is now endemic worldwide. It is the leading cause of 
death, not only in Ireland but globally, accounting for 17.3 million deaths per year 
(30% of global deaths), a number that is expected to grow to greater than 23.6 
million by 2030 [1]. Despite our comprehensive knowledge of prevention and 
treatment for hypertension, it is still the most prevalent treatable risk factor for 
CVD, affecting one billion people globally [2-4]. It has been estimated that 7.6 
million deaths worldwide, 54% of strokes, and 47% of cases of ischaemic heart 
disease can be attributed to high blood pressure (BP) alone [1]. The most recent 
estimates for the Republic of Ireland (ROI) conducted by the Institute of Public 
Health using data from the SLÁN 2007 study estimated that more than 850,000 
(25.1%) adults in ROI have hypertension with the figure set to rise to almost 
1,220,000 adults (28.3%) by 2020 [5]. 
In order to accurately ascertain a “normal BP” level it is not simply enough to 
arbitrarily take one BP measurement and based on this single reading conclude 
whether an individual is above or below the generally accepted value of 140/90 
mmHg. It is well known that BP does not remain stationary and is a haemodynamic 
variable that fluctuates from second to second making the diagnosis of 
hypertension challenging. In addition it has long been known that each individual 
has their own diurnal BP trajectory that varies over a 24h period, known as a 
circadian rhythm. Early evidence illustrated that BP tended to be higher during the 
day and much lower during the night [6]. This led to the term “dippers” being 
coined during the late 1980’s referring to individuals whose BP fell or dipped at 
night [7]. Modelling and extracting features of longitudinal data, specifically BP data 
that is circadian in nature offers a unique challenge for researchers.  
Awareness, treatment and control levels are problematic worldwide [4]. In Ireland, 
The Irish Longitudinal Study on Ageing (TILDA) reported that among those over 50 
with hypertension, only 55% were aware of their hypertension status [8]. In 
addition, only 59% of those were on treatment, of whom only 52% were controlled 
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to suitable levels. Furthermore, there is on-going controversy that what we have 
always considered a normal hypertension cut-off (above 140/90mmHg) may still be 
too high. Results from the internationally acclaimed Systolic Blood Pressure 
Intervention Trial (SPRINT) suggest target levels of 120/70 mmHg are desirable [9]. 
SPRINT randomly assigned 9361 people without diabetes with systolic BP (SBP) 
above 130 mmHg and an increased cardiovascular risk to a target of less than 120 
mmHg (intensive treatment) or a target of less than 140 mmHg (standard 
treatment). After 3 years the trial was stopped early due to a significant difference 
between treatment arms. Those assigned to the intensive group had a 25% lower 
relative risk of major cardiovascular events and 27% lower relative risk of all-cause 
mortality. Potential weaknesses of the study have been highlighted [10, 11]. 
Cushman et al. pointed out that BPs were measured with patients seated in a quiet 
room with an automated device without any observer present and argue this 
method can present BP values up to 20 mmHg lower than clinic readings [10]. The 
SPRINT trial is not alone in suggesting the threshold should be lower however and a 
recent meta-analysis examining the effect of intensive BP reduction found a 14% 
reduction in major cardiovascular events and 13% reduction in myocardial 
infraction when BP was reduced to 133/76 mmHg compared to standard treatment 
(140/90 mmHg) [12].  
Measurement 
Accurately measuring something that is fluctuating so frequently can be 
problematic. However, advancements in technology and wearable devices make 
the task of obtaining accurate BP readings throughout a 24h period much more 
achievable [13]. Ambulatory blood pressure monitoring (ABPM) is recognised as the 
gold standard of BP measurement [13] and involves wearing a small digital BP 
device that is attached to a belt around your body and which is connected to a cuff 
strapped around your upper arm. The devices are usually set to record BP values 
over a 24h period every 30mins, but can be set to 15mins or 20min [13]. After the 
device has been worn it can be removed and connected to a computer where the 
data are extracted, giving a print out of the average BP values and a visual 
representation of the circadian pattern. ABPM offers a unique insight into an 
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individual’s underlying circadian rhythm and has many advantages over a single 
clinic reading; measurements can be obtained as individuals go about their daily 
lives giving a more accurate measure of their real BP values, it allows the detection 
of white-coat and masked hypertension, but also offers estimates of the night BP 
and dip parameters. Detecting white-coat is important as it may prevent the 
unnecessary commencement of antihypertensive medication. We now know that 
the dip at night is associated with more favourable outcomes, and mean night BP is 
established as a stronger predictor of outcomes than mean day values [14-16]. For 
example, in the Dublin Outcome Study, for each 10-mmHg increase in mean night 
SBP, the mortality risk increased 21% while adjusting for clinic BP [14]. 
In primary care according to NICE guidelines [17], ABPM is offered if the clinic BP 
(average of two single readings) is above 140/90 mmHg. Hypertension diagnosis is 
then based on thresholds that vary slightly based on average day/night values [13, 
18]. Recently there have been strong calls advocating for the mandatory use of 
ABPM and even suggesting that failure to provide it amounts to medical ineptitude 
[13, 19, 20]. In Ireland the recent national cardiovascular health policy 
recommended general practises (GP) be encouraged to invest in BP technology 
(ABPM) that will improve BP management [21]. As a result the Health Service 
Executive (HSE) has acknowledged the importance of ABPM having recently 
approved the reimbursement of ABPM in primary care for those with a medical 
card [22]. Kario argues that in order to obtain perfect 24h BP control it is not 
enough to focus on the reduction of mean 24h BP, we must also reduce 
exaggerated blood pressure variability (BPV) and obtain an undisrupted or smooth 
circadian pattern [23]. Thus, one of the potential benefits of ABPM is that it offers 
us an opportunity to obtain measures beyond average day/night/24h BP values. 
More specifically, it allows us to quantify and explore the additional prognostic 
significance of variability in BP.  
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Blood Pressure Variability (BPV) 
It is important to note there are primarily two types of BPV- long-term variability 
which refers to variation in readings often taken over months or years and short-
term variability which refers to variation in readings taken over minutes or hours. 
There has been a recent surge in interest in the prognostic value of long-term BPV 
since the publication of work by Rothwell et al. [24, 25].  In treated hypertensive 
patients enrolled in ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial–
Blood Pressure Lowering Arm), higher visit-to-visit variability in SBP was associated 
with stroke and coronary events. Rothwell also found that SBP variation between 
visits was a strong predictor of stroke and coronary events, independent of mean 
clinic BP. To synthesize findings from subsequent studies, Tai et al. recently 
conducted a meta-analysis of 13 studies to evaluate the prognostic value of visit-to-
visit SBP variability by different parameters in 77,299 patients [26]. They found a 
pooled age and mean SBP-adjusted hazard ratio (HR) for all-cause mortality of 1.03 
(95% CI, 1.02-1.04; p<0.001) per 1-mmHg increase in SBP standard deviation (SD) 
and 1.04 (1.02-1.06, p<.001) per one precent increase in SBP coefficient of variation 
(CV), with the corresponding values for cardiovascular mortality being 1.10 (1.02-
1.17, p<.001) and 1.01 (0.99-1.03, p=.32), respectively. In addition, a 1-mm Hg 
increase in SD was significantly associated with an increased stroke risk, with an HR 
of 1.02 (1.01-1.03, P<.001).  
The prognostic value of short-term BPV obtained from ABPM has also been 
examined, but with inconsistent results. Parati et al. were the first to demonstrate 
high BPV was associated with an increased risk of target organ damage (TOD) 
specifically left ventricular hypertrophy (LVH) [27]. There have been a number of 
other studies also reporting associations between short-term BPV and both TOD 
[28-31] and cardiovascular events [25, 32]. However, other studies have shown no 
or only weak associations after adjustment for the mean BP [32-35]. The majority of 
these studies however, have used SD as a measure of BPV. The appropriateness of 
such an index has been disputed because it only reflects the dispersion of 
measurements around a single value (mean) and does not account for the order in 
which BP measurements were obtained and the longitudinal variation in the 
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circadian data [36, 37]. Alternatively, studies have explored other indices of 
variability including:  
 coefficient of variation which attempts to adjust for the tendency of those 
with a higher average BP to also have a higher SD [25, 38, 39]; 
 average real variability (ARV) which is the average absolute difference 
between successive readings, and is thought to give a true reflection of real 
variability [28, 33, 36] and; 
  a weighted 24h SD (wSD) which attempts to remove the influence of the 
day-night BP difference from the estimate of BPV [28, 30, 33, 40].   
Mule et al. demonstrated an association between BPV using ARV, SD and 
microalbuminuria among a group of 328 hypertensives after adjustment including 
mean BP [41]. In a separate study, Mule et al. found that ARV SBP was associated 
with microalbuminuria in 315 untreated essential hypertensives after adjustment 
for covariates including mean SBP [42]. However wSD, and SD of day and night 
periods were not found to be independently associated with microalbuminuria. 
Moreover, there has also been extensive work examining variability during the 
morning period alone where BP rises rapidly to its peak, known as morning surge, 
before falling again throughout the day [23].  There is substantial evidence 
indicating that the morning is the most important period and is when 
cardiovascular events most frequently occur [23, 43, 44]. It has been shown that 
the morning surge (calculated as mean SBP during the 2 hours after awakening 
minus mean SBP during the hour that included the lowest sleep BP) is 
independently related to organ damage and risk of cardiovascular events [45-47]. 
Different indices of short-term BPV and various morning surge parameters can be 
seen in Table 1-1. The short-term summary measures are outlined in more detail in 
Chapter 3.  
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Table 1-1 Short-term BPV Summary Indices 
Measure of BPV Description 
24h SD Standard deviation over 24 hour period  
Day SD Standard deviation over day period usually 9am-9pm 
Night SD Standard deviation over night period usually 1am-6am 
wSD Weighted standard deviation (of day and night standard deviation) 
CV Coefficient of variation 
ARV Average real variability 
Morning Surge 
Parameters* [45] 
 
Sleep-trough surge 2h morning BP minus 1h lowest night BP 
Prewaking surge 2h morning BP minus 2h prewaking BP 
Rising surge BP on rising minus last ABPM in a supine position <30m before rising 
*Kario [45] 
Despite increased interest and research conducted on BPV we are still unclear as to 
what the best method or index is to quantify variability, and its clinical relevance. In 
addition, all the above studies have used direct summary measures of BPV. That is, 
measures that can be directly obtained from the raw data without the need for 
advanced statistical methods. This thesis aims to explore other possible novel 
measures that describe BPV. Considering the clinical importance of BP it is 
surprising to learn of so few studies that fully utilise the benefits of the longitudinal 
nature of ABPM. Lambert et al. [48] who explored the use of cubic splines to model 
the trajectory of ABPM emphasised the lack of research on the longitudinal analysis 
of 24h ABPM while Edwards et al. [49] who utilised orthonormal polynomials 
stressed there is no current “standard” method for analysing ABPM. These and 
other longitudinal models of ABPM variation are described in more detail in 
Chapter 2 (Longitudinal Data Analysis and Application to ABPM).  
Biological Plausibility of BPV  
Although the precise mechanisms responsible for BPV are not entirely understood 
[50], there are a number of acknowledged factors that influence variations in BP. 
Parati et al. [51, 52] argue it is primarily modulated by neural (increased central 
sympathetic drive and reduced arterial and cardiopulmonary reflexes), humoral 
(angiotensin II, insulin, bradykinin, nitric oxide) and vascular effects (elastic 
properties of arteries). The night-time dipping phenomenon that occurs during 
sleep is associated with a marked drop in sympathetic drive, while the morning 
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surge is associated with a remarkable sympatho-activation [53, 54]. In addition, 
behavioural influences such as sleep, physical activity and postural changes can 
induce significant changes to BP [52, 55]. Emotional or psychological stress can also 
sporadically increase BP values [50]. An emotional condition that is often seen in 
clinical practice is that of the “white-coat effect” [50]. This well-known 
phenomenon is characterised by a sharp increase in BP values during the course of 
a doctor’s visit which then disappears once the doctor leaves.  Even high altitude 
[56] and environmental (seasonal effects) [57] factors are known to have an effect 
on BP values.  
BPV and Antihypertensive Medication  
The interest in BPV and the importance of how it is quantified comes to the fore 
when we begin to examine therapeutic approaches to treat hypertension. In 2005, 
the ASCOT trial reported that antihypertensive medications (amlodipine and 
perindopril combination) significantly improved outcome compared to older dated 
alternatives [58]. However, of particular interest was that the difference in mean BP 
between treatments was only 1.6 mmHg at the end of the trial. This small 
difference suggested that the improvement in outcome between arms was unlikely 
to be as a result of reducing mean BP alone. In the subsequent years more analyses 
published from the study showed that the newer medication had significantly 
reduced central BP (pressure exerted on the heart and brain), night-time BP and 
BPV [25, 59, 60], suggesting we should not be solely focusing on mean BP. It 
highlighted the potential benefit of obtaining new indices of BP and the advantage 
of exploring ABPM data. There is growing evidence to suggest that although 
different antihypertensive classes have the same effect in terms of reducing mean 
BP, they have significantly different effects on BPV, particularly calcium channel 
blockers (CCB) or calcium antagonists [61, 62].  The X-CELLENT trial examined the 
efficacy of calcium antagonists in reducing BPV (measured as wSD and ARV) among 
577 patients before and after anti-hypertensive treatment [63].  Larger reductions 
were obtained with amlodipine (CCB) compared to indapamide (diuretic), 
candesartan (angiotensin receptor blocker (ARB)) and placebo where the 
differences even remained significant after adjustment for mean BP. Further 
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evidence was found in a large cohort of 2780 hypertensive patients, where those 
receiving either CCBs or diuretics, alone or in addition to other drugs had 
significantly lower 24h SBP SD compared with angiotensin-converting enzyme 
inhibitors (ACEIs), ARBs or β-blockers alone or in combination [64]. CCB-based 
combinations again performed better than other combinations in post hoc analysis 
of the COPE (Combination Therapy of Hypertension to Prevent Cardiovascular 
Events) trial in reducing visit-to-visit BPV (SD & CV) [65]. The cope trial was the first 
clinical trial to examine the treatment of hypertension with combination therapies. 
This raises the question of whether BPV could be an additional therapeutic target of 
antihypertensive treatment to improve cardiovascular protection. And highlights 
potential benefits of obtaining new BP measures which can provide new 
information and bring about greater insights into the mode of action of new 
antihypertensive medication [52, 66]. 
These variability indices may be particularly useful for the analysis of chronotherapy 
effects which refers to the treatment of an illness or disease by administering a 
drug at a time of day believed to be in harmony with the body’s natural rhythms. 
There are no current recommendations for when BP-lowering medications should 
be ingested but most people are instructed by their physicians and pharmacists to 
take the medication during the morning period. As explained previously, the 
morning period is a crucial time coinciding with a surge in BP and perhaps the 
administration of medication before this period may be more beneficial in reducing 
BP rather than during it. The MAPEC study was the first to examine the benefits of 
bedtime chronotherapy with one or more conventional hypertension medications 
on BP control and CVD risk reduction versus conventional morning therapy [67, 68]. 
They found subjects ingesting antihypertensive medication at bedtime showed 
significantly lower night BP, reduced prevalence of non-dipping and lower relative 
risk of both total CVD and major CVD events after a median follow-up of 5.6 years. 
In a similar study conducted among 448 hypertensive patients with type 2 diabetes, 
comparable results were found [69]. After a median follow up of 5.4 years patients 
with diabetes ingesting at least one hypertension medication at bedtime showed 
significantly lower night BP, higher prevalence of controlled ambulatory BP (ABP) 
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and a significantly lower cardiovascular risk than those taking medication upon 
awaking. Improved BP control was also shown in a separate study of 250 patients 
with resistant hypertension [70]. Indeed a systematic review [71] and a Cochrane 
review [72] have suggested that patients with evening dosing of antihypertensive 
drugs had better 24h BP control than those with a morning dosing regimen. 
Although the clinical significance of night-time administration needs to be explored 
further it does emphasize the need to be able to quantify the immediate effect of 
ingesting an antihypertensive drug so that we have the ability to compare different 
drug classes.  
 
Summary 
The primary focus of the management of hypertension to date has centred on 
lowering mean BP with little consideration for other factors, such as BPV, maximum 
BP reached, episodic hypertension or its circadian pattern. Hypertension guidelines 
have only focused on mean BP, which is clearly important, but fail to mention BPV 
[17]. As ABPM is more widely available and we begin to collect more and more 
data, it begs the question of whether we are maximising the rich data available. 
Recently published ABPM guidelines have highlighted that most ABPM studies have 
reported results derived from investigating mainly one unique ABPM characteristic, 
e.g., either a BP mean value, or a variability measure, or morning surge, without 
comparison or appropriate adjustment for the prognostic value of additional ABPM-
derived characteristics [73]. It is clear that the full potential available from ABPM 
measurements is not currently being explored. This thesis explores current 
approaches and suggests novel alternatives to capture circadian BP patterns. 
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1.2 Study Design – Motivating Dataset 
The motivating ABPM data for this thesis comes from a study examining the 
prevalence of major CVD risk factors in a middle-aged population in Ireland. The 
analysis utilises existing data obtained from the Mitchelstown Cohort Study, a 
population based study of middle-aged men and women, recruited in Ireland in 
2010-2011. A detailed description of the study design is available elsewhere [74] 
but a summary is provided here. 
The primary aim of the study was to provide a profile of cardiovascular health and 
their related factors in an Irish adult general population sample. The study 
comprised of 2047 adults aged 47-73 years (response rate: 67%) recruited from 
patients attending a single large primary care centre, the Livinghealth Clinic (LHC) in 
Mitchelstown, County Cork. The clinic is a GP developed independent advanced 
Primary Care Centre. The clinic serves a catchment area of 20,000 people, with a 
mix of urban and rural residents. At baseline, participants completed a detailed 
health and lifestyle questionnaire and were invited to attend the LHC for a physical 
examination to be carried out by a nurse trained in the study research protocols. 
Clinic measurements included height, weight, BP and in addition, fasting blood 
samples (minimum of 8-h fast) and urine samples were collected. Participants also 
underwent standard 12-lead electrocardiogram (ECG). ABPM was offered to all 
2047 participants, and it was completed by 1207 (response rate: 58%). All 
participants provided written informed consent and ethical approval was obtained 
from the Clinical Research Ethics Committee of the Cork Teaching Hospitals. 
 
BP measurement 
With the participant in a seated position, study BP was measured using an OMRON 
M7. Three readings of BP were obtained and the average of the second and third 
measurements was used. ABP was measured using dabl ABPM system (dabl ltd., 
Ireland) with the Meditech ABOM-05 Monitor (Meditech LTD., Hungary). The 
monitors were programmed to obtain readings every 30mins and remained in place 
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for 24h. Participants kept diaries of wake and sleep periods, which were used to 
calculate day and night BP respectively. If no diary was kept, the period from 1am 
to 6am was used as the night period and from 9am to 9pm as the day period.  
Subclinical Target Organ Damage (TOD) 
To explore the prognostic value of BPV and for purposes of illustration of some of 
the methods, subclinical TOD is used as a surrogate marker of cardiovascular events 
where the association between BPV and TOD is investigated.  Subclinical TOD, 
which is the development of asymptomatic functional and structural abnormalities 
in the human body, often precedes the occurrence of major cardiovascular events 
[75]. It usually refers to damage that occurs in major organs fed by the circulatory 
system e.g. heart, kidneys, brain and eyes. As they are subclinical, they are nearly or 
completely asymptomatic i.e. showing no signs or symptoms. Two examples of TOD 
are microalbuminuria (kidney) and LVH (heart). 
Microalbuminuria is the persistent elevation of albumin in the urine [76]. It occurs 
when the kidney leaks small amounts of albumin into the urine. Specifically, it 
signals increased permeability (capacity of a blood vessel wall to allow for the flow 
of small molecules or whole cells in and out of the vessel) of the endothelial cells 
and signifies that some level of injury is present and vascular responsiveness is 
comprised [76]. It is a marker of increased risk for cardiovascular morbidity and 
mortality especially, but not exclusively, in high risk populations such as diabetes 
and hypertensives [77].  Microalbuminuria is measured in spot morning urine 
obtained from the patient and sent for measurement of both albumin and 
creatinine. A meta-analysis in 2010 demonstrated increased risk of mortality with 
urine - albumin:creatinine ratio (ACR) ≥ 1.1 mg/mmol and as a result 
microalbuminuria was defined using this cut-point [78].   
LVH is enlargement and thickening (hypertrophy) of the walls of the heart’s main 
pumping chamber (left ventricle). LVH can develop in response to factors such as 
increased BP or a heart condition that causes the left ventricle to work harder. 
Complications of LVH include atrial fibrillation, diastolic heart failure, systolic heart 
failure, and sudden death [79]. Both earlier recognition and improved 
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understanding of cardiac hypertrophy may lead to more effective therapeutic 
strategies for this cardiovascular risk factor [79]. An electrocardiogram (ECG) is 
usually used to detect the presence of LVH. In this study, a 12-lead ECG was 
obtained in the standard manner using a Siemens – Eclipse 850i machine. ECGs 
were reviewed and coded for LVH voltage criteria by a cardiologist. The presence of 
LVH was defined by Cornell Product ECG voltage criteria i.e. SV3 + RaVL (+6 in 
women) X QRS duration ≥ 2440 mm x ms [80]. 
Reproducibility Sub-study (Follow-up Data) 
Based on the initial ABPM results the sample was divided into 4 groups: 
normotension, isolated nocturnal hypertension, isolated daytime hypertension and 
day-night hypertension [81]. Twenty participants were randomly selected from 
each group and invited to attend for follow-up ABPM measurements in 2014 using 
the Spacelabs 90217 monitor. Data was stored using the Spacelabs 92506 
Ambulatory BP Report Management System software. At four years follow-up a 
subsample of fifty (response rate: 63%) of these participants consented to 
participation in this study. The mean period of follow up was 3.9 years. 
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1.3 Aims and Objectives  
The aim of this thesis was to explore and identify circadian BP patterns between 
individuals and groups, and extract meaningful measures that describe these 
patterns. 
Specifically the objectives were:  
1. To conduct an extensive literature review to determine current summary 
measures that is used to quantify BPV and explore their association with the 
presence of TOD, specifically LVH. 
2. To determine the association between short-term BPV extracted from 24h 
ABPM and subclinical TOD in middle aged adults based on the measures 
found in (1). 
3. To implement models that adequately describe patterns of BP and which 
can provide novel measures of short-term BPV taking into account the full 
temporal and circadian nature ABPM.  
4. To outline an approach that can be used to comprehensively interrogate the 
reproducibility of ABPM readings taken at two different occasions 
incorporating some of the approaches outlined in (3). 
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1.4 Thesis Outline 
This thesis is comprised of four papers, Figure 1-1 illustrates each aim and objective 
and the corresponding chapter.  
This thesis focuses on extracting features of longitudinal data, specifically data that 
is circadian. Although the focus is BP, the methods covered could be easily applied 
to other physiological processes that follow this circadian cycle. Chapter 2 first 
outlines approaches suitable for modelling longitudinal data in general but then 
focuses on specific techniques that may be appropriate for BP. 
Chapter 3 is a systematic review that examines the prognostic significance of short-
term BPV on the presence of TOD, specifically LVH. The review identifies variability 
summary measures that are currently used to quantify BPV. A meta-analysis 
exploring the correlation between short-term BPV and left ventricular mass index 
(LVMI) is included.  
Chapter 4 explores the association between short-term BPV over 24h and 
subclinical TOD in middle aged adults using data from the Mitchelstown study. 
Chapter 5 illustrates a method of describing and quantifying circadian BP patterns 
using piecewise linear mixed-effects models while ensuring periodicity. 
Chapter 6 examines the traditional ABPM model (cosinor) using random-effects and 
illustrates how it can be extended and used as a method to determine morning BP 
surge. The model is compared to a functional principle component analysis.  
Chapter 7 explores approaches to determine the reproducibility of ABPM 
trajectories taken at two different occasions. 
Chapter 8 summarises the findings from the analysis, discussed the strengths and 
limitations of the thesis, and makes some suggestions for future research.  
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Figure 1-1 Overview of thesis including aims and objectives. 
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2. LONGITUDINAL DATA ANALYSIS & APPLICATION TO 
ABPM 
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2.1 Chapter Overview 
This chapter introduces hierarchical and specifically longitudinal data structures. 
This is followed by a detailed description of statistical techniques available that are 
suitable for the analysis of ABPM both in terms of accounting for the longitudinal 
nature of the data but also methods that are capable of capturing non-linear 
circadian BP curves. A graphical illustration of each technique is presented using the 
motivating dataset as an example. This is followed by a summary of its application 
in the literature, paying particular attention to the use of the technique to analyse 
BP data. Particular attention is drawn to the techniques used in this thesis; however 
alternative methods are described briefly. A comparison of the different 
approaches is given at the end the chapter. 
2.2 Overview of Longitudinal Data 
Many epidemiological studies have a natural hierarchical data structure associated 
with them where there are different levels of information. For example, data from a 
number of different hospitals would comprise of hospital level information but 
within each hospital (or cluster) we could have patient level information. The term 
hierarchical (or nested/multilevel) data is given to data with this structure. 
Longitudinal data (panel data or repeated measures) can be considered a special 
case of hierarchical data where a sample is followed up over time with information 
collected at several occasions or time points. This type of data can be considered as 
a two level cluster where there are repeated measurements (level 1 units) with a 
natural ordering nested within individuals (level 2 units). It is important to highlight 
the natural ordering of the measurements which are not exchangeable, unlike for 
example patients nested within hospitals. Recognising both the hierarchical 
structure of the data points and the natural ordering in time of the data points is 
critical. Measurements within clusters or subjects will tend to be more similar than 
measurements from different subjects. In addition, the ordering of time points 
means that within-subject readings close together may be more correlated than 
points further away. Both issues of correlation must be accounted for in the 
analysis and renders traditional regression analysis techniques, which assume 
34 
 
independence of observations for non-hierarchical data to be inappropriate. ABPM 
is a perfect example of such hierarchical data where there are many repeated BP 
readings on an individual taken over a 24h period with a natural order (in time) to 
the observations. An example of four individual ABPM readings from the 
Mitchelstown ABPM dataset is provided in Figure 2-1. 
 
Figure 2-1 Example of four individual ABPM readings  
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2.3 Statistical Approaches for Modelling Longitudinal Data 
Before the specific analysis of ABPM is introduced, a general description of 
statistical approaches for the modelling of longitudinal data is outlined.  
There have been substantial developments in statistical methodology for the 
analysis of longitudinal data over the last 40 years. One of the key drivers has been 
improvements in technology which means computationally complex problems can 
now be solved in a fraction of the time taken previously. This, coupled with 
increased widespread availability of software programs and packages which are 
becoming more and more accessible to users, means researchers have access to a 
variety of more rigorous approaches for the analysis of longitudinal data [82]. Two 
of the most widely used approaches are generalised estimating equations (GEE) 
models [83-85] and mixed-effects models [86, 87]. As both methods make an 
adjustment for the dependency of the observations within an individual, both are 
suitable for the analysis of longitudinal data. However, there are differences in how 
both methods adjust for this correlated data leading to different model 
assumptions. In addition, the two models can be implemented to answer different 
questions relating to longitudinal data.  
Generalised Estimating Equations  
GEE models (or marginal models) are often referred to as population-average 
models where the target of inference is the population [88]. The term marginal is 
used as the focus is on the mean response, which depends only on the covariates of 
interest and does not specify the joint distribution of the individual’s observations. 
An important point in the analysis of marginal models is that the mean response 
and the within-subject association are modelled separately. The latter is referred to 
as a nuisance characteristic that must be accounted for in the analysis so that 
correct inferences about the changes in the population mean response (primary 
goal) can be made [88, 89]. Separately modelling the mean response and the 
within-subject association has the important implication that the regression 
coefficients derived from GEE models have population-average interpretations, 
where they describe features of the mean response and how these relate to 
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covariates.  GEE uses a partial-likelihood approach to estimate the parameter of 
interest.  
A GEE model can be defined as the following three-part specification [88]: 
The marginal expectation of the response, E(Yij|Xij) = µij, depends on the covariates, 
Xij, through a known link function  
   (   )          
   (1) 
 
The variance of each Yij, given the covariates, depends on the mean  
                        (2) 
where v(µij) is a known “variance function” (known function of the mean, µij) and   
is a scale parameter that needs to be estimated when the response is continuous 
[88].  
The pairwise (or two-way) within-subject association among the vector of repeated 
responses, given the covariates, is assumed to be a function of the means, µij, and 
an additional set of within-subject association parameters, α. Given a model for the 
pairwise correlations, the corresponding covariance matrix can be constructed as 
the product of standard deviations and correlations 
      
   
          
   
  (3) 
where Ai, is a diagonal matrix with                       along the diagonal (and 
Ai
1/2 is a diagonal matrix with standard deviations, √        , along the diagonal), 
and Corr(Yi) is the correlation matrix (here a function of α). To distinguish it from 
the true underlying covariance among the Yi, Vi is known as a working matrix which 
acknowledges the uncertainty about the assumed model for the variances and 
within-subject associations. Unless they have been modelled correctly, our model 
for the covariance matrix may not be correct [88]. 
The GEE estimator of β for marginal models (or generalised linear models for 
longitudinal data) can be obtained by minimizing the following function (where N is 
the sample size): 
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It can be shown that if a minimum of the function given by equation (4) exists then, 
it must solve the following GEE: 
 
∑  
   
            
 
   
 (5) 
where Di =          is the derivative matrix containing the derivative of µij with 
respect to the components of β [88]. 
 
Mixed-Effects Regression Models 
While GEE models are focused on inference for the population, mixed-effects 
(subject-specific) models target inference at the individual level. The full-likelihood 
approach associated with mixed-effects models provides estimates of subject-
specific effects (e.g. subject-specific trajectories) that are useful for understanding 
between individual variability in the longitudinal response [82]. These are known as 
random-effects which are coefficients that are allowed to vary between individuals 
(clusters). The estimation of the random-effects determines the subject-specific 
curves and explains the correlation structure of the longitudinal data [90]. Mixed-
effects models allow us to estimate both the degree of variation within a person 
(within-subject variation) and in the population of individuals (between-subject 
variation) [82].  
The simple linear mixed-effects model [86-88], which is an extension of the simple 
linear regression model, can be written as: 
                            (6) 
where yij is the response value for the j
th measurement on the ith subject, at time tij, 
the β’s are the fixed effects coefficients associated with the population (average) 
intercept at β0 (equivalent to linear regression model) and the population slope (β1), 
b’s are the random-effects where b0i and b1i are the intercept and slope deviations 
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respectively for the ith subject, and eij represent the individual-level residuals from 
the model. A comparison between the traditional linear regression and the linear 
mixed-effects model is presented in Figure 2-2 where we have a response (y) 
plotted against time (t). In the fixed-effects linear regression plot all observations 
are considered independent. However, in reality the data may be clustered with 
repeat readings on different subjects, represented as colour coded dots in the 
mixed-effects plot. The black line represents the population average which is 
described by intercept β0 and slope β1 in the model. In addition, each individual 
obtains their own random-effects (b0i and b1i) which can be added to the 
population coefficients to obtain subject-specific curves (Figure 2-2).  
 
Figure 2-2 Illustration of simple linear regression model and simple linear mixed 
effects model where the data are clustered 
The individual level residuals are assumed to be independent and have mean zero 
and variance 2. It is assumed the random-effects have zero mean and follow a 
bivariate normal distribution with a variance-covariance matrix Σb: 
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where 2b0 and 
2
b1 represent the between-subject variation of the intercept and 
slope random-effects respectively. The magnitude and direction of the covariance 
term (b0b1) gives information about the interaction between the random slope and 
intercept. In Figure 2-2 subjects with a high intercept have a steeper slope, giving a 
positive correlation between b0i and b1i, resulting in a positive covariance. 
Accounting for this is an important aspect of longitudinal modelling. 
Although the model presented above is quite flexible some of the assumptions may 
be too restrictive when examining certain data structures. It can however, easily be 
extended to accommodate many situations. Like linear regression, the model can 
adequately make adjustment for confounding variables. The model assumes the 
response changes linearly over time but for many biological processes, the mean 
profile is a non-linear function of time [91]. One approach is to model the non-
linearity by including non-linear functions of time such as quadratic or cubic terms. 
It is important to note the model will remain linear in the random-effects. There are 
however, many other alternative approaches for modelling the mean (see section 
2.4).  
One of the defining properties of linear mixed-effects models is that it allows for 
the explicit analysis of between-subject and within-subject sources of variation i.e. 
the random-effects covariance structure can be explicitly defined [88]. This 
essentially involves defining two separate variance-covariance structures, one for 
the random-effects across subjects and one for the within-subject random errors 
[92]. This can be illustrated by rewriting the variance of b’s (random-effects) and eij 
(random errors) in matrix form: 
 
    (
  
  
)  (
  
   
) (8) 
where G is the variance-covariance matrix for the random-effects across subjects. 
This is equivalent to the variance-covariance matrix defined in equation (6).  The 
matrix Ri is the variance-covariance matrix for the within-subject random errors. 
The bi (random-effects) and ei (random errors) are assumed to be independent. As 
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assumed in the mixed-efffects model above, the Ri matrix is often simplified as 
2I, 
where I is the identity matrix, assuming within-subject random errors to be 
conditionally independent with homogeneous variance, that is, they are 
independent conditional on the bi random-effects which accounts for the 
intraindividual correlation [90, 92]. In order to get the total variance of yi, we first 
rewrite the simple linear mixed-effects model (equation (6)) in matrix form where 
the response is given as: 
                  (9) 
where Xi and Zi are design matrix of covariates. From this, the total variance (Vi) 
becomes: 
         
      (10) 
By constructing the design matrix Zi and specifying structures for G and Ri matrices, 
the variance of repeated measurements can be adequately specified in linear mixed 
models [92]. The subscript i on the Vi matrix indicates that the total variance-
covariance matrix depends on the subjects covariates. Under matrix notion the 
repeated measurements of the response Yi follows the following multivariate 
normal distribution: 
        
        (11) 
where β is a vector of the population parameters, with the first element 
representing the intercept. 
The structure of G is often left unspecified when more than one between-subjects 
random term is specified in a linear mixed-effects model. When there is no explicit 
structure assumed, it is referred to as an unstructured pattern. This has the 
advantage that no assumptions have to be made about the variances and 
covariances of the random-effects [88, 92].  
Regarding the Ri matrix, Fitzmaurice et al. argue that in their experience of 
longitudinal data, variances are rarely constant over time and emphasize the 
benefits of the absence of restrictions on the variances [88]. Ideally we would like 
to use a unstructured pattern for all models but the number of parameters that 
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have to be estimated grows rapidly with the number of measurement occasions. 
This can affect the computational stability; where a large number of covariance 
parameters need to be estimated, relative to the sample size (both subjects and 
repeat readings), estimation is likely to be unstable [88]. There are alternatives that 
try to simplify the problem such as the compound symmetry or exchangeable 
structure that specifies that observations on the same subject have homogeneous 
covariance and variance. Other structures can be specified for the Ri
 matrix such as 
Toeplitz or autoregressive residual structure where the correlation between 
observations on the same subject are not equal, but decrease towards zero with 
increasing lag.  We are not confined to these structures however. For example, the 
between-subject or within-subject variation could increase or decrease over time in 
which case the variance could be modelled as a function of time [93]. A similar 
situation could arise where we allow variation to vary depending on a grouping 
variable [94]. Selecting the appropriate structure involves finding a compromise 
between over fitting and under-fitting the model which results in a parsimonious 
model. Liu suggests the structure can be selected according to theory or empirically 
[92] while Zuur et al. emphasizes that it is “important to model the correlation 
structure in a reasonable and meaningful way rather than to model the correlation 
structure perfectly” [93].  
The parameters from a mixed-effects model (fixed coefficients, variances, 
covariances) can be estimated by a number of methods. Maximum likelihood (ML) 
is the best known technique of obtaining estimates of unknown parameters. The 
maximum likelihood estimates (MLEs) of the parameters are the values of the 
parameters that maximise the likelihood function (i.e. the values of the parameters 
that make the observed values of the dependent variable most likely, given the 
distributional assumptions) [95]. For the case of the linear mixed-effect model, it 
can be shown by obtaining the likelihood of the multivariate normal probability 
density functions of the model that the log-likelihood function is defined as:  
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The natural log is introduced to simplify the mathematics as it converts the product 
of the individual density functions to a sum of log-density functions. In the case of 
linear regression (independent observations), maximising the likelihood function 
results in estimates that can be solved relatively easily as the equations have closed 
form solutions. In the case of linear mixed models, ML estimation can involve non-
linear equations for which there is no closed form solution for the parameters [93]. 
Instead, the ML estimates can be obtained using an iterative technique. There are a 
number of different algorithms that can be applied to obtain MLEs including 
iterative generalised least squares and iteratively re-weighted least squares which 
are discussed in detail elsewhere [94]. One drawback of the ML approach is that the 
estimates for the parameters of the covariance matrix are biased by a factor of (n-
2)/n. The reason for this is because it ignores the fact that the intercept and slope 
are estimated [93]. Restricted (or residual) maximum likelihood (REML) estimation 
was developed to address this problem based on a slight modification on the 
likelihood above where it is defined only in terms of the covariance matrix Vi, thus 
separating it from β (estimated parameter). It is recommended to use REML over 
ML when possible as it will provide less biased estimates, although it is less of an 
issue with significantly large sample sizes [88].  
The likelihood ratio tests (LRT) can be used for hypothesis testing. The LRT 
compares the maximised log-likelihood of two models, a full model with a nested 
model. A formal test is obtained by taking twice the difference in the maximised 
log-likelihood and comparing the statistic to a chi-squared distribution [88]. Despite 
the recommendation to use REML, in order to be able to compare models using LRT 
we first estimated the models using MLE to obtain ML solution. 
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Comparison of GEE and Mixed-Effects Analysis 
GEE models use partial-likelihood methods to estimate parameters of interest 
whereas mixed-effects models are based on full-likelihood methods. The 
advantages of partial-likelihood is that they are computationally easier than full-
likelihood methods and they do not require distributional assumptions for the 
observations as there is no specification of the joint distribution, only the mean 
response [82, 88]. One of the appealing properties of the GEE approach is that 
when the data is balanced and under the condition that the mean response is 
modelled correctly, it produces consistent and unbiased estimates of regression 
parameters and corresponding standard errors even when the covariance structure 
is misspecified [88, 96]. This robustness can be attributed to the use of the 
empirical or sandwich estimator [97, 98] which produces valid standard errors for 
the parameters of the model even when the assumed covariance among the 
repeated readings is not correct. However, Fitzmaurice et al. argue that correctly 
specifying the covariance structure makes optimal use of the available data for 
estimation of the parameters of interest [88]. One of the main drawbacks of the 
sandwich estimator is that it is best suited to balanced longitudinal designs where 
there are a large number of individuals with a small number of observations. In 
situations where the design is severely unbalanced, with each individual having a 
unique sequence of measurement occasions in addition to having few subjects, 
sandwich based standard errors can be biased downward and result in 
underestimation of the variance of the regression coefficient [88]. For linear models 
with balanced data, GEE coefficients and the fixed-effects coefficients from a 
mixed-effects model will yield the same values. However, they are not equivalent 
for non-linear models [88]. By comparing the GEE function in equation (4) and the 
mixed-effects function in equation (12) similarities between the two can be seen. 
The larger mixed-effects function is essentially the GEE function with an additional 
variance component. 
One of the key advantages of random-effects models over other techniques (e.g. 
GEE models, traditional analysis-of-variance approaches) is that they make full use 
of all available data from each individual and do not require balanced datasets. GEE 
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assumes that missing data are missing completely at random (MCAR). Full-
likelihood estimation random-effects rely on a weaker assumption that missing 
data are missing at random (MAR). Missing data are known to be completely at 
random (MCAR) when their absence is not related to both the observed and 
unobserved data [99]. MAR however refers to missing data that depends on 
observed data but not on unobserved data [99]. In the case of random-effects, 
missing data are ignorable if the missing responses can be explained either by 
covariates in the model or by the available responses from a given subject [82, 88]. 
A mixed-effect analysis does not require a balanced dataset because the covariance 
can be expressed as an explicit function of times of measurement (when times of 
measurement, or functions of time are included in Zi) [88]. In theory each individual 
can have their own unique sequence of time points. Additionally as highlighted 
previously, random-effects can allow the variance and covariance to be modelled as 
a function of time unlike other techniques which force the variance to be constant 
over time. Unbalanced data can however, have implications on specifying the 
autocorrelation residual structure when there are irregular gaps making it 
necessary to parameterise the autocorrelation function (ACF) explicitly [91]. For 
example, applying a continuous autoregressive error (CAR) structure is similar to 
applying a autoregressive structure but uses the actual value of measurement time 
which helps account for the issue of unbalanced data [94, 100].  
It is the ability to estimate both between and within-subject variation that makes 
the use of mixed-effects models so appealing for the analysis of ABPM in general, 
but also specifically to help answer the questions posed in this thesis where the 
focus is on obtaining population and subject-specific measures of BPV and 
quantifying this variation both between and within individuals. For this reason the 
use of mixed-effects models is preferred over the GEE approach in this thesis.  
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2.4 Statistical Approaches for Modelling Individual ABPM Profiles 
This section explores different approaches for modelling ABPM using random-
effects models from which variability measures can be obtained. Previous 
longitudinal modelling approaches to ABPM from the literature are discussed as 
well as suggesting other novel techniques. A comparison of the suggested 
techniques is also included at the end. 
Summary Measures of BPV 
The simplest form of random-effects is in essence subject-specific summary 
parameters, where the parameter is random. The idea is that multiple 
measurements on an individual are collapsed into one (sometimes more than one) 
summary measurement which is an estimate of a subject-specific measure. This can 
then be related to an outcome measure. The advantage of this method is that data 
with a longitudinal structure are converted to a cross-sectional problem where 
traditional regression techniques are valid without worrying about correlation 
between readings. This can lead to straightforward analysis and does not require 
statistical knowledge of multilevel modelling.  
With the focus of the thesis on patterns of BP, summary measures in this context 
relate to short-term summary measures of variability, as opposed to say mean BP 
values. As highlighted in Chapter 1, summary measures have been the focus of 
much of the literature to date in relation to short-term BPV. This simple approach 
can also be considered a simple two-stage model where the summary measures of 
variability such as SD over 24h, are obtained first (first-stage) and then these values 
are entered into a subsequent second model (second-stage), such as a logistic 
regression model, exploring its effect on an outcome such as TOD. The main 
disadvantage of this method is the loss of information as the statistical power 
associated with longitudinal data is removed by collapsing the data into one value. 
The other issue is that quantifying variability is difficult as highlighted in Chapter 1 
and attempting to do this with one measure makes the task significantly more 
challenging. Nevertheless, this does not mean that summary measures should be 
discarded. In fact many ABPM software programs routinely include estimates of 
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variability measures such as SD (dabl ABPM system, dabl LTD, Ireland) in their 
reports and are an important reference point. Because of the ease with which these 
can be obtained and included in an ABPM report, the exploration of suitable 
summary measures that capture variability deserves substantial attention prior to 
exploring more complex methods. For this reason Chapter 3 is a systematic review 
identifying summary variability measures while Chapter 4 applies these measures 
to our dataset and explores their association with TOD.  
 
Polynomials  
As is evident from Figure 2-1, like many biological processes, BP is not linear over 
time. Polynomial regression is a simple, but useful tool in the analysis of 
longitudinal medical data to cope with non-linear or curvilinear relationships [101]. 
The general principle of polynomial regression is to use increasing powers of time 
(t) as separate predictor variables to model the mean of the response variable of 
BP. For an individual, the model can be expressed as: 
                       
           
      (13) 
 
where BPij is the BP value for the j
th measurement on the ith person, at time tij, the 
β’s are the polynomial regression coefficients that comprise of the average fixed-
effect and the subject-specific random effect. The ej represents the individual-level 
residuals from the model.  
This model can be problematic however as the powers of t will be correlated, often 
quite highly so, which may not only lead to multicollinearity issues but also 
software convergence difficulties. Some of these issues can be overcome by 
centring the predictor variables, time in our case [102]. However, a better approach 
is to transform the powers into orthogonal polynomials, an equivalent set of 
predictor variables which are uncorrelated. These contain the same information, 
address the issue of collinearity while also helping to reduce the problem of 
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convergence. To illustrate the flexibility that can be obtained from polynomial 
analysis, raw data were plotted for four individuals along with the fitted values 
from a 6th order polynomial model, Figure 2-3. 
 
Figure 2-3 Raw data for four individuals along with predicted 6th order polynomial 
model 
Corrao et al. implemented a 3rd degree polynomial on ABPM and demonstrated 
that the prevalence of TOD (LVH or ischemia) was higher in hypertensives with 
absence or inversion in BP circadian rhythm compared with hypertensives with 
preserved BP circadian rhythm [103]. Zwinderman et al. found that a 4th order 
polynomial fitted ABPM data quite well and could obtain trough-peak values from 
the predicted curves which could be used to compare antihypertensive medication 
but the sample size was a major limitation (n=10) [104]. More recently, Edwards et 
al. utilised a linear mixed model with orthonormal polynomials across time in both 
the fixed and random-effects in a group of hypertensive subjects [49].  Edwards 
demonstrated that a 9th order polynomial was the best fit to the data. Although a 
9th order is unrealistic, Edwards correctly argues that using high order polynomials 
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is a valid method to smooth individual trajectories eliminating excess “noise” and 
providing researchers the ability to construct additional measures of 24h ABPM.  
Splines – Cubic and restricted cubic splines 
Another approach commonly used for modelling non-linear data involves the use of 
regression splines. Polynomials and regression splines are intrinsically related. 
Regression splines involve splitting a continuous covariate (usually time) into 
separate sections. Within each section a polynomial is fitted, and the fitted values 
from each section are then connected to form a smooth curve [93]. The points 
where these meet are known as knots. To ensure that there are smooth 
connections at these knots, certain conditions are imposed. In the instance when 
there are no knots, the function is a special case of regression splines and the 
function reverts to being a simple polynomial model. When a cubic polynomial is 
fitted within each interval it is known as a cubic regression spline with the 
constraint that it is has continuous first and second derivatives at each knot point. 
This is the most common type of spline but there is an array of splines now 
available in different software packages including B-splines, penalised splines, 
natural splines, thin-splines and smoothing splines, all of which have the capacity to 
produce well-fitting curves to non-linear data [105].  
In the context of ABPM, Selwyn et al. used a hierarchical model incorporating a 
cubic spline model with eight knots [106] to model mean BP profiles. Lambert et al. 
expanded on this by incorporating restricted cubic splines to model the mean BP 
profiles [48]. Restricted cubic splines are an extension of regression splines with a 
constraint that the tails are linear. An unrestricted regression spline will have four 
more parameters to estimate than that of a restricted spline with the same number 
of knots. Figure 2-4 illustrates a cubic and restricted cubic curve. The assumption of 
linear tails is suggested as often there are sparse data at tails and suggesting that a 
polynomial fits this data best can be dangerous or unrealistic.  
Both polynomials and cubic splines, by their nature, have the ability to produce 
well-fitting curves to the data. Increasing the degrees of freedom/knots that are 
added to these models inevitably increases the fit but can lead to over fitting of the 
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data. The main disadvantage of polynomials and splines is that the corresponding 
coefficients are challenging to interpret directly.  Moreover, interpretation becomes 
more difficult with increasing complexity in the model when the number of 
parameters increases. Also, when the current sample data is over fitted it can also 
lead to difficulty in extrapolating to other data. However, using these methods to 
obtain smoothed curves from which new ABPM measures can be extracted is one 
practical way of using them. Although this approach was not considered as a 
separate chapter in the thesis, this method was applied to the dataset using a 6th 
order polynomial (see Appendix A for details and results). Briefly, the maximum, 
minimum, number of minutes spent above certain hypertensive guidelines and 
variation about the curve (residual sums of squares) were calculated as measures of 
variability from the subject-specific fits from the polynomial random-effects model. 
The association between the extracted BPV measures and the presence of 
microalbuminuria was assessed using logistic regression with adjustment for age, 
sex, smoking status, BMI, diabetes and antihypertensive treatment. Additional 
models adjusted for mean BP. We found all measures were significantly related to 
microalbuminuria but the association did not persist after additional adjustment for 
mean BP. 
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Figure 2-4 Illustration of cubic and restricted splines 
 
Splines – Piecewise Linear Splines 
In addition to the previous approaches a method that allowed direct meaningful 
interpretation of regression coefficients was a requisite of this thesis. Piecewise 
linear splines in a mixed-effects model were explored as an alternative approach for 
modelling ABPM. This approach can be seen as a simplification of the principle idea 
of smooth regression splines where a BP pattern is broken into different segments 
of time over the 24h period. Rather than fitting polynomials between knot points 
however, linear splines (straight lines) are used to connect knots. These simple 
spline models are known as piecewise linear or “broken-stick” models. The benefit 
of this simple modification is that coefficients represent something meaningful, in 
this case the slope of BP at different periods of the day. Applying piecewise linear 
splines in a mixed-effects model allows us to obtain new measures of short-term 
BPV; the variation about an individual’s trajectory and also the variation in slopes 
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between individuals. This method also allows slopes at a group level to be easily 
compared. Although linear splines have been used extensively in growth models 
[107, 108] and even specifically to model BP change over years and gestational age 
[109], using them to explore daily patterns of BP represents a novel application for 
analysing ABPM data. 
A full analysis using piecewise linear splines on ABPM curves is presented in 
Chapter 5 but a brief illustration is given here. For each individual m linear splines 
can be created, where the kth spline: 
 sk (t) = 0 if t ≤ tki 
sk (t) = ti - tki if tk < t ≤ tki+1     for 
k=1,…,m 
  sk (t) = tki+1 - tki if t > tki+1 
(14) 
 
These can easily be incorporated into the linear mixed effects model outlined 
previously: 
 
               ∑           
 
   
      (15) 
 
Figure 2-5 illustrates an example of piecewise linear splines on individual ABPM 
curves. As Howe et al. explain there are a number of methods to determine the 
number and position of knot points [91]. One option is to place knot points at 
centiles of the distribution of the x-axis (time in this case), or implement a stepwise 
regression to select knots where there is statistical evidence of a difference 
between slopes either side of the knot point [110]. Obtaining a smooth curve for 
the data and extracting derivatives of this curve represents another approach to 
help inform the number and positions of knot points [111].  
Crucially Howe et al. argue that subject knowledge of the underlying physiological 
process being examined can help the choice of knot point positioning [91]. 
Considering the circadian nature of BP, this is especially relevant for the analysis of 
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ABPM where we try to incorporate prior known characteristics of BP, see Chapter 5. 
Alternatively, the data itself can help decide knot positions [91]. There is no perfect 
way to determine the number and position of knots but in order to keep the 
number of parameters that have to be estimated to a minimum it is important to 
try and have as few knots as possible.  Again, similar to picking the correct 
covariance structure, it is about achieving a compromise between over fitting and 
under-fitting the model which results in a parsimonious model.  
One issue with these methods is there is no constraint to force the model to be 
periodic. In Chapter 5, a constraint is introduced and presented for a piecewise 
linear model that ensures periodicity, so that on the average subject-specific BP is 
the same 24h later.  
 
Figure 2-5 Illustration of piecewise linear splines 
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Cosinor Analysis 
Cosinor analysis, which was first developed by Halberg [112, 113], has been the 
most common approach to modelling 24h BP [114-118]. The single-component 
cosinor uses a cosine function as a model for physiological processes that have a 
circadian rhythm:  
            (
   
 
   )       (16) 
 
where M is the MESOR (Midline Estimating Statistic Of Rhythm, the average value 
over the period), A is the amplitude (half the difference between the highest and 
lowest values, or the distance between the MESOR and the highest (lowest) value), 
τ is the period or duration of one cycle, ϕ is the acrophase (a measure of the time of 
the overall high values recurring in each cycle) and e is the error term. Incorporating 
a 24h period and rewriting the equation in a linear form gives: 
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where the amplitude and acrophase can be obtained:  
 
  √  
    
  (18) 
 
         (
  
  
) (19) 
 
A graphical representation of this model fitted to raw data for an individual can be 
seen in Figure 2-6. Cosinor can be incorporated into a mixed-effects model. 
However, the majority of the studies to date exploring the use of sinusoidal 
functions have used fixed-effects models where the inference is on population 
54 
 
effects [114-118]. For example, typical inferences are based on estimated 
differences in model parameters between particular groups of patients, such as 
comparing the estimated amplitude or MESOR between-groups (fixed-effects) of 
individuals on different antihypertensive agents [116]. The single component 
cosinor has a number of limitations. It has been suggested that this method 
imposes too many restrictions on the shape of the profile and has been shown to fit 
real profiles poorly [119]. Wang et al. [120] suggest problems with fitting a 
sinusoidal function to a circadian pattern include (i) that the pattern over 24h may 
not be symmetric; that is, the peak and nadir may not be separated by 12 hours 
and/or the amplitude and width of the peak may differ from those of the nadir, (ii) 
sometimes there are local minimum and maximum points. 
 
Figure 2-6 A simple cosinor fit to observed SBP readings of an individual 
(period=24h) 
 
Additionally Wang et al. [121] suggests that the sinusoidal function is too restrictive 
and “rhythms with a shape closely approximating a cosine curve are uncommon” 
[122]. The method has some advantages however; a BP curve can be described with 
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the use of only three parameters that have been shown to be related to clinical 
markers. Also, inherent in the model is the assumption of periodicity – that BP on 
the average is the same 24h later. Extension of the simple cosinor model to include 
multiple sin and cosine terms result in more flexible models and overcome many of 
the disadvantages stated above. Although not as common as the single-component 
cosinor model, attempts to extend the model by including multiple cosine terms 
(Fourier analysis) allow more flexible curves to be obtained which has previously 
been implemented on BP data [123-125]. This is illustrated in Figure 2-7 where a 
complex curve (red curve) can be broken up into a linear combination of sines and 
cosines (blue curves). The main advantage of this method is that many complex 
curves can be obtained by including more terms. However, similar to the single-
component model, the majority of studies to date exploring the use of multiple 
terms have only focused on fixed-effect models [123-125].  A key feature of ABPM 
analysis however is the exploration of subject-specific effects (random-effects) 
where its use in cosinor models has been limited [126]. The fitting of a multiple-
component cosinor random-effects model is outlined in detail in Chapter 6. We 
determine how the rate of change or “morning surge” changes over time by using 
first-order derivatives of the multiple-component cosinor model. To the best of our 
knowledge this is the first use of the cosinor model to determine a measure of 
morning surge. 
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Figure 2-7 Fourier series – a linear combination of sines and cosines can produce a 
complex curve [127].  
 
 
Functional Principle Component Analysis (FPCA) 
Another possible approach to help identify patterns in BP that builds on the idea of 
combining multiple curves outlined in the previous section is a method known as 
functional data analysis (FDA), specifically FPCA [128, 129]. FDA refers to an 
advanced methodology that consists of a set of techniques designed for the analysis 
and smoothing of curves or functions which makes it appealing for analysing 
repeated measures data [129, 130]. In addition one of the major advantages of FDA 
is it does not make any a priori assumption about the curves. Often FDA is applied 
to data with high sampling frequency such as accelerometers, which takes readings 
as regularly as every second of a day. The initial aim is to replace the original 
observations with curves or functions which are then used for further analysis 
[131]. This is achieved by smoothing the data using a set of building blocks ϕk, 
k=1,…,K called basis functions, which are combined linearly [129]. A function x(t) 
can be expressed as a base function expansion: 
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         (20) 
where c1, c2,…,ck are the coefficients of the expansion, the matrix expression in the 
last term uses c to stand for the vector K coefficients and ϕ to denote a vector of 
length K containing the basis functions. There are two main types of basis systems; 
Fourier series and splines. Spline bases are more flexible and complex than Fourier 
series [129]. There are many types of splines but B-splines are typically used. 
Although Fourier series are generally used for periodic data, splines are flexible 
enough to capture a periodic cycle as long as the order of the spline is large enough 
[129].  
To simplify, FPCA can be considered an extension of traditional principle 
component analysis (PCA) to the case of time series data. For example, rather than 
having separate variables measured on individuals and performing a PCA on these, 
as in the case of standard analysis, we instead have one variable (BP) measured 
multiple times for each individual which creates a time series or “function” over 
time. Each time-point can be essentially considered a variable similar to 
multivariate PCA. As in multivariate statistics, eigenvalues of the bivariate variance-
covariance function are indicators of the importance of the principle components 
and plotting them, known as a scree plot, can help illustrate how many are 
necessary to produce a reasonable summary of the data [129]. Rather than an 
eigenvector, in FPCA there is an eigenfunction associated with each eigenvalue.  
The resulting output is also similar to that of regular PCA with the only difference 
being the focus is on functional data where we can identify the main forms of 
variability in curves [130]. The eigenfunctions describe the major variational 
components. Similarly, FPCA allows for each feature to be expressed in terms of its 
percentage of explained variance. FPCA is the most flexible approach outlined as it 
tries to estimate the “optimal” functions that explain the variability in the data 
without pre-specifying a particular pattern. As opposed to saying the pattern 
follows a certain function e.g. cosine function, it is a data driven process where we 
do not pick the form of the functions. It can be shown that the random function x(t) 
is           ∑        
 
    , where       {    } and    ∫ {     
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    }         are uncorrelated random variables with mean zero and variance λk 
(eigenvalues) [132]. These random variables are the principle component scores or 
loadings. 
As mentioned, FDA has traditionally been implemented on high sampling frequency 
data (e.g. every second) but when there are fewer data points, several FDA 
methods become inefficient [133, 134]. In the case of sparse data, such as ABPM, 
Yao et al. developed a version of FPCA in which functional principle component 
(FPC) scores are framed as conditional expectations which is referred to as principal 
component analysis through conditional expectation (PACE) for longitudinal data 
[134]. In essence this approach is similar to a random-effects model where a mixed 
model framework is used to estimate curve-specific scores and variances. Unlike 
traditional FDA where curves are analysed and smoothed separately first, this 
method first ignores the hierarchical structure of the data and a smooth curve is 
fitted to the pooled data [133]. This estimate of the mean curve is then used to 
obtain the covariance matrix of the deviations from the mean for each pair of time-
points. This covariance matrix is smoothed using a bivariate smoother and the main 
diagonal is removed.  This smoothed covariance matrix is then decomposed 
(summarized) into a linear combination of orthogonal (uncorrelated) eigenfunctions 
and eigenvalues i.e. into its principal components and scores [133]. In the context 
of random-effects models these FPCs can be seen as patterns of within-subject 
variation remaining after the mean fit. The first FPC summarizes the main pattern of 
deviations from the mean trajectory. The second FPC which is uncorrelated to the 
first explains the next main pattern of variation from the mean and so on. 
Therefore, a linear combination of a few efficient functions can account for high 
proportion of the variance. The weights that define the optimal fit to each function 
are the principle component scores. These can be used to obtain individual BP 
curves by multiplying the weights by the functions. Zero scores for an individual 
would result in their trajectory following the mean pattern. The scores would 
usually be estimated through numerical integration but with sparse data, the 
approximation is sometimes deemed inadequate and in this case the scores are 
estimated by the PACE method [133, 134]. Using this method the scores are 
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estimated for each individual using their repeated measures while borrowing 
strength from the cohort with sample estimates of the mean function, covariance, 
eigenvalues and eigenfunctions [133, 134].  
Although similar, this is not the same as a traditional random-effects model. FPCA 
will be inherently more flexible. For example, if we consider a two-component 
cosinor random-effects model as outlined in the previous section – it would assume 
a mean and two cosine terms with two different periods, FPCA however will try to 
estimate the “optimal” functions that explain the variability in the dataset. 
However, if the mean, a one-period cosine and two-period cosine are close to 
optimal then the rest of FPCA and the model fitting will be similar: random-effects 
will be used to estimate the subject-specific coefficients for each of these functions. 
To account for missing data, smoothing (denoising) and interpolation of the ABPM 
data is incorporated in the FPCA instead of a pre-processing step. Missing data can 
be problematic for pre-defined smoothing. To elaborate the process, we first 
estimate the mean and principle component basis functions (common to all ABPM 
profiles) by using all the available data across subjects. Secondly, we estimate 
subject-specific curve loadings by using the data available for that curve, and we 
combine them with the mean and basis functions to estimate the curve over the full 
domain. The issue of missing and sparse data is accounted for in this approach. 
The implementation of FPCA on ABPM as described above is outlined in Chapter 6 
and is compared to the multiple-component cosinor model. The rationale is that by 
using B-spline basis functions it allowed the FPCA to detect the primary patterns in 
the data without exactly specifying a model. In comparing the resulting individual 
FPC scores with the cosinor parameters using the individual random-effects 
estimates it allowed us to determine the adequacy of our proposed simpler 
multiple-component cosinor model. If the FPC scores from the more flexible 
approach correlated well with the cosinor model it would suggest that the model 
was close to the “optimal” model determined by the FPCA and would provide 
support for the use of our model. In addition, the use of FPCA enabled us to 
determine the main patterns of variation in the data and the percentage of the 
total variation that each principle component contributed. This offers a novel 
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method to describe variation within BP that to our knowledge has not been used 
before on ABPM data. 
Other Possible Approaches  
On occasion, there have been other attempts to model ABPM using different 
approaches than those outlined in the previous sections. Degaute et al. attempted 
to quantify the overall 24h variation by building a best-fit curve based on 
periodogram calculations [135, 136]. The method is quite similar to a Fourier 
analysis approach but is optimized for unevenly time-sampled data where trough-
to-peak values can be obtained along with an acrophase parameter. Another 
method that has been purposed is the cumulative sums (cumsums) method [137]. 
This method draws a reference line across an individual’s pattern at their mean 
value, and successive deviations of the data from that line are then summed and 
plotted. It is argued changes in the cusums reveal changes in the trend of data from 
the baseline much more sensitively than do the data themselves [137]. It is argued 
that the values obtained are not restricted to follow a symmetrical pattern or fixed 
period of time e.g. sleep or awake times. The resulting parameters include the crest 
and trough of BP which are similar to the values that can be obtained using the 
amplitude in cosinor analysis. However, multiple-component cosinor is more 
flexible and offers more parameters that describe the curve. 
Another approach proposed to model ABPM trajectories was a method used in 
growth curve analysis literature. Beath introduced a method of data reduction to 
simplify comparisons between individual growth curves by describing a shape 
invariant model of infant weight [138]. Cole et al. extended this to create the SITAR 
model (SuperImposition by Translation and Rotation) [139, 140]. The idea is that 
there is an underlying mean curve which can be applied to all subjects and by 
applying just three subject-specific translations and rotations of the curve, 
individual trajectories can be obtained [140]. In the context of BP and mixed-
effects, the model is: 
 
         (
    
        
) (21) 
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where BPit is BP for subject i at time t, h(t) is a natural cubic spline curve of BP vs 
time, and αi, βi and γi are subject-specific random-effects. Essentially the three 
parameters shift the curve up or down (α), left or right (β), and stretch or squash 
the time-axis (γ) [91]. Although the model has primarily been developed for 
examining data over years (growth curves), it does not mean it is not suitable for 
examining non-linear circadian data. Cole et al. recently applied the model to 
growth curves of insulin-like growth factor 1 (IGF-1) [141]. Unlike height for 
example, IGF-1 follows a curvilinear shape that does not stop when it reaches a 
maximum and is similar in shape to a polynomial (during adolescent years). Despite 
the non-linear pattern of the data Cole et al. found that the model explained 65% of 
the variance in IGF-1 [141].  
A SITAR model was applied to our ABPM dataset. The model summarizes the set of 
BP curves with a mean BP curve as a cubic regression spline, plus the three fixed 
and random-effects (αi, βi and γi) defining how individual BP curves differ from the 
mean curve. Only these three parameters were random, with the spline terms 
fixed. The fitted models used regression splines with seven degrees of freedom. 
Figure 2-8 shows the raw ABPM data plotted against time along with the data re-
plotted after adjustment was made for the subject-specific parameters (αi, βi and 
γi).   
The plot indicates that although it is difficult to see a pattern in the raw data, after 
adjustment a somewhat clearer image can be seen. It suggests that adjusting for 
these three parameters can partially explain some of the variation in BP. These 
random-effects could then potentially be used as pseudo variability measures and 
applied in further models to explore their prognostic significance. One disadvantage 
of the method is that it is not periodic and additional work would need to be done 
to make it so. Furthermore the interpretation and clinical meaning of the three 
parameters that are obtained from the model are not instantly clear. However, if 
we compare the SITAR to the single-component cosinor model and their 
parameters, similarities can be seen between both models.  They both essentially 
have parameters that represent a mean and phase shift (left to right). The SITAR 
also has a stretching parameter which is not directly equivalent but is similar to the 
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period in the cosinor which is fixed. Although not immediately obvious, with a little 
manipulation, the exp(-γi) term could be considered similar to that of the amplitude 
parameter. The main difference between the models is that one uses a cubic spline 
(SITAR) and the other uses a cosine (cosinor) as a function of time. Although the 
parameters from the SITAR model may not seem that interpretable on first glance, 
they do have similarities to the cosinor parameters. However, implementing a 
cosinor analysis over a SITAR model seemed more appropriate for the analysis of BP 
data as the parameters are directly relevant and easier to understand with the 
advantage that the model is naturally periodic.  
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Figure 2-8 Illustration of the SITAR model for SBP over 24h. The black line indicates the mean BP curve.  
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Comparison of Potential ABPM Models 
A number of different approaches to capture circadian BP patterns have been 
outlined and choosing a model amongst them is challenging. The ultimate goal 
remains the development of a physiological model that captures known features of 
the pattern while not over-fitting the data so that we can obtain clinically relevant 
parameters [142]. It is widely acknowledged that achieving this is a difficult task and 
there is no perfect model that captures all the features of the circadian rhythm 
simultaneously [49, 142-144]. To help compare models, Table 2-1 considers the 
main features that are deemed important in deciding on a final ABPM model. It 
reiterates the point that no model is optimal on all of the suggested features and 
choosing one involves making a compromise based on what the researcher deems 
most important for their particular research question.  
We believed the two most important features that should influence our decision on 
model choice were flexibility and ease of parameter interpretability (which included 
clinical relevance). Flexibility referred to the ability of the model to capture the 
circadian pattern in the data. Although, as highlighted previously, summary 
measures such as SD are the crudest form of analysis, their ease of interpretation 
and widespread use (often included in standard ABPM reports) made their inclusion 
in the thesis mandatory (Chapter 3 and 4). By their nature polynomials and splines 
are flexible and can provide good fits to the data that can be particularly useful 
when exploring data. However, they have the problem that their resulting 
coefficients are not directly interpretable (excluding piecewise splines). For this 
reason they were not considered as a separate chapter in the thesis. Piecewise 
linear splines on the other hand are more interpretable and depending on the 
number of knots included can offer a flexible fit to the data. In addition, to the best 
of our knowledge the method has not been applied to ABPM data before thus 
offering novel measures of BPV (Chapter 5).  
Considering the traditional single-component cosinor model has been the most 
commonly used approach for the longitudinal analysis of ABPM, further research in 
an attempt to extend the model seemed warranted for inclusion in this thesis. The 
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single-component model has the advantage of parameters being easy to 
understand but the disadvantage that the shapes available are very restricted. 
Although a multiple-component model is not as interpretable as a single-
component model, it is still quite intuitive compared to spline models and their 
coefficients. The model also had the benefit of being periodic. For these reasons the 
exploration of a multiple-component cosinor model seemed reasonable (Chapter 
6). 
As outlined, FPCA is the most flexible approach and tries to estimate the “optimal” 
functions that explain the variability in the data without pre-specifying a particular 
pattern. Given a fixed number of functions, it will find the optimal fit. This was used 
in conjunction with the cosinor method to determine how well the model identified 
patterns in the data (Chapter 6).  
Periodogram which has rarely been used is almost identical to Fourier analysis and 
was not considered due to the similarity with the resulting output from a cosinor 
analysis. Similarly, the method of cumulative sums has rarely been used and was 
not considered in the thesis as the resulting output is too similar to that of cosinor 
amplitude values. The SITAR model has never been used on BP data but does have 
similarities to a single-component cosinor model. We felt that the cosinor method 
gave similar output but with easier interpretation and for this reason the SITAR was 
not considered in a full analysis.  
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Table 2-1 Comparison of different modeling approaches for the analysis of ABPM data. 
Modeling Technique  Flexibility Implemented on ABPM  Naturally 
Periodic 
Ease of Parameter 
Interpretability  
Summary Measures 1 Often No Excellent 
Polynomials 2 Sometimes No† Poor 
Splines     
     Cubic 3 Rarely No† Poor 
     Piecewise 2 Never* No† Excellent 
 Cosinor         
     Single-component 1 Sometimes Yes Excellent 
     Multiple-component 3 Rarely Yes Good 
FPCA 3 Never* No Not Implicitly known‡ 
SITAR  2 Never* No Poor 
Periodogram  2 Rarely Yes Good 
Cumulative Sums 2 Rarely No Good 
Flexibility rating: 1,2, 3, where 1 is the least flexible and 3 represents the most flexible; Implemented on ABPM scale: Never, rarely, sometimes, often; 
Interpretability scale: Poor, good, excellent 
*not to the best of our knowledge, †not directly but with manipulation they can be forced to be periodic, ‡Depending on the ease of interpretation of 
the FPCs – this won’t be known until the results are explored 
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3.1  Abstract 
Long term BPV has been associated with cardiovascular events but the prognostic 
significance of short-term BPV remains uncertain, including its influence on the 
presence of TOD, specifically LVH. A meta-analysis exploring the correlation 
between short-term BPV and LVMI was performed. Studies were identified by 
systematic searches in Pubmed and EMBASE. Any summary measure of short-term 
BPV obtained from ABPM was included. Twelve studies were included. SD, ARV, 
wSD and CV across 24h/day/night periods were identified as measures of 
variability. Meta-analysis showed the pooled subgroup correlation coefficients of 
LVMI with 24h SBP SD, day SBP SD, wSD SBP and 24h ARV SBP were 0.22 (95% CI: 
0.12-0.31 ), 0.19 (95% CI: 0.15-0.25), 0.23 (95% CI: 0.13-0.33), 0.37 (95% CI: 0.01-
0.65) respectively. This meta-analysis suggests there is a weak positive correlation, 
between BPV and LVMI. 
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3.2 Introduction 
Hypertension is a well-established risk factor for CVD [3, 145]. To date guidelines on 
the management of hypertension have focused on reducing mean BP, which is 
clearly important, but don’t mention BPV [17], for which there is increasing 
evidence of prognostic value. Evidence from meta-analyses suggest that although 
different antihypertensive-drug classes have similar effects in terms of reducing BP 
levels, pronounced differences in their ability to reduce BPV are observed [61, 62]. 
These differences additionally accounted for effects on stroke risk independent of 
mean BP. Studies have also shown that SBP variation from one visit to the next may 
be associated with a poor cardiovascular prognosis. In treated hypertensive 
patients enrolled in ASCOT-BPLA (Anglo-Scandinavian Cardiac Outcomes Trial–
Blood Pressure Lowering Arm), higher visit-to-visit variability in SBP was associated 
with stroke and coronary events independent of mean BP [25]. In a population 
based observational study higher visit-to-visit variability in SBP was associated with 
increased mortality risk over a 14-year follow-up [38]. Importantly visit-to-visit BPV 
predicted all-cause mortality among those with normal BP, suggesting it may be a 
prognostic marker before hypertension develops. 
Short-term BPV refers to fluctuations of BP across minutes or hours usually taken 
over a 24h period and can be obtained through the use of ABPM [146]. The 
predictive value of short-term BPV is less well established than that of visit-to-visit 
variability. Hansen et al. [33] using a large population cohort (8938 subjects) 
explored the relationship between BPV recorded at base line with cardiovascular 
events over a median period of 11.3 years and determined that although short-
term reading-to-reading BPV was an independent predictor, it did not contribute 
significantly to risk stratification over and beyond 24h BP. Evidence from the 
ASCOT-BPLA trial which included both long and short-term variability suggests that 
although not as strong a predictor as visit-to-visit BPV, short-term BPV measured by 
the CV still predicted risk of vascular events independently of average daytime 
mean SBP [25].  
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The occurrence of major cardiovascular events is usually the result of long-term 
exposure to hypertension and other risk factors and is often preceded by the 
development of asymptomatic functional and structural abnormalities known as 
TOD [75]. Little is known about the influence of short-term BPV on the presence of 
TOD, specifically LVH. LVH can be determined by ECG or quantified more accurately 
by measuring left ventricular mass by echocardiography and indexing this to body 
surface area to give the LVMI [147]. In their seminal paper Parati et al. [27] 
demonstrated that higher diurnal BPV measured as 24h SD was associated with an 
increased risk of LVH (determined by ECG) in 108 mild-to-severe essentially 
hypertensive patients. They also showed that for nearly any level of 24h mean BP, 
subjects in whom the 24h BPV was low had a lower prevalence and severity of TOD 
those in whom BPV was high, indicating an independent association. However as 
highlighted evidence since suggests the predictive value of short-term BPV remains 
unclear and may not contribute much more than mean levels alone [33]. To 
advance our knowledge of short-term variability, this review attempts to assess and 
quantify the correlation between BPV and LVMI. A meta-analysis on the various 
correlation coefficients will be performed.  
 
3.3 Methods 
Types of studies 
Cohort, cross-sectional or case-control studies that explored the relationship 
between 24h BPV and LVMI. 
Study populations 
Participants recruited to observational studies that underwent 24h non-invasive 
ABPM and an assessment of LVMI. Studies of pregnant women and children were 
excluded.  
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Predictor variables  
Any summary measure of short-term BPV, where short-term refers to variations 
across minutes or hours taken over a 24h period obtained by non-invasive ABPM. 
Summary measures refer to those that can be obtained without the need for 
advanced statistical methods. 
 
Outcomes 
LVMI determined with echocardiography. 
Search methods for identification of studies 
Studies were identified by systematic searches in Pubmed and EMBASE (up to June 
2015). The following search terms were used as keywords and/or MESH terms: 
((ambulatory blood pressure) OR (blood pressure) OR (ambulatory blood pressure 
monitoring) OR (short-term blood pressure) OR (24 hour blood pressure)) AND 
(variability) AND ((left ventricular hypertrophy) OR (left ventricular mass index) OR 
((end OR target) organ (damage OR disease))). The full search strategy can be seen 
in the Appendix B which includes different spellings and combinations of words.  
Potentially relevant articles were identified and duplicates were removed. Only 
original research articles were included. We supplemented our electronic search by 
crosschecking the reference lists of all identified studies. There were no date or 
language restrictions. Non-English papers were translated with an online translation 
programme.  The full texts of relevant articles were obtained and an independent 
reviewer reviewed selected papers against the inclusion criteria and assessed their 
quality using the guidelines recommended by Hayden et al. [148] for quality 
appraisal in systematic reviews of prognostic studies. Our systematic review and 
meta-analysis was conducted according to the checklist of Meta-analysis of 
Observational Studies in Epidemiology (MOOSE), and the Preferred Reporting Items 
for Systematic reviews and Meta-Analyses guidelines (PRISMA), see Appendix B. 
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Data Extraction 
The study characteristics extracted included sampling approach, study design, 
sample size, mean age, BPV index and value, mean LVMI, correlation coefficients 
and relative information, such as p-values and if it was indicated that they were 
statistically significant or not. The data was extracted independently by two 
researchers (JMM and AMOF). 
 
 
Statistical Analysis 
For the meta-analysis, correlation coefficients were converted into Fisher’s z-scores 
and standard errors which in turn were used to calculate 95% confidence intervals. 
The overall effect size was the weighted inverse variance of the adjusted individual 
effect sizes (z-scores). The overall effect sizes from the meta-analyses were then 
back transformed which corresponded to the overall correlation coefficients. Data 
from the various studies were pooled using the random-effects model. 
Heterogeneity between studies was assessed using the I2 statistic. The Begg’s test 
and Egger’s test were used to assess the extent of publication bias. All analysis was 
performed using Stata software [149].  
3.4 Results 
Basic characteristics of studies 
After removal of 218 duplicates a total of 440 articles were identified during the 
search, of which 416 were excluded based on their titles and abstracts alone, Figure 
3-1. After reviewing the remaining 24 full-text articles, 12 were eligible for inclusion 
in the review, Table 3-1. Reasons for exclusion included articles didn’t calculate 
LVMI as an outcome, summary measures of variability weren’t calculated and no 
effect size was reported. Of the 12 studies, 11 were cross-sectional and one had a 
case-control design. The population sample sizes ranged from 33 to 1822. The 
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various indexes used in the studies along with their definitions are presented in 
Table 3-2. The SD of either 24h/day/night BP readings were used as indexes of BPV 
in all studies with the exception of two: one which only reported CV [150], and 
another study [151] only reported average real variability (ARV). In addition to SD, 
two studies also included CV [39, 152] and a further two included wSD [28, 40]. 
Leoncini et al. [28] also explored ARV. The average value of 24h SBP SD, day SD, 
night SD had range 13.0-19.7, 10.9-19 and 11.5-13.6 mmHg respectively. As there 
were so few studies exploring the other indices we have not reported their range 
here but can be found in Table 3-3. The correlation between 24h SBP SD, day SD, 
night SD and LVMI had range 0.05-0.52, 0.13-0.21 and 0.04-0.21 respectively. These 
correlations were all statistically significant with the exception of day SD (r=0.19) 
[153], 24h SBP SD (r=0.05) and night SD (r=0.04) [40]. In the three studies in which it 
was explored, wSD had a statistically significant correlation of r= 0.15, 0.26 and 0.31 
[28, 30, 40]. Similarly in the two studies which examined 24h SBP ARV, a statistically 
significant correlation of 0.53 and 0.19 with LVMI was observed [28, 151]. 
Of the studies that adjusted for covariates (including mean BP), findings were 
mixed. Schillaci et al. [34] who considered 1822 untreated subjects with essential 
hypertension, reported a weak univarite statistically significant correlation between 
daytime and night-time SD and LVMI but the association didn’t persist after 
adjustment for various confounders. Similar findings were found by Roman et al. 
[39] who found daytime and night-time SD were univariately associated with LVMI 
but the association did not persist after adjustment for confounders including 
average BP. Pascual et al. [154] also found similar results after adjustment for age, 
sex and mean BP. 
In contrast, Tatasciore et al. [30] in a study examining 180 untreated hypertensive 
patients, found daytime SD and wSD to be statistically significantly associated with 
LVMI even after adjustment for other covariates, including mean BP. Similarly Bilo 
et al. [40] found wSD was statistically significantly related to LVMI in a study which 
investigated 339 hypertensive patients. Zhang et al. [151] also found 24h ARV to be 
significantly related to LVMI after adjustment.  
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Using the guidelines recommended by Hayden et al. [148], the quality appraisal of 
each paper was assessed and is presented in Table 3-4.  
Meta-analysis  
Figure 3-2 presents converted correlation coefficients (z-scores) with subgroup 
meta-analysis reported for each BPV index. An overall z-score for all studies was 
omitted as combining different indexes would not be appropriate. After conversion 
from z-scores the pooled subgroup correlation coefficients of LVMI with 24h SBP 
SD, day SBP SD, wSD SBP and 24h ARV SBP were 0.22 (95% CI: 0.12-0.31 ), 0.19 
(95% CI: 0.15-0.25), 0.23 (95% CI: 0.13-0.33), 0.37 (95% CI: 0.01-0.65) respectively. 
All but one index (wSD) showed heterogeneity (p<0.05) across the studies and as a 
result random-effects models were used to combine coefficients. Begg’s and 
Egger’s tests indicated no evidence of publication bias within each variability index.  
3.5 Discussion  
Overall our review suggests that there is a weak positive correlation, between BPV 
and LVMI. We carried out a separate analysis for each measure of variability, 
resulting in reduced power in the meta-analysis. Our review highlights the lack of 
good epidemiological studies exploring the relationship between BPV and LVMI. As 
eleven of the twelve studies were cross-sectional, we cannot assess cause-effect 
relationships. Although all studies reported univariate coefficients we found just 
over half of the studies did any further analysis or appropriate adjustment for 
covariates. Despite these limitations, the results are still worth exploring and the 
review raised some important issues in relation to BPV in general and also 
specifically to LVMI. 
Veerman et al. [153] reported a non-statistically significant correlation with day SD. 
We cited the small sample size (n=33) as a potential reason for the discrepancy 
between day SD compared to the other studies. Bilo et al. [40] also reported a non-
statistically significant correlation of LVMI with 24h SD but interestingly in the same 
study found both day SD and wSD were significantly correlated with LVMI even 
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after adjustment. This finding highlights that results are sensitive to the index 
chosen and leads to the issue of variability measurement.  
Most studies have used SD as a measure of BPV and the appropriateness of such an 
index has been disputed because it only reflects the dispersion of measurements 
around a single value (mean) not accounting for the order in which BP 
measurements were obtained [36, 37]. The discrepancies between day and 24h SD 
in the study by Bilo et al. [40] may be explained by the fall of BP at night (dip). A 
large dip which is known to be associated with healthier individuals will lead to a 
larger 24h SD. The wSD attempts to remove the effect of the dip and was found to 
be significantly correlated unlike the 24h SD. This suggests that perhaps SD, at least 
over 24h may not be a good measure of BPV. Mena et al. [36] first explored, and 
later Pierdomenico et al. [37], ARV in relation to BP which is the average absolute 
difference between successive readings, and is thought to give a true reflection of 
real variability. In both studies high ARV was found to be an independent predictor 
of cardiovascular risk in hypertension patients while high SD was not. The two 
studies that included ARV in this review both found a statistically significant 
correlation with LVMI [28, 151]. In one study association remained significant after 
adjustment [151] while the other study found it to be an independent predictor of 
multiple TOD where the majority of these had LVH [28]. As ARV is thought to give a 
true reflection of real variability it may be the most appropriate marker of short 
term BPV over other indexes and could potentially be used to predict outcome in 
patients even before BP becomes elevated and ultimately provide a means of 
identifying at risk patients before they develop hypertension.   
Other studies exploring the relationship between BPV and TOD have found varied 
results. As mentioned Parati et al. [27] found an association between 24h BPV and 
severity of TOD (a score based on presence of LVH, chest x-ray abnormalities, 
abnormalities of the fundus plus a clinical event and/or a renal abnormality). The 
same group conducted another follow-up study with a follow-up period of 7 years 
to assess the prognostic relevance of short-term BPV on 73 hypertensive patients 
[155]. They found an independent association between 24h BPV at baseline and 
TOD at follow-up. Similarly, in another study of over 700 hypertensive and 
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normotensive patients, daytime systolic SD was found to be associated with degree 
of TOD. However in the same study, after adjustment for mean BP no strong 
association was found between BPV and LVH [156]. Hansen et al. explored the 
relationship between BPV and cardiovascular events [33]. ARV predicted all fatal 
and nonfatal outcomes even after adjustment for mean BP but found that it added 
only 0.1% to the explained risk of an event occurring. They concluded that the main 
risk factor remained mean BP. 
Another point that must not be overlooked when considering the importance of the 
results from the individual studies is the issue of statistical and clinical significance. 
All the studies have decided on the importance of the correlation coefficient based 
solely on a statistical significance threshold level of 0.05. It is critical to remember 
that the smaller the p-level the more significant the relationship but the larger the 
correlation, the stronger the relationship. It is for this reason that we must be 
careful how we interpret findings from such studies. For example Bilo et al. found a 
statistically significant correlation between wSD and LVMI but the value of the 
coefficient was only 0.15 which would be considered a weak association [40]. In this 
case, with a large sample size (n=339), researchers should not solely focus on 
statistical significance. Here, we should not over emphasise the statistical 
significance finding as the correction coefficient is in fact quite low. Sterne and 
Smith argue that a p-value<0.001 provides much stronger evidence against the null 
hypothesis, in comparison to a p-value <0.05 and suggest that results of medical 
research should generally not be reported as “significant” or “non-significant” 
where appropriate [157]. It is important to take a practical but sensible approach 
where statistical and clinical significance are both given equal thought when 
deciding on the importance of a relationship.  
As the studies are cross-sectional in nature we are not able to determine whether 
higher BPV initiates increases in LVMI or do increases in LVMI represent a risk factor 
for increased BPV rather than being a consequence of it. It is however argued that 
vascular hypertrophy induced by exaggerated and large BPV may lead to an 
impaired arterial distensibility of the large arteries, resulting in increased cardiac 
afterload and as a result increases LVMI [158]. Clinical trials have recently shown 
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that some classes of anti-hypertensive drugs significantly outperform others in 
terms of lowering BPV, and that this reduction in short-term and long-term BPV 
contributes to the prevention of cardiovascular events in hypertensive patients [25, 
159]. Results indicate that CCB and to a lesser extent thiazide diuretics are superior 
to other drugs in reducing BPV and preventing stroke and other vascular events 
compared to the older β-blocker atenolol which increases BPV [61, 160]. Similar 
findings were reported in a more recent observational study assessing the efficacy 
of mono and combination therapy on short-term BPV of 2780 hypertensive patients 
[64]. Again CCB’s, followed by diuretics were correlated with lower short-term BPV 
compared with ARB’s, ACEI’s and β-blockers. In addition combination of CCB’s and 
diuretics resulted in the lowest BPV compared to others. In those with marked BPV, 
the prescribing of these drugs may offer a better alternative and could help reduce 
the risk of LVH especially in individuals where hypertension has not yet developed.  
The major limitation of this review is that we have pooled together studies in a 
meta-analysis in regard to their correlation coefficients which are a very weak 
marker of association. As a result of using correlation coefficients there is an 
implicit assumption that the association between BPV and LVMI is linear which in 
reality may not be the case. The strength of this review is its focus on short-term 
BPV which has recently been receiving growing attention. It is also the first review 
to our knowledge that quantifies the correlation between BPV and LVMI. The 
review identifies a research gap where stronger epidemiological studies are needed 
to explore the relationship further and understand the prognostic value, if any, of 
short-term BPV.  
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Figure 3-1 Flow diagram of study selection 
 
  
658 articles identified through 
database searching  
(388 MEDLINE, 270 EMBASE) 
440 articles screened 
218 duplicate articles removed  
24 full-text articles assessed for 
eligibility screened  
12 articles included in review 
416 articles excluded based on 
title and abstract  
12 articles excluded based on 
full-text inclusion criteria 
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Figure 3-2 Pooled meta-analysis of z-scores by BPV index.  
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Table 3-1 Study characteristics 
Study Population Sampling Approach Design n (women, %) Mean age (SD 
or range), yr 
BPV index Outcome 
measure 
Colivicchi 
(1996) 
Elderly untreated HTN males 
with matched normotensives 
Convenience Case-control 50 (0%) 74 (4) 24h, day, night -
SD 
LVMI  
Veerman 
(1996) 
Referred to hypertension 
clinic due to suspected 
hypertension 
Convenience Cross-sectional 33 (48%) 41 (26-59) Day- SD LVMI 
Schillaci (1998) Hospital based untreated 
HTN  
Convenience Cross-sectional 1822 (47%) 50 (12) 24h, day, night- 
SD 
LVMI  
Pascual (1999) Untreated HTN Convenience Cross-sectional 149 (33%) 38 (7) 24h, day, night –
SD, CV 
LVMI  
Kristensen 
(2001) 
Untreated HTN from general 
practice and subjects drawn 
at random from Danish 
national register 
Convenience  & 
random 
Cross-sectional 566 (52%) 48 (20-79) 24h, day, night – 
SD,CV 
LVMI  
Roman (2001) Subjects from a worksite-
based study and who were 
evaluated at a hospital 
NR Cross-sectional 511 (44%) 50 (12)   
 
Day, night – SD,CV LVMI  
Polonia (2005) Population sample  NR Cross-sectional 743 (56%) 
185 (LVMI 
measured) 
52 (14) Day SD LVMI  
Tatasciore 
(2007) 
Outpatients referred to clinic 
by GP 
Convenience Cross-sectional 180 (40%) 53 (8) 24h, day, night – 
SD 
wSD 
LVMI  
Bilo (2007) Two hypertension centres NR Cross-sectional 3863 (54%) 
339 (50%) 
(Echo taken)  
54 (12) 24h, Day, night – 
SD, wSD 
LVMI  
Zhang (2011) Elderly hospitalised HTN and 
normotensive controls 
Convenience Cross-sectional 197 (35%) 76.5 (7.8) 24h, day, night-
ARV 
LVMI 
Ajayi (2011) 
 
Nigerian HTN  Convenience Cross-sectional 130 (26%) 54 (12) (31-85) 24h – CV LVMI 
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Study Population Sampling Approach Design n (women, %) Mean age (SD 
or range), yr 
BPV index Outcome 
measure 
Continued on following page 
Leoncini 
(2013) 
Untreated HTN attending 
outpatient clinic 
Convenience Cross-sectional 169 (33%) 47 (10) 24h, day, night – 
SD 
ARV, wSD 
LVMI 
Abbreviations: SD: Standard Deviation, CV: coefficient of variation, wSD: weighted standard deviation, LVMI: Left ventricular hypertrophy index, TOD: target organ damage, LVH: 
left ventricular hypertrophy, ARV: average real variability, HTN: Hypertensives, GP: general practitioner , NR: not reported 
 
 
 
Table 3-2 BPV definitions 
Measure of BPV Description 
24h SD Standard deviation over 24h period  
Day SD Standard deviation over day period usually 9am-9pm 
Night SD Standard deviation over night period usually 1am-6am 
wSD Weighted standard deviation which is the mean of day and night standard deviation values corrected for the number of hours included in 
each of the two sub-periods which attempts to eliminate the effect of nocturnal fall.  
wSD=((day standard deviation x day hours) + ((night standard deviation x night hours)))/total number of hours 
CV Coefficient of variation = (Standard deviation over 24h/mean 24h) x 100 
ARV Average real variability which averages the absolute differences between successive readings which is the average absolute difference 
between successive readings.     
 
   
 ∑            
   
   , where k ranges from 1 to N-1 and N is the number of BP measurements 
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Table 3-3 Extracted Results 
Study SBP Variability SD Mean LVMI (SD) 
g/m
2
 
Multivariate 
analysis adjusted 
for: 
Method of 
adjustment for mean 
BP 
Correlation Coefficient (r) Beta coefficients 
(multivariate analysis) 
β (se) 
Colivicchi 
(1996) 
16.2 (3.5) 24h SD 
19 (5.4) day SD 
12 (2.9) night SD 
134.9 (27.5) 
(LVH=16%) 
- - r=0.52† 24h SD (HTN only) 
r=NS day & night SD 
- 
Veerman 
(1996) 
12.7 (7.5-22) day SD 
 
115 (67-153) 
(LVH=13%) 
Day BP Regression r=0.19 day SBP SD 
r=0.35* day DBP SD 
3.16 (1.18)* Day DBP SD  
Schillaci 
(1998) 
NR NR Age, body height, 24h 
BP, DBP, BMI, 
duration of 
hypertension, 
alcohol, smoking 
Subjects divided into 
similar levels of BP, 
then subdivided if 
below or above median 
BPV & separately a 
regression analysis 
(r=0.13, p<0.01) day SBP SD 
(r=0.1, p<0.01) night SBP SD 
r=NS day & night DBP SD 
 
NS 
Pascual 
(1999) 
14.0 (3.4) 24h SD 
10.3 (2.4) 24h CV 
10.9 (2.8) day SD 
13.8 (3.3) day CV 
11.7 (3.5) night SD 
11.7 (3.7) night CV  
126 (34.6) Age, sex, BP Regression r=0.23† (24h & day SBP SD) 
r=NS (24h, day, night DBP SD & 
CV; 24h, day, night SBP CV & 
night SBP SD) 
0.87 (.83) 24h SBP SD 
Kristensen 
(2001) 
NR 102.7 (28.3) - - r=0.24 (p<0.01) NR 
Roman 
(2001) 
NR NR Age, age
2
, sex, basal 
SBP or DBP, serum 
cholesterol, smoking, 
antihypertensive 
medication 
Regression r=0.29‡both day & night SBP SD 
r=0.19‡ DBP SD day 
r=0.26‡ DBP SD night 
r=0.08 SBP CV day 
r=0.022 SBP CV night 
r=0.00 DBP CV day 
r=0.06 DBP CV night 
NS  
Polonia 
(2005) 
13.2 (3.4) day SBP SD 
14.3 (3.4) 24h SBP SD 
11.5 (3.8) night SBP SD 
100 (40)  - - r=0.162* day SBP SD - 
83 
 
Study SBP Variability SD Mean LVMI (SD) 
g/m
2
 
Multivariate 
analysis adjusted 
for: 
Method of 
adjustment for mean 
BP 
Correlation Coefficient (r) Beta coefficients 
(multivariate analysis) 
β (se) 
Tatasciore 
(2007) 
13.0 (4.1) 24h SBP 
10.9 (4.0) 24h DBP 
96.7 (17.8) Age, sex, alcohol, 
triglycerides, SBP, 
DBP, SBP load, DBP 
load 
Regression r=0.312‡ 24h SBP SD 
r=NS – 24h DBP 
r=0.310‡ wSD SBP 
r=NS wSD DBP 
0.633 (p=0.028) 24h SBP 
Bilo (2007) NR for echocardiographic 
group 
109.5 (33.8) 24h BP, sex Regression r=0.05 24h SBP SD  
r=0.15† 24h wSD 
r=0.16† day SBP SD 
r=0.04 night SBP SD 
0.15 (p<0.01) 24h wSD SBP 
0.16 (p<0.01) day SBP SD 
0.04 (p=NS) 24h SD 
Zhang 
(2011) 
11.9 (2.6) 24 ARV SBP 
8.6 (2.6) 24 ARV DBP 
9.3 (2.3) day ARV SBP 
8.2 (2.1) day ARV DBP 
9.2 (3.3) night ARV SBP 
7.8 (2.1) night ARV DBP 
145.1 (43.2) Age, duration of HTN, 
total cholesterol, low-
density lipoprotein 
cholesterol, 24h BP 
Regression r=0.525† 24h ARV SBP 
r=NS NR 24h ARV DBP 
 
0.593† 24h ARV SBP 
Ajayi (2011) NR 109.65 (38.1) - - r=0.379* 24h CV SBP 
r=0.124 24h CV DBP 
- 
Leoncini 
(2013) 
19.7 (5.9) 24h SD 
18.5 (6.3) day SD 
13.6 (5.5) night 
16.8 (5.3) 24h wSD 
15.1 (4.8) 24h ARV 
15.9 (5.7) day ARV 
13.0 (5.3) night ARV 
15.1 (5.0) wARV 
(All SBP, DBP not 
displayed) 
46 (11) (LVM g m 
-2.7
) Office BP, age, BMI, 
sex, smoking, 
triglycerides, 
cholesterol, glucose, 
duration of HTN, AASI 
Logistic regression r=0.24† 24h SD 
r=0.19* 24h ARV 
r=0.26‡ 24h wSD 
r=0.21† day SD 
r=0.21† night SD 
r=0.19* day ARV 
r=0.14 night ARV 
all for LVMI indexed for BSA 
Odds ratio reported but for 
overall TOD presence (2 or 
more) 
1.103 (1.003-1.212)† 24h 
SD 
1.114 (1.012-1.227)† day 
SD 
1.140 (1.004-1.295)† 24h 
ARV 
Abbreviations: SD: Standard Deviation, CV: coefficient of variation, wSD: weighted standard deviation, LVMI: Left ventricular hypertrophy index, TOD: target organ damage, LVH: left 
ventricular hypertrophy, ARV: average real variability, HTN: Hypertensives, NR: not reported, BP: blood pressure, SBP: systolic blood pressure, AASI: Arterial stiffness index based, NS: 
non-significant and no value was reported, *p<0.05; † p<0.01; ‡p<0.001  
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Table 3-4 Quality Assessment 
Study Study Participation 
 
Study Attrition 
 
Prognostic Factor 
Measurement /Outcome 
Measurement 
Confounding Measurement and 
Account 
 
Analysis 
 
Colivicchi (1996) No No Yes No No 
Veerman (1996) Partly No Partly No No 
Schillaci (1998) Yes Partly Yes Yes  Yes 
Pascual (1999) Partly Partly Partly Partly  Partly 
Kristensen (2001) Partly No Yes No No 
Roman (2001) Partly No Partly Partly Yes 
Polonia (2005) Partly No Partly No  No 
Tatasciore (2007) Yes Yes Yes Yes Yes 
Bilo (2007) Partly Partly Partly Partly Partly 
Zhang (2011) Partly No Yes Yes Partly 
Ajayi (2011) Partly No Yes No Yes 
Leoncini (2013) Partly Yes Yes Partly Partly  
 
 
 
 
 
 
85 
 
 
4. SHORT-TERM BLOOD PRESSURE VARIABILITY OVER 24 
HOURS AND TARGET ORGAN DAMAGE IN MIDDLE-AGED 
MEN AND WOMEN (PAPER 2) 
 
J. M. MADDENa   
A. M. O’FLYNNa  
E. DOLANc  
               A. P. FITZGERALDa,b  
                P. M. KEARNEYa 
a Department of Epidemiology & Public Health, University College Cork, Ireland 
a,b Department of Statistics, University College Cork, Ireland  
c Stroke and Hypertension unit, Connolly Hospital, Blanchardstown, Dublin, Ireland 
 
 
 
 
This paper was published in Journal of Human Hypertension in 2015 (See Appendix 
J) 
86 
 
4.1 Abstract  
BPV has been associated with cardiovascular events but the prognostic significance 
of short-term BPV remains uncertain. As uncertainty also remains as to which 
measure of variability most accurately describes short-term BPV, this study explores 
different indices and investigates their relationship with subclinical TOD.  
We used data from the Mitchelstown Study, a population based study of Irish 
adults aged 47-73 years (n=2,047). A subsample (1,207) underwent 24h ABPM. As 
measures of short-term BPV we estimated the SD, wSD, CV and ARV. TOD was 
documented by microalbuminuria and ECG LVH. 
There was no association found between any measure of BPV and LVH in both 
unadjusted and fully adjusted logistic regression models. Similar analysis found ARV 
(24h, day and night), SD (day & night) and wSD were all univariately associated with 
microalbuminuria and remained associated after adjustment for age, gender, 
smoking, BMI, diabetes and anti-hypertensive treatment. However, when the 
models were further adjusted for mean BP the association did not persist for all 
indices. 
Our findings illustrate choosing the appropriate summary measure which accurately 
captures short-term BPV is difficult. Despite discrepancies in values between the 
different measures there was no association between any indexes of variability with 
TOD measures after adjustment for mean BP.   
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4.2 Introduction 
The prognostic value of BPV in addition to mean BP has been receiving growing 
attention [161, 162]. In addition to showing a strong association with increased 
mortality risk, visit-to-visit variability in BP has been shown to predict stroke and 
coronary events independent of mean clinic BP [25, 38]. It has also been linked with 
TOD [38, 163, 164]. However, the predictive value of short-term BPV, i.e. 
fluctuations of BP across minutes or hours usually taken over a 24h period, and 
obtained through the use of ABPM remains contentious. While a number of studies 
have reported associations between short-term BPV and TOD [27-31] and 
cardiovascular events [25, 32], others have shown none or only weak associations 
after adjustment for mean BP [33, 34, 39].  
There have been a number of different indices of variability proposed to describe 
short-term BPV with most studies considering SD [25, 27, 28, 30-34, 38, 39]. The 
appropriateness however, of such an index as an indicator of BPV has been 
disputed because it only reflects the dispersion of measurements around a single 
value (mean) not accounting for the order in which BP measurements were 
obtained [36, 37]. As a consequence, other indices of variability that have been 
used include: CV which attempts to adjust for the tendency of those with a higher 
average BP to also have a higher SD [25, 38, 39], ARV which is the average absolute 
difference between successive readings, and is thought to give a true reflection of 
real variability [28, 33, 36] and wSD which attempts to remove the influence of the 
day-night BP difference from the estimate of BPV [28, 30, 33, 40]. 
As the prognostic significance of short-term BPV remains uncertain with no 
consensus as to which measure of variability most accurately describes BPV, this 
study explores different indices of BPV and investigates their relationship with two 
parameters of subclinical TOD; LVH and microalbuminuria. 
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4.3 Methods 
Study Population 
The analysis utilises data from the Mitchelstown Study, a population based study of 
middle-aged men and women, recruited in Ireland 2010-2011. A detailed 
description of the study design is available from a previous publication [74]. In brief, 
the primary aim of the study was to provide a profile of cardiovascular health and 
their related factors in an Irish adult general population sample. The study recruited 
patients attending a single large primary care centre, the LHC, in Mitchelstown. 
Participants completed a detailed health and lifestyle questionnaire including a 
question on use of anti-hypertensive medication, and were invited to attend their 
primary care provider’s surgery for a physical examination to be carried out by a 
nurse trained in the study research protocols. Study measurements included height, 
weight, BP and in addition, fasting blood samples (minimum of 8-h fast) and urine 
samples. Participants also underwent standard 12-lead electrocardiogram (ECG) 
and ABPM was offered to all participants. All participants provided written 
informed consent and ethical approval was obtained from the Clinical Research 
Ethics Committee Cork.  
 
BP Measurements 
Study BP was measured three times after 5 minutes of rest in a seated position by 
experienced research nurses using an OMRON M7 BP monitor (OMRON Healthcare, 
The Netherlands). The average of the second and third measurements was used. 
ABPM was measured using dabl ABPM system (dabl ltd., Ireland) with the Meditech 
ABOM-05 Monitor (Meditech LTD., Hungary). The monitors were programmed to 
obtain readings every 30mins and remained in place for 24h. Participants kept 
diaries of wake and sleep periods, which were used to calculate day and night BP 
respectively. If no diary was kept, the period from 1am to 6am was used as the 
night period and from 9am to 9pm as the day period. Only participants with a 
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minimum of 14 measurements during the day and a minimum of 7 measurements 
during the night period were included in the analysis [165].  
As indices of short-term reading-to-reading BPV, we estimated the SD over 24h, 
wSD, CV ((SD 24h BP/mean 24h BP)*100) and ARV. The wSD is the mean of day and 
night SD values corrected for the number of hours included in each of these two 
sub-periods [40]. The ARV averages the absolute differences between consecutive 
measurements. To illustrate the subtle differences between each measure we have 
included 24h SBP profiles of four participants from the study along with their 
corresponding 24h variability measures (Figure 4-1.a-d). The two individuals 
illustrated in Figure 4-1.a and Figure 4-1.b have different overall levels of BP with 
the individual in Figure 4-1.b having substantially lower BP. In addition to this, the 
two BP patterns can be seen to fluctuate quite differently throughout the 24h but 
despite this, they have the same 24h SD, emphasizing the disadvantage of using SD 
as it only reflects dispersion around the average. Visually it is hard to justify that the 
two profiles have the same variability when it seems the first participant (Figure 
4-1.a) has larger variation between each consecutive measurements compared to 
the second participant (Figure 4-1.b). In comparison, their 24h ARV differ 
considerably and highlights the benefit of using this measure as it accounts for the 
order of the BP readings. wSD and 24h CV values are also presented in Figure 4-1. 
The bottom two profiles are provided as another illustration where fluctuations and 
overall BP levels are different yet 24h SD values are similar but 24h ARV values vary 
(Figure 4-1.c & Figure 4-1.d). 
Additional indices SD, CV, and ARV were calculated for both day and night periods. 
To investigate if BPV was influenced by nocturnal BP fall, a night to day BP fall 
(nocturnal dip) parameter was calculated as the ratio of mean BP between night-
day periods. Additionally, the time rate of variability was calculated which is similar 
to ARV but is independent of the time intervals between measurements. All indices 
were calculated for both SBP and DBP. 
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Target organ damage 
Each participant had a blood sample taken after a minimum of 8-h fast and in 
addition provided an early morning spot urine sample on the day of their 
appointment. Laboratory analyses included analysis for glycosylated haemoglobin 
(HbA1C) and ACR. A meta-analysis in 2010 demonstrated increased risk of mortality 
with urine ACR ≥ 1.1 mg/mmol and as a result microalbuminuria is defined using 
this cut-point [78]. A 12-lead ECG was obtained in the standard manner using a 
Siemens – Eclipse 850i machine. ECGs were reviewed and coded for LVH voltage 
criteria by a cardiologist. The presence of LVH was defined by Cornell Product ECG 
voltage criteria i.e. SV3 + RaVL (+6 in women) X QRS duration ≥ 2440 mm x ms [80]. 
 
Other Measurements 
The questionaires provided data on participants smoking habits and were 
categorized as never, former and current smoker. Diabetes mellitus was defined as 
HbA1c level greater than or equal to 6.5% [166] or self-reported doctor diagnosis of 
diabetes. The classification of hypertension was based on SBP≥140 mmHg and/or 
DBP≥90 mmHg and/or on anti-hypertensive treatment. Weight was measured using 
a Tanita weighing scales and height measured with the use of a portable Seca 
length measure. Body mass index (BMI) was calculated as body weight in kilograms 
divided by height in meters squared. Participants with a BMI ≥30, 25-30 and <25 
kg/m2 were classified as obese, overweight and normal/underweight respectively.  
 
Statistical Analysis 
All of the data are expressed as arithmetic mean (SD) or as percentages where 
appropriate. Normally distributed continuous variables were compared using 
student’s t-test. Correlations among variables were assessed by Pearson correlation 
coefficient (r). The association between BPV and the presence of TOD was assessed 
using logistic regression with adjustment for age, sex, smoking status, BMI, diabetes 
and anti-hypertensive treatment. Additional models adjusted for mean 24h BP. 
Multicollinearity issues between mean BP and variability measures were assessed 
by checking for inflated standard errors, correlation coefficients and variance 
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inflation factors. Results are presented as odds ratios for a one-SD change with 95% 
confidence intervals (CI). The association between BPV and microalbuminuria was 
further explored by excluding those with diabetes from the analysis. Models were 
also separately run on those classified as hypertensive by ABPM and/or on anti-
hypertensive treatment. In addition we examined just those on anti-hypertensive 
treatment alone. Receiver operating characteristic (ROC) curves were plotted to 
evaluate the predictive value of BPV. Additionally ACR was included in a linear 
regression model as a continuous outcome. To investigate the impact that the 
white-coat effect may have on variability, the analysis was repeated after the first 
hour of readings were excluded. Often, it is recommended to allow for multiple 
testing when examining independent measures and protect against data dredging 
where we might find a significant finding by chance alone when there is no real 
association. Typically an adjustment such as the Bonferonni correction is made but 
when measures are highly correlated as in our case, this method is inappropriate, 
as it will be highly conservative and may miss real differences [167]. Importantly in 
our study however, each variability index is in fact capturing different 
characteristics of variability and as we are interested in each measure separately or 
in isolation as opposed to seeing them as a collective, multiple testing is not 
required. If we were testing an overall hypothesis that BPV was related to our 
outcome then adjusting for multiple testing may have been considered. All of the 
statistical analyses were performed with the use of Stata version 12 (StataCorp., 
College Station, TX, USA). A value of P<0.05 was considered statistically significant. 
Figure 4-1 was plotted with the use of the R programming language. 
 
 
4.4 Results 
Of 3051 individuals invited to participate, 2047 (response rate: 67%) completed the 
questionnaire and physical examination component. ABPM was offered to all 2047 
participants and it was completed by 1207 (response rate: 58%) of which 1134 had 
satisfactory amount of measurements recorded. The average numbers of day and 
night readings were 27 and 16 respectively. The main clinical characteristics of the 
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1134 participants are presented in Table 4-1 separately for those with and without 
LVH and microalbuminuria. Overall, participants had a mean (SD) age of 60.2 (5.5) 
and the majority were female (54%). Over half were classified as hypertensive 
(59%) and almost a tenth had diabetes (9.3%). The overall prevalence of LVH and 
microalbuminuria was 6.6% and 11.4% respectively.  
Table 4-2 and Table 4-3 provides mean (SD) of different indices used to characterise 
BPV including the nocturnal dip, by 24h/day/night for both LVH and 
microalbuminuria respectively. With the exception of the nocturnal dip ratio there 
were no significant differences in BPV indexes between those with and without LVH 
(Table 4-2). However, night ARV, SD and wSD (both SBP & DBP) were significantly 
higher in those with microalbuminuria compared to those without. Additionally 24h 
ARV, day ARV, day SD (all SBP) and 24h ARV (DBP) were also higher in those with 
microalbuminuria (Table 4-3). Although the variability was higher in those with 
microalbuminuria, the nocturnal dip was significantly higher in those without 
microalbuminuria for both SBP and DBP. All four indices taken over the 24h period 
were significantly correlated with one another (correlation coefficient ranged 0.40-
0.91 (p<0.001)).  
Presented in Table 4-4 and Table 4-5 are results from regression analysis for both 
LVH and microalbuminuria respectively. Univariate logistic regression showed that 
none of the variability indices during any period were associated with LVH. In 
contrast, mean 24h ABPM was significantly associated with LVH in both univariate 
and adjusted models (OR=1.37(1.07-1.75)) (Table 4-4). The nocturnal dip was 
associated with a protective effect on LVH but the association did not persist when 
additionally adjusted for mean SBP (Table 4-4). In comparison ARV (24h, day and 
night), SD (day & night) and wSD were all univariately associated with 
microalbuminuria and the association persisted after adjustment for age, gender, 
smoking, BMI, diabetes and antihypertensive treatment (Table 4-5). However, 
when mean SBP was added to the model the association did not persist for all 
indices (Model 2, Table 4-5). Nocturnal dip was significantly associated with a 
protective effect on microalbuminuria in both the unadjusted and the fully adjusted 
models including mean BP (Table 4-5).  
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When analysis focused on only those classified as hypertensive by ABPM and/or 
taking antihypertensive treatment no differences to the findings above were 
observed. When those on antihypertensive treatment were analysed separately, 
models gave similar results to what we had seen already in relation to LVH and 
broadly similar in relation to microalbuminuria with the exception of 24h ARV. 
Despite adjustment for mean 24h BP in addition to age, gender, smoking, BMI and 
diabetes; 24h ARV was significantly associated with microalbuminuria (OR=1.43 
(1.04-1.99). The prevalence of microalbuminuria in this sub-group was 14.7%. 
The time rate of variability measure gave similar results to ARV (results not shown). 
No significant results were observed when mean BP was included in the models 
including when those on anti-hypertensive treatment were explored separately.  
The stability of the models after the adjustment of mean BP was assessed to 
identify any multicollinearity issues. After adjustment standard errors were not 
inflated and were similar to the values before the inclusion of mean BP indicating 
stable models. Additionally; correlation coefficients were obtained between mean 
BP and all BPV indexes. The values ranged from -0.02-0.47. Finally, variance 
inflation factors were calculated in each model and all values were under 1.5 
indicating that multicollinearity issues did not arise. 
To evaluate the additional predictive value of BPV, ROC curves were plotted. The 
plots compared a model which included mean BP and BPV to a model which just 
included mean BP while adjusting for age, gender, smoking, BMI, diabetes and anti-
hypertensive treatment. There was no significant difference between the areas 
under the curves regardless of which BPV measure or period of time was used 
(24h/day/night) (results not shown, plots in Appendix C).  
All analyses were repeated for DBP. ARV (24h/day/night), night SD and wSD were 
found to be significantly related to microalbuminuria but the association did not 
persist once mean BP was added to the model. No other associations were 
observed with either LVH or microalbuminuria. Omitting the first hour of readings 
to explore the white-coat effect had no impact on our findings (data not shown). 
Results presented include the first hour of readings. The exclusion of participants 
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with diabetes in the analysis of microalbuminuria did not alter our findings. Similar 
findings to that of the logistic regression model were obtained when ACR was 
included in a linear regression model as a continuous outcome.    
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4.5 Discussion 
In this large population based study we have explored the association between 
short-term BPV and subclinical TOD. Much debate remains in the literature as to 
the best measure of BPV and as a result four different indices were calculated and 
each assessed for their prognostic significance. Our work highlights the difficulties 
in accurately describing short-term variability with one summary measure. To 
illustrate this we provided cases of individuals who have distinctly different BP 
profiles and overall mean BP levels throughout the day yet have similar values in 
terms of SD but quite different values based on the other indices calculated. 
Despite the discrepancies between different measures our results indicated that 
there was no association between any index of variability we calculated and LVH 
even in unadjusted models. The associations between ARV (24h, day and night), SD 
(day & night), wSD, with microalbuminuria persisted following adjustment for a 
range of important potential confounders but did not persist after the models were 
additionally adjusted for mean BP. However, in a sub-analysis of those only taking 
anti-hypertensive treatment the association between 24h ARV with 
microalbuminuria persisted following adjustment for all confounders including 
mean BP.  
The relationship between mean BP and TOD is well established and the literature 
does not question the importance of lowering mean levels of BP as is 
recommended in guidelines [18]. As a consequence, to identify BPV as an additional 
independent predictor we adjusted our analysis for mean 24h BP. The intrinsic 
relationship that can exist between mean BP and BPV can lead to invalid measures 
of variability and Hansen et al. [168] also claims the strong association between the 
two may cause problems in building stable regression models (although our analysis 
did not find such problems). Furthermore, SD is widely used as a measure of BPV 
but the appropriateness of such an index has been disputed because it only reflects 
the dispersion of measurements around a single value (mean) not accounting for 
the order in which BP measurements were obtained [36, 37]. This issue was 
highlighted in the different BP profiles presented in Figure 4-1. The CV has also 
been used and adjusts for the tendency of those with a higher average BP to also 
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have a higher SD as was found in this study. However these two measures (SD, CV) 
are still inherently linked to mean BP and this helps to advocate the use of ARV and 
wSD as more suitable measures of BPV.  
Many studies have proposed ARV as an appropriate measure of variation which 
averages the absolute difference between successive readings and accounts for the 
order in which the BP readings are obtained [28, 33, 36], while wSD has also been 
utilised and is a weighted average of both day and night SDs which specifically 
attempts to remove the day-night difference in mean BP from the estimate of BPV 
[28, 30, 33, 40].  As a result 24h ARV and wSD are not strongly influenced by the 
difference between day-night mean BP levels. This is in contrast to SD and CV in 
which a large nocturnal dip will increase both values. The protective effect on the 
presence of microalbuminuria that was observed with nocturnal dip after 
adjustment for mean BP is not surprising. An absence in BP fall at night has been 
cited in many studies as a prognostic marker of cardiovascular events both in 
hypertensive [15, 169, 170] participants and the general population [171, 172]. 
Although the associations between ARV (24h, day and night), SD (day & night), wSD, 
with microalbuminuria did not persist after additionally adjusting for mean BP we 
plotted ROC curves to check if the combination of mean BP and BPV had more 
predictive power over that of just mean BP. Despite discrepancies between the 
different measures and the problems outlined above the plots revealed no 
additional benefit in including BPV over and beyond 24h BP irrespective of the BPV 
index used.  
While there was no association overall between 24h ARV and microalbuminuria 
once adjusted for mean BP, among those on anti-hypertensive treatment the 
association persisted. We do not have data on specific treatment classes so we 
were unable to assess if this effect was mediated by a particular anti-hypertensive 
class. Some individual drug data was collected but sufficient numbers were not 
obtained to explore classes separately. Our finding does suggest however that anti-
hypertensive treatment is having an effect on BPV. Evidence from meta-analyses 
suggest that although different anti-hypertensive-drug classes have similar effects 
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in terms of reducing BP levels, pronounced differences in their ability to reduce BPV 
[61, 62]. 
Considering the strong relationship that exists between mean BP and the presence 
of LVH, which was also evident in this study, it is interesting that no associations 
were identified with any measure of BPV even under unadjusted conditions alone. 
One contributing factor may be that LVH was determined based on the evaluation 
of a 12-lead ECG which is known to have low sensitivity in the detection of LVH [18]. 
Although it has its own technical issues, use of echocardiography would have been 
preferred as it is more sensitive than ECG in diagnosing LVH. Despite this however, 
guidelines promote the use of ECG as part of routine assessment of all hypertensive 
patients [18]. In addition to low sensitivity, we also had a low prevalence of LVH 
(6.6%) in the study. When these two factors are considered in combination, they 
may have had a large confounding effect on the relationship between BPV and TOD. 
When prevalence is low, there are few true positives in the sample, and false 
positives can be large compared to the number of true positives. It is clear that 
these factors may have masked the true underlying association in our data.  
It is important to highlight that other studies have found an association between 
BPV and TOD even after adjustment for mean BP. Among hypertensive patients, 
Tatasciore et al. [30] found an association between awake SBP SD and LVMI in 
multivariate analysis even with the inclusion of awake SBP. Similarly, in multivariate 
analysis including daytime SBP Zakopoulos et al. [31] found an association between 
the daytime rate of SBP variation and left ventricular mass. Perhaps the use of 
echocardiography in the measurement of the outcome in these studies can, in part, 
explain discrepancies between these and our findings. 
Another argument may be that visit-to-visit variability is a better prognostic 
predictor. Many large studies have demonstrated a strong relationship between 
visit-to-visit variability and all-cause mortality [38], cardiovascular events [25, 173] 
and TOD [163, 174]. However there is still no consensus on the matter and as 
highlighted in a recent review there is a need to design studies to prospectively 
determine the causes of visit-to-visit variability and determine if treatments that 
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reduce variability lead to improved clinical outcome [175]. Correctly determining 
the prognostic significance of both short-term and visit-to-visit BPV could have 
important implications for the prescribing of anti-hypertensive medication.  
Limitations 
The study is cross-sectional in nature and as mentioned above we are not able to 
determine whether increases in BPV promotes the development of TOD or if TOD 
represents a risk factor for increased BPV rather than being a consequence of it. 
Hansen et al. [168] argues that as TOD is a forerunner of cardiovascular 
complications, BPV will inevitably increase. This leads to the issue of reverse 
causality with increased BPV being a marker of underlying disease rather than being 
an independent predictor. The low sensitivity of ECG in the detection of LVH was a 
concern as previously highlighted. Although there are few guidelines focusing on 
BPV, O’Brien et al. suggests small intervals (15min) between measurements is best 
when measuring BPV [13]. Our monitors were set to intervals of length 30min and 
this is recognized as a limitation although there is still no strong consensus on the 
optimal interval size to measure BPV. Despite a response rate of only 58% the 
ABPM subsample was found to be representative of the full sample based on sex, 
age and education. In addition the prevalence of TOD in both the full sample and 
ABPM subsample were similar (LVH 6.0% vs 6.6%, ACR 10.6% vs 11.4%). The main 
strengths of the study lie in the robust community based design and large sample of 
ABPM data recorded. 
4.6 Conclusion 
The findings of this study have highlighted that accurately measuring short-term 
BPV over 24h is not straight forward and different indices can be heavily influenced 
by factors such as mean BP or nocturnal BP fall. Without consideration for these 
confounding factors inferences made on the true prognostic value of BPV could be 
misleading. Based on our findings variability indices such as ARV and wSD that are 
not influenced by the difference in mean BP between day-night periods best 
describe short-term BPV but were not associated with LVH or microalbuminuria 
after adjustment for mean BP. Future research should focus on long-term studies 
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where short-term BPV is measured at baseline and participants followed to view 
the development of TOD.  
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Figure 4-1 Four study participants and their 24h BP profiles. Panels (a) & (b) illustrate different patterns yet have similar 24h SD but 
different values based on the other indices. Both (c) & (d) demonstrate a similar issue (values rounded).
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Table 4-1 Baseline Characteristics by LVH and Microalbuminuria  
  LVH  Microalbuminuria 
Characteristic Total 
(n=1134) 
No 
(n=1058) 
Yes 
(n=75) 
No 
(n=996) 
Yes 
(n=128) 
Age, y 60.2 (5.5) 60.5 (5.5) 62.8 (4.7)** 60.1 (5.5) 61.1 (5.8) 
Gender, Male n(%) 527 (46.5) 486 (45.9) 40 (53.3) 457 (45.8) 65 (50.8) 
BMI, n (%) 
  Underweight/normal 
  Overweight 
  Obese 
 
230 (20.3) 
498 (44.0) 
405 (35.7) 
 
216 (20.4) 
468 (44.3) 
373 (35.3) 
 
13 (17.3) 
30 (40.0) 
32 (42.7) 
 
207 (20.8) 
451 (45.3) 
338 (33.9) 
 
22 (17.3)** 
41 (32.3) 
64 (50.4) 
Smoking, n (%) 
   Never 
   Former 
   Current 
 
564 (51.9) 
355 (32.7) 
168 (15.4) 
 
529 (52.2) 
325 (32.1) 
160 (15.8) 
 
35 (48.6) 
30 (41.8) 
7 (9.7) 
 
495 (52.1) 
307 (32.3) 
149 (15.7) 
 
67 (52.8) 
42 (33.1) 
18 (14.2) 
HbA1C 5.9 (0.8) 5.9 (0.7) 6.1 (1.2) 5.8 (0.7) 6.2 (1.2)** 
Diabetes, n (%) 103 (9.3) 94 (9.1) 9 (12.2) 82 (8.4) 21 (16.4)** 
Office SBP, mm Hg 134.2 (17.5) 133.8 (17.3) 140.4 (19.4)** 133.4 (17.1) 140.4 (20.4)** 
Office DBP, mm Hg 82.7 (10.1) 82.5 (10.1) 84.7 (11.8) 82.4 (9.9) 84.8 (12.3)* 
Hypertension, n (%) 665 (58.7) 607 (57.4) 58 (77.3)** 563 (56.6) 96 (75.0)** 
Sleep time, hours 8.6 (1.3) 8.7 (1.3) 8.3 (1.3) 8.6 (1.3) 8.8 (1.3) 
ABPM measurements 
  24h SBP, mm Hg 
  24h DBP, mm Hg 
  Awake SBP, mm Hg 
  Awake DBP, mm Hg 
  Sleep SBP, mm Hg 
  Sleep DBP, mm Hg 
 
124.1 (13.3) 
71.8 (8.3) 
131.4 (14.1) 
77.4 (9.0) 
112.3 (14.0) 
62.8 (8.3) 
 
123.8 (13.1) 
71.8 (8.2) 
131.1 (14.0) 
77.4 (9.0) 
111.9 (13.6) 
62.7 (8.2) 
 
128.9 (15.4)** 
72.0 (9.5) 
135.1 (16.0)* 
77.0 (9.9) 
118.6 (17.1)** 
63.6 (10.2) 
 
123.1 (12.7) 
71.4 (8.0) 
130.5 (13.6) 
77.0 (8.7) 
111.2 (13.3) 
62.3 (8.0) 
 
131.5 (15.4)** 
74.6 (10.0)** 
138.1 (16.1)** 
80.0 (11.0)** 
121.2 (16.2)** 
66.4 (9.4)** 
Data are mean (SD). SBP: Systolic Blood pressure, DBP: Diastolic blood pressure, BMI:Body mass index, LVH: Left ventricular 
hypertrophy, ABPM: Ambulatory blood pressure monitor. Microalbuminuria: albumin:creatinine ratio ≥ 1.1 mg/mmol. * p<0.05, 
**p-value<0.01, p-values comparing those with/without target organ damage 
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Table 4-2  Variability Indices and Nocturnal Dip by LVH  
Variability 
Measure 
24-hour (mm Hg) Day (mm Hg) Night (mm Hg) 
No Yes No Yes No Yes 
ARV SBP 11.3 (2.5) 11.7 (2.4) 11.9 (3.1) 12.0 (3.1) 10.6 (3.3) 11.2 (2.9) 
ARV DBP 7.8 (1.7) 7.5 (2.0) 8.1 (2.4) 7.8 (2.8) 7.3 (2.1) 7.1 (2.2) 
SD SBP 15.8 (4.0) 16.0 (4.1) 12.8 (3.5) 13.4 (3.5) 11.2 (3.6) 11.5 (3.2) 
SD DBP 11.5 (2.8) 11.1 (2.7) 8.9 (2.8) 8.7 (2.7) 8.0 (2.4) 7.7 (1.8) 
CV SBP 12.8 (2.9) 12.4 (2.9) 9.8 (2.4) 10.0 (2.4) 10.0 (3.0) 9.7 (2.7) 
CV DBP 16.1 (3.7) 15.6 (3.9) 11.7 (3.6) 11.5 (3.8) 12.9 (3.8) 12.4 (3.2) 
wSD SBP 12.3 (2.9) 12.8 (2.7) - - - - 
wSD DBP 8.7 (2.1) 8.4 (2.0) - - - - 
Dip SBP 14.5 (6.7) 12.0 (9.0) * - - - - 
Dip DBP 18.7 (7.5) 17.2 (9.8) - - - - 
Data are mean (SD). ARV: Average real variability, SD: Standard deviation, wSD: Weighted standard deviation, CV: coefficient 
of variation, SBP: Systolic Blood pressure, DBP: Diastolic blood pressure, *p<0.05; represents significance between those with 
and without LVH during each period of the day 
 
 
Table 4-3 Variability Indices and Nocturnal Dip by Microalbuminuria  
Variability 
Measure 
24-hour (mm Hg) Day (mm Hg) Night (mm Hg) 
No Yes No Yes No Yes 
ARV SBP 11.2 (2.5) 12.4 (2.9) ** 11.8 (3.1) 12.7 (3.5) ** 10.5 (3.2) 11.9 (3.5) ** 
ARV DBP 7.7 (1.7) 8.2 (2.1) ** 8.1 (2.3) 8.5 (3.0) 7.2 (2.1) 7.9 (2.3) ** 
SD SBP 15.8 (4.0) 16.2 (4.2) 12.8 (3.4) 13.8 (4.1) ** 11.1 (3.5) 12.3 (3.7) ** 
SD DBP 11.4 (2.8) 11.5 (2.9) 8.9 (2.7) 9.2 (3.1) 7.9 (2.3) 8.7 (2.5) ** 
CV SBP 12.8 (2.9) 12.4 (2.9) 9.8 (2.3) 10.0 (2.8) 10.0 (3.0) 10.2 (2.9) 
CV DBP 16.1 (3.7) 15.6 (3.9) 11.7 (3.6) 11.7 (4.2) 12.8 (3.8) 13.3 (4.0) 
wSD SBP 12.2 (2.8) 13.3 (3.3) ** - - - - 
wSD DBP 8.6 (2.0) 9.0 (2.3) * - - - - 
Dip SBP 14.6 (6.9) 12.1 (7.3) ** - - - - 
Dip DBP 18.8 (7.7) 16.7 (7.4) ** - - - - 
Data are mean (SD). ARV: Average real variability, SD: Standard deviation, wSD: Weighted standard deviation, CV: coefficient 
of variation, SBP: Systolic Blood pressure, DBP: Diastolic blood pressure, *p<0.05; ** p<0.01 represents significance between 
those with and without microalbuminuria during each period of the day  
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Table 4-4 Association between SBP BPV and LVH 
Variability (per SD 
change in mm Hg) 
Unadjusted OR 
(95% CI) 
Model 1 OR 
(95% CI) 
Model 2 OR 
(95% CI) 
ARV:  24h ARV 
           Day ARV 
           Night ARV 
1.13 (0.90-1.41) 
1.04 (0.83-1.31) 
1.19 (0.96-1.49) 
1.01 (0.79-1.30) 
0.97 (0.76-1.25) 
1.08 (0.84-1.39) 
0.87 (0.66-1.14) 
0.87 (0.67-1.13) 
0.97 (0.74-1.26) 
SD:    24h SD 
          Day SD 
          Night SD 
1.03 (0.82-1.30) 
1.17 (0.94-1.46) 
1.09 (0.87-1.36) 
1.01 (0.79-1.30) 
1.09 (0.86-1.39) 
1.02 (0.79-1.32) 
0.91 (0.70-1.18) 
0.98 (0.76-1.28) 
0.90 (0.69-1.19) 
CV:    24h CV 
          Day CV 
          Night CV 
0.88 (0.68-1.12)  
1.08 (0.86-1.36) 
0.91 (0.71-1.16) 
0.89 (0.69-1.14) 
1.01 (0.79-1.29) 
0.87 (0.67-1.13) 
0.91 (0.71-1.17) 
1.02 (0.80-1.30) 
0.87 (0.67-1.14) 
wSD 1.18 (0.94-1.46) 1.08 (0.85-1.40) 0.94 (0.71-1.24) 
SBP Nocturnal Dip 0.71 (0.57-0.89)** 0.78 (0.62-0.98)* 0.81 (0.64-1.02) 
24h SBP 1.42 (1.14-1.76)** 1.37 (1.07-1.75)* - 
ARV: Average real variability, SD: Standard deviation, wSD: Weighted standard deviation, CV: coefficient of variation, LVH: 
Left ventricular hypertrophy, SBP: Systolic blood pressure, BP: Blood pressure, BPV: Blood pressure variability, OR: Odds 
ratio, * p<0.05, **p-value<0.01 
Each variability measure entered separately and adjusted as follows: Model 1: Age, gender, smoking, BMI, diabetes, anti-
hypertensive treatment; Model 2: Age, gender, smoking, BMI, diabetes, anti-hypertensive treatment, 24h SBP 
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Table 4-5 Association between SBP BPV and Microalbuminuria   
Variability (per SD 
change in mm Hg) 
Unadjusted OR 
(95% CI) 
Model 1 OR 
(95% CI) 
Model 2 OR 
(95% CI) 
ARV:  24h ARV 
           Day ARV 
           Night ARV 
1.51 (1.27-1.79)** 
1.31 (1.11-1.56)** 
1.46 (1.24-1.74)** 
1.44 (1.19-1.73)** 
1.31 (1.10-1.57)** 
1.35 (1.12-1.63)** 
1.20 (0.97-1.47) 
1.12 (0.93-1.37) 
1.16 (0.95-1.42) 
SD:    24h SD 
          Day SD 
          Night SD 
1.10 (0.92-1.31) 
1.29 (1.09-1.53)** 
1.35 (1.15-1.60)** 
1.09 (0.90-1.31) 
1.29 (1.07-1.54)** 
1.27 (1.06-1.52)** 
0.89 (0.72-1.09) 
1.09 (0.89-1.33) 
1.06 (0.87-1.30) 
CV:    24h CV 
          Day CV 
          Night CV 
0.84 (0.70-1.02) 
1.09 (0.92-1.30) 
1.07 (0.89-1.27) 
0.87 (0.72-1.06) 
1.11 (0.92-1.34) 
1.02 (0.84-1.23) 
0.89 (0.73-1.08) 
1.12 (0.92-1.35) 
1.01 (0.84-1.23) 
wSD 1.39 (1.18-1.64)** 1.35 (1.12-1.62)** 1.10 (0.89-1.35) 
SBP Nocturnal Dip 0.70 (0.59-0.84)** 0.74 (0.62-0.90)** 0.78 (0.65-0.94)* 
24h SBP 1.78 (1.49-2.13)** 1.67 (1.38-2.02)** - 
ARV: Average real variability, SD: Standard deviation, wSD: Weighted standard deviation, CV: coefficient of variation, SBP: 
Systolic blood pressure, BP: Blood pressure, BPV: Blood pressure variability, Microalbuminuria: albumin:creatinine ratio ≥ 1.1 
mg/mmol, OR: Odds ratio *p<0.05; ** p<0.01 
Each variability measure entered separately and adjusted as follows: Model 1: Age, gender, smoking, BMI, diabetes, anti-
hypertensive treatment; Model 2: Age, gender, smoking, BMI, diabetes, anti-hypertensive treatment, 24h SBP 
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5.1 Abstract  
There are many examples of physiological processes that follow a circadian cycle 
and researchers are interested in alternative methods to illustrate and quantify this 
diurnal variation. Circadian BP deserves additional attention given uncertainty 
relating to the prognostic significance of BPV in relation to CVD. However, the 
majority of studies exploring variability in ABPM collapse the data into single 
readings ignoring the temporal nature of the data. Advanced statistical techniques 
are required to explore complete variation over 24h.    
We use piecewise linear splines in a mixed-effects model with a constraint to 
ensure periodicity as a novel application for modelling daily BP. Data from the 
Mitchelstown Study, a population based study of Irish adults aged 47-73 years 
(n=2,047) was utilized. A subsample (1,207) underwent 24h ABPM. We compared 
patterns between those with and without evidence of subclinical TOD 
(microalbuminuria). 
We were able to quantify the steepest rise and fall in SBP, which occurred just after 
waking (2.23 mmHg/30min) and immediately after falling asleep (-1.93 
mmHg/30min) respectively. The variation about an individual’s trajectory over 24h 
was 12.3mmHg (SD). On average those with microalbuminuria were found to have 
significantly higher SBP (7.6 mm Hg, 95%CI: 5.0-10.1) after adjustment for age, sex 
and BMI. Including an interaction term between each linear spline and 
microalbuminuria did not improve model fit. 
We have introduced a practical method for the analysis of ABPM where we can 
determine the rate of increase or decrease for different periods of the day. This 
may be particularly useful in examining chronotherapy effects of antihypertensive 
medication. It offers new measures of short-term BPV as we can quantify the 
variation about an individual’s trajectory but also allows examination of the 
variation in slopes between individuals (random-effects).  
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5.2 Introduction  
There are many examples of physiological processes that follow a circadian cycle 
such as cortisol, intraocular pressure and body temperature where abnormalities in 
these patterns have been shown to be related to depression [176], glaucoma [177] 
and delayed sleep-phase disorder [178]. The ability to analyse and capture features 
of these cycles remains a challenge but is necessary to get a deeper understanding 
of the mechanisms behind them. For example, the cardiovascular system shows 
clear circadian rhythmicity where researchers are interested in alternative methods 
to illustrate and quantify this diurnal variation [179]. Circadian BP represents a 
situation where diurnal variation deserves additional attention given the 
uncertainty relating to the prognostic significance of BPV [25, 32-34]. The benefits 
of using ABPM in addition to clinic measurements in the diagnosis and management 
of hypertension are well established [13, 18].  As well as mean day, night and dip 
values, ABPM provides measures of short-term BPV and individual profile patterns. 
The majority of studies examining short-term BPV have focused on summary 
measures such as the SD of ABPM readings over the day. These summary measures 
are easily obtained without the need for advanced statistical techniques [25, 32-34, 
37, 39] but ignore the temporal nature of the data. To date relatively little work has 
modelled 24h ABPM profiles to exploit the full potential of ABPM data to capture 
short-term BPV [48]. Moreover, there are a lack of studies exploring circadian 
patterns and specifically, studies examining differences in patterns among different 
groups of individuals.  
Cosinor analysis which incorporates a sinusoidal function has been the most 
common approach to modelling 24h BP [114-117], while a similar method, Fourier 
analysis [123, 124], has also been implemented. These approaches have focused on 
between-group effects (fixed-effects) where typically inferences are based on 
estimated differences in model parameters between particular groups of patients, 
such as comparing the estimated amplitude or MESOR between groups of 
individuals on different antihypertensive agents obtained in cosinor analysis [116]. 
The focus of fixed-effects is on population trajectories. However one of the main 
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advantages of ABPM is that we obtain individual BP profiles and modelling subject-
specific trajectories involves incorporating subject-specific effects (random-effects).  
To model mean profiles Selwyn et al. [106] used a hierarchical model incorporating 
a 4th degree polynomial. Lambert et al. extended on this by incorporating restricted 
cubic splines to model the mean BP profiles [48]. More recently, Edwards et al. [49] 
utilised orthonormal polynomials in a linear mixed model in a group of hypertensive 
subjects. Both polynomials and cubic splines, by their nature, have the ability to 
produce well-fitting curves to the data but have the disadvantage that the 
corresponding coefficients are challenging to interpret directly.   
As an alternative we propose using piecewise linear splines in a mixed-effects 
model as a different approach for modelling ABPM data. Although linear splines 
have been used to model BP change over years and gestational age [109], using 
them to explore daily patterns of BP represents a novel method for analysing 
ABPM. This approach has the advantage that coefficients represent something 
meaningful, in this case the slope of BP at different periods of the day. To date it is 
unclear if different underlying circadian BP patterns exist across various groups of 
the population. This method allows slopes at a group level (and individual level) to 
be easily compared. Furthermore, using random-effects we want to predict and 
plot curves at an individual level and to explore BPV within each period of the day. 
Thus the aim of this study is twofold 1) to introduce and describe a mixed-effects 
piecewise linear model in relation to BP; 2) to apply our method to a middle-aged 
population sample and explore their circadian BP patterns. We also introduce and 
present a constraint for our model that ensures periodicity, so that on the average 
BP is the same 24h later. We are particularly interested in identifying distinct 
differences in the shape of mean curves at a group level. For purposes of illustration 
of the models at a group level, we will compare those with and without evidence of 
subclinical TOD, specifically microalbuminuria.  
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5.3 Methods 
Study Population 
The analysis utilises data from the Mitchelstown Study, a population based study of 
middle-aged men and women, recruited in Ireland 2010-2011. A description of the 
study design is available from previous publications [74, 180]. The study recruited 
patients attending a single large primary care centre, the LHC, in Mitchelstown. 
Participants completed a detailed health and lifestyle questionnaire, and attended 
for a physical examination including height, weight, BP, fasting blood samples and 
urine samples. ABPM was offered to all participants. All participants provided 
written informed consent and ethical approval was obtained from the Clinical 
Research Ethics Committee Cork.  
BP Measurements 
Study BP was measured three times after 5 minutes of rest in a seated position by 
experienced research nurses using an OMRON M7 BP monitor (OMRON Healthcare, 
The Netherlands). The average of the second and third measurements was used for 
analyses. ABPM was measured using dabl ABPM system (dabl ltd., Ireland) with the 
Meditech ABOM-05 Monitor (Meditech LTD., Hungary). The monitors were 
programmed to obtain readings every 30mins and remained in place for 24h. 
Participants kept diaries of wake and sleep periods, which were used to calculate 
sleep and waking times. Only participants with a minimum of 20 measurements 
during the day and a minimum of 7 measurements during the night period were 
included in the analysis (see Appendix E) [13, 181]. Additionally, any participants 
with data lacking for more than two consecutive hourly intervals were excluded [13, 
73, 181]. 
Target Organ Damage 
Each participant provided an early-morning spot urine sample on the day of their 
appointment. Laboratory analyses included analysis for ACR. Microalbuminuria is 
defined as ACR⩾1.1 mg mmol-1 [78]. 
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Statistical Analysis 
Linear Mixed Model - Linear Splines 
The linear mixed model [87, 88] is a well-recognised tool in the analysis of 
longitudinal data and its ability to obtain both population (fixed-effects) and 
subject-specific (random-effects) trajectories makes it particularly appealing for the 
analysis of ABPM data. However, its use to-date has focused on BP following a 
smooth curvature trajectory which results in spline and polynomial coefficients that 
are of no direct clinical relevance. Piecewise linear functions or linear splines offer 
an alternative. These involve segregating the data into different segments across 
time initially assuming the segments are the same for everyone. Within each 
partition, a linear spline is fitted and where these are connected are known as knot 
points. The corresponding coefficient of each spline represents the rate of increase 
or decrease of BP during each time period.  
Knot selection 
The position of the knot points were determined based on a number of factors. 
Firstly, to get a general sense of the shape of the data and determine regions of 
interest (how many knots were required), we plotted an average curve of BP 
including all participants to determine common knot points. In addition we 
incorporated prior known characteristics of BP. The period of awakening 
corresponds with an abrupt and steep acceleration of BP and for many the 
maximum value obtained during this morning period corresponds to their 
maximum BP reached throughout the day [182]. We also know that BP gradually 
falls throughout the day and usually dips to its lowest value during the sleeping 
period [18]. Since waking and sleeping times are clearly important in terms of 
changes in BP we decided that the use of these times as two additional subject-
specific knot points was appropriate. We were able to create these subject-specific 
knots using the wake and sleep times reported by the participant. We had 49 
readings for each individual, where the first reading was t1 (12pm) and the final 
reading was t49 (12pm the following day). Individual waking and sleeping times 
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were included within this range (t1- t49). For each individual we created m linear 
splines, where the kth spline: 
 sk (t) = 0 if t ≤ tki 
                                              sk (t) = ti - tki if tk < t ≤ tki+1   for k=1,…,m                                                 
sk (t) = tki+1 - tki if t > tki+1 
(22) 
 
Incorporating these linear splines into a linear mixed effects model for BP we get: 
 
               ∑           
 
   
                     
                           ∑           ∑                          
 
(23) 
where BPij is the BP value for the j
th measurement on the ith person, at time tij, the 
β’s are the fixed effects coefficients associated with the average intercept at β0 (BP 
at 12pm) and the average slopes (βk’s) between knot points, b’s are the random-
effects associated with the average intercept (b0i) and average slopes between knot 
points, and ij representing the individual-level residuals from the model. The model 
is extended by incorporating the subject-specific knots in the sk term. It is assumed 
the random-effects (bi) have zero mean and an unstructured variance-covariance 
matrix Σb. The individual level residuals have mean zero and variance-covariance 
matrix Σ.  
To expand equation (23) to include the restriction that on the average BP is the 
same 24h later we define an equation which states average, subject-specific change 
in BP over 24h is zero: 
 
∑      
 
   
   (24) 
 
where wki is the width of the k
th interval (and where those involving wake and sleep 
times are subject-specific width intervals). Rewriting this in terms of β1 gives: 
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which implies: 
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where    
      
   
   
    , which allows us rewrite (23) as 
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                     (27) 
 
To explore a group effect the model can easily incorporate a variable of interest, in 
this case TOD (microalbuminuria), as a dichotomous covariate. We further 
extended the model allowing the shape of the trajectory to depend on TOD by 
including interactions between TOD and each linear spline slope. Comparing this 
model with one without any interactions allowed us to test if the overall trajectory 
of BP was different between the two groups across the day. Additionally we were 
able to test if slopes between the groups differed at specific locations throughout 
the day. We adjusted for confounders by adding them into the model as fixed 
effects. In additional models we tested the effect of allowing the residual variance 
to differ between those with and without microalbuminuria. Similarly we tested the 
impact of allowing the interaction terms of microalbuminuria with each linear 
spline to be random to determine if there was heterogeneity of variance between 
the groups at any period of the day. Although we used an unstructured covariance 
structure for our models, we assumed these interaction terms to be independent of 
the other random-effects parameters. These interactions represented the 
difference in variation between the microalbuminuria groups within each segment. 
For all models explored we allowed all the linear spline terms to be random.   
As individual ABPM readings taken close in time are likely to be correlated, a model 
with an independent residual correlation structure may not be appropriate. We 
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compared this to a model with a first-order autoregressive AR(1) structure and 
examined a plot of the ACF to detect violations of the assumption of independence. 
Allowing for temporal correlation can potentially result in a large improvement in 
the precision of parameter estimates [93]. 
Models were compared formally by a LRT [88, 183]. The appropriate variance and 
residual function structures were also identified using a LRT in addition with an ACF 
plot. R-squared (R2) statistic is often presented as a summary measure for linear 
models but due to theoretical or practical problems is rarely presented for mixed-
models. Nakagawa and Schielzeth discuss these issues and present a general but 
simple method for calculating an appropriate R2 for random intercept mixed-
models [184]. Johnson extended this to include random slope models which we 
implement in our analysis [185].  
The parameters for our final models were estimated using REML as this method 
produces unbiased estimates unlike ML estimation [93]. Subject-specific 
trajectories were estimated using Empirical Best Linear Unbiased Predictors 
(EBLUPs) of the random-effects [88]. Residual diagnostic plots were examined to 
verify model distribution assumptions. In addition a visual predictive check (VPC) 
was performed in which the estimated mean and the 90% prediction interval from 
our model were plotted together with the observed BP values and the 90% 
interquantile range of the observations. The purpose of the VPC is to assess 
graphically if predictions from the fitted model reproduce the central trend and 
variability of BP in the observed data, when plotted against time. It is an internal 
validation method that assesses the goodness-of-fit. [186] All analysis was 
completed for both SBP and DBP. All analysis were implemented in R [187] and 
parameter estimation for the mixed-effect model was carried out by means of the 
lme command in nlme package [188].   
Validation 
Although difficult to interpret the coefficients, polynomial regression can still be a 
useful tool in the analysis of medical data to plot the trajectory of non-linear or 
curvilinear relationships [101]. As a method of validation for our approach we 
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additionally implemented a linear mixed model with orthogonal polynomials across 
time in both the fixed and random-effects, similar to that of Edwards et al. [49]. We 
wanted to determine if linear splines were capable of capturing the circadian 
rhythm of BP. This was investigated by comparing the trajectories obtained from 
both methods to determine if they followed similar patterns. A similar process to 
that of the piecewise model was followed when fitting the polynomial model. As we 
were only concerned to know if the general shape could be captured by our 
piecewise approach we were not worried about over-fitting the polynomial model. 
We implemented a model up to a 6th order polynomial allowing all the terms to be 
random.   
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5.4 Results 
Of 3051 individuals invited to participate, 2047 (response rate: 67%) completed the 
questionnaire and physical examination component. ABPM was offered to all 2047 
participants and it was completed by 1207 (response rate: 58%) people, of whom 
1008 had a minimum of 20 day and 7 night measurements respectively. Of these 
886 had no data missing for more than two consecutive hourly intervals, and the 
main clinical characteristics of these participants are presented in Table 5-1. 
Overall, participants had a mean age of 59.9 (5.5) and the majority were female 
(55%). Sixty percent were classified as hypertensive. Also presented in Table 5-1 are 
the characteristics of the full sample which shows the ABPM sub-sample follows a 
similar distribution in terms of age, sex, BMI and the presence of microalbuminuria. 
However, the proportion of those with hypertension was higher amongst those in 
ABPM sub group than in overall study population (60% vs 47%).  
The plot of average SBP for the 886 subjects is presented in Figure 5-1. Based on 
this plot we identified two common knot points where the trajectory of SBP 
changed notably at 6pm and 4am. In addition to these two points we were able to 
include two subject-specific knot points for each participant based on the time an 
individual woke and went to sleep (Figure 5-1).  This meant each participant was 
assigned 4 knot points which in turn resulted in their SBP pattern being broken into 
5 linear segments.  
Figure 5-2 represents subject-specific trajectories as a function of time only from a 
linear mixed-effects model using both orthogonal polynomials (6th order) (red line) 
and piecewise linear splines (blue lines). The plots suggest that the individual curves 
can be adequately captured by using piecewise linear splines.  
We initially included the 5 linear splines as fixed-effects. A significant improvement 
in fit was observed when additionally including each term individually as a random-
effect, based on a LRT (all p<0.001). As a consequence we included all the linear 
spline terms as random-effects. To allow for temporal correlation we incorporated 
an AR1 structure which resulted in a significant improvement in fit (p<0.001) 
(rho=0.27). Examining the ACF plot indicated that the inclusion of an AR1 residual 
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structure adequately accounted for the auto-correlation in the data. This 
unadjusted model, which only incorporates linear splines as a function of time was 
our base model, Table 5-2 (Model 1). Presented are the parameter estimates (fixed-
effects, random-effects correlation matrix, the autocorrelation decay ρ along with 
fit criteria values). With the exception of the slope for the period from 12.00 to 
18.00 (0.02(0.04) mmHg/30min), all slopes differed significantly from zero (all 
p<0.001). This suggests that on average this is the period during the day where 
average SBP remains constant. The largest rise and fall in SBP occurred between 
wake and 12.00 (2.23 mmHg/30min) and, between sleep and 04.00 (-1.93 
mmHg/30min) respectively. These segments correspond to the period when an 
individual wakes up and the period immediately after they fall asleep. The variation 
in slopes was lowest from 12.00 to 18.00 where the variance was 0.51. The largest 
variation in slopes was observed between waking and 12.00 where the variance 
was 2.05 which is substantially larger in comparison to the rest of the day. The 
model R2 value which illustrates the proportion of variance explained by both the 
fixed and random factors was quite high (0.67). 
In subsequent models we adjusted for age, sex and BMI. We also included our 
variable of interest, microalbuminuria, to determine if it could help explain the 
larger variation in the period, wake to 12.00 (Model 2, Table 5-2). The residual 
variance, which represents the variation about an individual’s trajectory, was 
12.3mmHg. We additionally allowed the residual variance to vary between 
microalbuminuria groups (ratio of SD of those with to without microalbuminuria 
was 1.09). On average, over the day, those with microalbuminuria were found to 
have significantly higher SBP (7.6 mm Hg, 95% CI: 5.0-10.1, p<0.001). However, 
adjusting for age, sex, BMI and microalbuminuria had almost no effect on the 
model parameter estimates (except the intercept). To determine if slopes were 
different between groups at different times of the day we included an interaction 
between each linear spline and microalbuminuria (Model 3, Table 5-2). Although 
two of the interaction terms were marginally significant, a LRT suggested that 
including interaction terms did not improve the overall fit to the data (p=0.12). 
Based on additional models (results not shown) we found no evidence that the 
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variance of the random-effects varied with microalbuminuria. With the inclusion of 
age, sex, BMI and microalbuminuria we concluded that Model 2 offered the best fit 
to the data (Model 2 vs Model 1, p<0.01). Residual diagnostic plots of the models 
showed no violation of assumptions (results not shown). The VPC plot showed the 
model was adequately predicting central trend and variability of SBP in the 
observed data, when plotted against time (see Appendix C). 
Figure 5-3 represents the average piecewise linear curve along with a 95% 
confidence interval for those with and without the presence of microalbuminuria 
using Model 2. The numbers on the plot correspond to the time periods presented 
in Table 5-2. It is clear that those with microalbuminuria have a higher average SBP 
throughout the day.  For the purposes of this plot we have set the sleep and wake 
time knots at 23.00 and 08.00 respectively. A similar plot using model 3 can be 
found in Appendix C. Similar findings were found for all analysis when repeated 
using DBP (results not shown). 
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5.5 Discussion 
In this large population based study we present an alternative method of modelling 
24h BP that can easily be applied to any physiological process that follows a 
circadian cycle. Our novel but simple approach utilising a piecewise linear random-
effects model, with an adjustment to ensure that the average level is the same at 
the beginning and end of each 24h period, offers a practical alternative to other 
methodological modelling techniques for researchers exploring circadian patterns. 
The flexible model has the ability to capture overall average, group and individual 
trajectories (in addition to being capable of examining slopes at different periods of 
the day).  
Despite the large amounts of literature relating to BP, those specifically modelling 
24h ABPM remain sparse. Our method offers new measures of short-term BPV as 
we can quantify the variation about an individual’s trajectory but it also allows 
examination of the variation in slopes between individuals (random-effects). Our 
results indicated that after adjustment for age, sex and BMI the sharpest fall in BP 
occurred just after an individual went to sleep and the steepest rise occurred just 
after waking. Although there was a significant difference on average between those 
with and without microalbuminuria we found there was no overall improvement in 
fit after including interaction effects with the spline terms. However interestingly 
we found that the variation after awaking, representing what is known as the 
morning surge was considerably larger than the other periods of the day.  
It has been acknowledged there is not a generally accepted “standard” method of 
analysing 24h ABPM [49]. Cosinor analysis has been highlighted as the most 
common approach [114-117] while Fourier analysis [123], has also been 
implemented which are both based on the idea that any time series can be 
described by a series of cosine (and sine) waves of various frequencies [189]. It has 
been suggested that these methods impose too many restrictions on the shape of 
the profile and have been shown to fit real profiles poorly [119]. Wang et al. [120] 
suggest problems with fitting a sinusoidal function to a circadian pattern include (i) 
that the pattern over time may not be symmetric; that is, the peak and nadir may 
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not be separated by 12 hours and/or the amplitude and width of the peak may 
differ from those of the nadir, (ii) sometimes there are local minimum and 
maximum points. Additionally Wang et al. [121] suggests that the sinusoidal 
function is too restrictive and “rhythms with a shape closely approximating a cosine 
curve are uncommon” [122]. Alternative methods have examined restricted cubic 
splines and more recently orthonormal polynomials [48, 49]. As we highlighted 
previously these approaches may model the data quite well and their curvature 
nature may look graphically appealing but it is difficult to understand and compare 
their resulting coefficients.  
Piecewise regression which allows separate slopes to be fitted to observations 
before and after a certain period or event (knot points) has been cited as a useful 
tool that should be implemented more often in the context of epidemiological 
studies [190] but has not, to the best of our knowledge been used with ABPM data 
or other physiological processes that are circadian. The benefit of this method as 
opposed to polynomials is that the regression coefficients represent something 
meaningful directly without the need for further manipulation of the results - in our 
context, the rate of increase or decrease of BP for a certain time of day. The 
position of the knot points can easily be altered depending on the requirements of 
a specific study. For example if we were examining the effect of dialysis on BP in 
haemodialysis patients we could fix knot points at the time their dialysis began and 
at period(s) a number of hours later.  
The morning is recognised as the most important period in relation to CVDs [23] 
and cardiovascular events occur more frequently in this period [23, 45, 46]. In our 
study we found that the steepest rise (slope) occurred during the period just after 
waking which is in line with the literature, thus verifying that our method is 
capturing known features of the data. It is suggested that the abrupt steep rise in 
BP may explain the link between cardiovascular events and the morning period 
[182]. In a review of morning surge with cardiovascular risk, 3 different definitions 
of morning surge were identified, all of which simply use BP differences where they 
subtracted some average night value minus an average of morning BP readings 
[45]. We argue that our method offers a more accurate estimate, as by definition of 
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a slope we can specifically quantify the rate of “surge”. In fact, Parati et al. argue 
that a method that would be capable of capturing a slope similar to one purposed 
by our method would provide an accurate method of estimating the morning surge 
[142].  Considering that morning surge has been cited as a predictor of stroke and 
advanced TOD independent of ambulatory BP and nocturnal BP [23, 46], accurately 
quantifying it remains an important issue, particularly when we are assessing the 
benefits of antihypertensive medication in their ability to reduce this steep rise. 
This may not only have health implications but also financial benefits. A similar 
argument could be put forward for the dipping effect at night which is usually 
quantified just as a ratio of the mean BP between night-day periods. The slope at 
night obtained by our approach may represent a more accurate measure but 
further work would be needed to explore this. 
Kario argues that the perfect 24h BP control is not limited to reducing mean BP but 
includes restoring disrupted circadian BP rhythms and reducing exaggerated BPV 
[23]. As highlighted previously most studies examining BPV have concentrated on 
summary measures of variability such as SD over 24h or separated into day and 
night values [25, 32-34, 37, 39, 180]. With the use of our mixed-effects model we 
were are able to obtain superior measures of BPV that take into account the 
temporal nature of the data. We were able to quantify the variation about an 
individual’s trajectory but also the variation in slopes between individuals. Our work 
highlighted that the largest variation between individuals occurred during the 
morning surge period. Adjusting for age, sex and BMI did not help explain this 
variation. Similarly the presence of microalbuminuria had little impact on the 
variation. Ideally we would have preferred to explore if the variation could in part 
predict cardiovascular events but as data is currently only available for wave one, 
we have been restricted to explore a surrogate marker in microalbuminuria and 
have acknowledged this as a limitation. Further work is warranted to include CVD 
endpoints but perhaps an underlining physiological phenomenon of BP is that it is 
most variable in the morning possibly because this period of the day has an abrupt 
rise. Although some of the knots are subject-specific, others are at common fixed 
locations which may not represent the best position for a specific individual and this 
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assumption is recognised as a limitation. In addition to the average plot, we have 
attempted to incorporate our knowledge of the underlying pattern of BP to help 
inform our knot positions as suggested by Howe et al. [91]. 
As debate remains in relation to how to correctly quantify short-term BPV [180, 
191] our approach offers new alternatives that utilise the full power of ABPM that is 
often lost when using summary measures such as SD because it only reflects the 
dispersion of measurements around a single value (mean) not accounting for the 
order in which BP measurements were obtained [37, 40]. The ability to determine 
variation over specific periods of the day offers a novel measure of variability in the 
analysis of BP which may have benefits when attempting to determine the optimal 
timing of antihypertensive medication administration in future studies. Finally, the 
approach and discussion outlined is not restricted to the use of BP and can easily be 
implemented on any physiological process that demonstrates a circadian cycle. BP 
is not the only biological process where disruptions to circadian rhythms are clinical 
relevant. Wang et al. found that those with Cushing syndrome exhibited no 
circadian rhythm of cortisol, while those with depression showed a dampened 
rhythm compared to the normal group [121]. Liu et al. found that larger short-term 
fluctuations in intraocular pressure are more common in glaucoma [192]. Similar to 
the morning BP surge, it was found that intraocular pressure was higher in the 
morning and more prevalent in those with glaucoma. This suggests that our 
approach may be beneficial to the exploration of other biological rhythms that have 
similar features to that of BP. 
 
5.6 Conclusion 
This study has introduced a novel but practical method for the analysis of ABPM 
data. Based on our work circadian BP patterns can be modelled using a mixed-
effects model with piecewise linear splines. The main advantage of our method 
compared to other approaches is that the resulting regression coefficients have 
direct interpretation. We can determine the rate of increase or decrease at 
different periods of the day. In addition we can determine alternative measures of 
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variability compared to classical BPV indices. Future research in this area should 
focus on the association between the measures obtained from this method to 
stronger clinical outcomes.  
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Figure 5-1 Plot of average SBP over 24h which helped identify 6pm and 4am as common knot points for all participants where there 
was a notable change in trajectory of BP. Also highlighted are the periods where individuals woke and went to sleep. In addition to 
the two common points, we were able to obtain additional (two) subject-specific knot points at wake and sleep times.   
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Table 5-1 Baseline Characteristics 
Characteristic Total (n=2047) 
ABPM (sub-sample) 
Total (n=886) 
Age, y 59.8 (5.5) 59.9 (5.5) 
Gender, Male n(%) 1008 (49.2) 401 (45.3) 
BMI, n (%) 
Underweight/normal (<25kg/m
2
) 
Overweight (25-30 kg/m
2
) 
Obese (≥30 kg/m
2
) 
 
447 (21.9) 
925 (45.3) 
668 (32.8) 
 
195 (22.0) 
380 (42.9) 
310 (35.0) 
Office SBP, mm Hg 129.6 (16.9) 134.7 (17.7) 
Office DBP, mm Hg 80.1 (9.8) 83.1 (10.2) 
Hypertension, n (%) 951 (46.5) 528 (59.7) 
Microalbuminuria 215 (10.6) 62 (7.0) 
Data are mean (SD). BMI:Body mass index, ABPM: Ambulatory blood pressure monitor. Hypertension: ≥140/90 
mmHg and/or on antihypertensive treatment.  
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Figure 5-2 Individual SBP readings along with predicted subject-specific trajectories from a linear mixed effects model as a function 
of time only using two different approaches; polynomials (red line) and piecewise linear splines (blue lines). 
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Table 5-2 Various models with parameter estimates for slopes at each segment along with corresponding correlations and 
variances 
Parameter Model 1 Model 2 Model 3 
Fixed effects (SBP mmHg/30mins) Estimate (SE) Estimate (SE) Estimate (SE) 
SBP at 12.00 134 (0.54) 119.2 (4.6) 119.3 (4.6) 
Microalbuminuria        - 7.57 (1.30)* 5.79 (1.67)* 
Slope for spline time period:    
1. 12.00 – 18.00 0.02 (0.04) 0.03 (0.04) 0.03 (0.04) 
2. 18.00 - Sleep -1.00 (0.04)* -1.00 (0.04)*       -1.01 (0.04)* 
3. Sleep – 04.00 -1.93 (0.05)* -1.95 (0.06)* -1.99 (0.06)* 
4. 04.00 - Wake 1.69 (0.05)* 1.70 (0.05)* 1.71 (0.05)* 
5. Wake – 12.00 2.23 (0.07)* 2.21 (0.07)* 2.26 (0.07)* 
Microalbuminuria x Spline 
interaction 
   
1. 12.00 – 18.00         -         - -0.06 (0.14)  
2. 18.00 - Sleep         -         - 0.05 (0.13)  
3. Sleep – 04.00         -         - 0.37 (0.18)** 
4. 04.00 - Wake         -         - -0.06 (0.16)  
5. Wake – 12.00         -         - -0.48 (0.22)** 
Continued on following page    
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Parameter Model 1 Model 2 Model 3 
Fixed effects (SBP mmHg/30mins) Estimate (SE) Estimate (SE) Estimate (SE) 
    
    
Random effects    
Σ 
223.6 
-0.23   0.51 
-0.23  -0.10   0.55   
-0.23  -0.45   0.03 1.39  
0.46  - 0.28  -0.74 -0.05  0.66    
0.34   -0.06  -0.21 -0.78  0.19 2.05 
199.5 
-0.23  0.50 
-0.25  -0.10  0.54   
-0.28  -0.46  0.02  1.41 
0.47  -0.31  -0.74  -0.05  0.65   
0.42  -0.03  -0.22  -0.80  0.23 2.00 
200.5 
-0.24  0.51 
-0.25  -0.11   0.55 
-0.28  -0.44   0.02 1.40 
0.49  -0.33  -0.73 -0.04  0.65   
0.42  -0.04  -0.20 -0.81  0.24  1.97     
 12.3 12.3 12.2 
ρ 0.27 0.27 0.27 
    
R
2 
0.67 0.68 0.68 
Log-likelihood -149608 -149505 
Model 2 vs Model 1 (p<0.001) 
-149502 
Model 3 vs Model 2 (p=0.12) 
Microalbuminuria: albumin:creatinine ratio ≥ 1.1 mg/mmol 
*P<0.001,**P<0.05 
Model 1: Fixed effects (5 linear splines), random effects (5 linear splines).  
Model 2: Fixed effects (5 linear splines, microalbuminuria, age, sex, BMI), random effects (5 linear splines).  
Model 3: Fixed effects (5 linear splines and interaction with microalbuminuria, age, sex, BMI), random effects (5 linear splines). 
Random Effects matrix shown has variances on the diagonal and correlation coefficients on off-diagonals. 
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Figure 5-3 Predicted average (95% CI) piecewise linear trajectory of those with/without presence of microalbuminuria adjusted for 
age, sex and BMI using a linear mixed-effects model (Model 2). Each linear spline represents the rate of SBP increase or decrease 
(slope) for that segment and has been given a corresponding number which is referred to in Table 5-2. For the purposes of this plot 
we have set the sleep and wake time knots at 23.00 and 08.00 respectively. 
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6.1 Abstract 
BP fluctuates throughout the day. The pattern it follows represents one of the most 
important circadian rhythms in the human body. For example it is well known that 
the absence of a dip in night-time BP is associated with poor cardiovascular 
outcomes. Similarly the morning BP surge has been suggested as a potential risk 
factor for cardiovascular events occurring in the morning but the accurate 
quantification of this phenomenon remains a challenge. Here, we outline a novel 
method to quantify morning surge that can also be used to obtain other measures 
of BP variability throughout the day. 
We demonstrate how the most commonly used method to model 24h BP, the 
single-cosinor approach, can be extended to a multiple-component cosinor 
random-effects model. We outline how this model can be used to obtain a measure 
of morning BP surge by obtaining derivatives of the model fit. The model is 
compared to a FPCA which determines the main components of variability in the 
data. Data from the Mitchelstown Study, a population based study of Irish adults 
(n=2,047) was utilized where a subsample (1,207) underwent 24h ABPM. 
Our findings demonstrate that the most common approach to model ABPM, the 
single cosinor, does not provide the best fit to the data. Our two-component model 
developed with random-effects analysis provided a significant improvement in fit. 
In addition, it provided a similar fit to the more complex three-component model 
and a model captured by b-splines using functional principle component analysis. 
The estimate of the average maximum slope obtained from the derivatives from 
the model was 2.857 mmHg/30min (bootstrap estimates; 95% CI: 2.855-2.858 
mmHg/30min). Simulation results allowed us to quantify the between-individual SD 
in maximum slopes which was 1.02 mmHg/30min.  
By obtaining model derivatives we have demonstrated a novel approach to quantify 
morning BP surge and its variation between individuals. This is the first 
demonstration of a cosinor approach to obtain a measure of morning surge. 
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6.2 Introduction 
Elevated BP is the most prevalent treatable risk factor for cardiovascular disease 
affecting one billion people globally [2, 3]. It is well known that BP does not remain 
stationary but fluctuates throughout the day and follows a circadian rhythm. 
Morning surge refers to the phenomenon that occurs in individuals during the first 
few hours after waking up in the morning when there is an exaggerated spike or 
surge in BP [23, 45]. It has frequently been suggested that this surge may be a risk 
factor for cardiovascular events occurring in the morning [23, 45, 46]. However, the 
accurate quantification of this phenomenon remains a challenge. A recent meta-
analysis examining the prognostic significance of morning surge in 17 studies, 
identified seven different calculations for the term which highlights the problem 
[193].  All but one of these seven estimates involved simple subtraction of BP values 
where they subtracted some average night value minus an average of morning BP 
readings. While these measures can easily be calculated without the need for 
advanced methodology, they may not accurately quantify a surge or rate of change. 
Rather than focusing on one value (mean BP) as obtained by traditional 
measurement techniques, ABPM which obtains multiple readings over a 24h period 
offers a unique insight into an individual’s underlying circadian rhythm [13]. Parati 
et al. argue that rather than simplifying ABPM data into mean summary measures, 
incorporating all the data in more advanced models can lead to more robust 
estimates of clinically relevant parameters such as dipping status and morning BP 
surge [142]. In order to get a more advanced measure of surge, it is paramount that 
we can first accurately model ABPM.  
To date, the main approaches proposed to model 24h BP that incorporate all the 
data and fully utilise the benefits of the longitudinal nature of ABPM include the 
cosinor method [114-118], cubic splines [48], polynomials [49] and recently a 
double logistic model [194, 195]. Moreover, there is no accepted “standard” 
method for analysing ABPM [49], and research on the longitudinal analysis of 24h 
ABPM is lacking [48]. Cosinor analysis has traditionally been the most common 
approach to modelling 24h BP. This method oversimplifies the data as it attempts 
to describe a 24h circadian pattern with the use of a single sinusoidal function. The 
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assumption of a simple symmetrical pattern for diurnal BP is unable to account for 
large variation in BP over a 24h period [142]. Although not as common as the 
single-component cosinor model, attempts to extend the model by including 
multiple cos terms (Fourier analysis) allow more flexible curves to be obtained 
while remaining periodic [123-125]. The majority of the studies to date exploring 
the use of sinusoidal functions have focused on fixed-effects where the inference is 
on population effects [114-118]. A key feature of ABPM analysis however is the 
exploration of subject-specific effects (random-effects) where its use in cosinor 
models has been limited [126]. 
Thus the purpose of this study is twofold. To first demonstrate that extending the 
traditional single cosinor to a multiple-component cosinor in a random-effects 
model can be achieved while offering a substantial improvement in fit to ABPM 
data compared to the single-component model. Moreover the model is compared 
to a FPCA which determines the main components that account for the majority of 
the variation in the data. The parameters from the cosinor model are compared to 
the functional principle component scores.  
Secondly, by calculating first-order derivatives of the model fit, we present a novel 
alternative method to locate and quantify the magnitude of slopes at critical points 
on the trajectory. This simple application of derivatives allows us to quantify a 
measure of morning BP that specifically represents a surge parameter. This may be 
beneficial in future studies exploring the prognostic significance of morning BP and 
chronotherapy effects of antihypertensive medication. For purposes of illustration 
of the models at a group level, we compare first derivative curves in those with and 
without evidence of subclinical TOD, specifically microalbuminuria.  
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6.3 Methods 
Study Design and ABPM 
The analysis utilises data from the Mitchelstown Study, a population based study of 
middle-aged men and women, recruited in Ireland 2010-2011. A description of the 
study design is available from previous publications [74, 180]. The study recruited 
patients attending a single large primary care centre, the LHC, in Mitchelstown. 
Participants completed a detailed health and lifestyle questionnaire including a 
question on use of anti-hypertensive medication, and attended for a physical 
examination including height, weight, blood pressure and fasting blood samples. 
Each participant provided an early-morning spot urine sample on the day of their 
appointment. Laboratory analyses included analysis for ACR. Microalbuminuria is 
defined as ACR⩾1.1 mg mmol-1 [78]. Study BP was measured three times after 5 
minutes of rest in a seated position by experienced research nurses using an 
OMRON M7 BP monitor (OMRON Healthcare, The Netherlands). The average of the 
second and third measurements was used. The classification of hypertension was 
based on SBP≥140 mmHg and/or DBP≥90 mmHg and/or on anti-hypertensive 
treatment. ABPM was offered to all participants and was measured using dabl 
ABPM system (dabl ltd., Ireland) with the Meditech ABOM-05 Monitor (Meditech 
LTD., Hungary). The monitors were programmed to obtain readings every 30mins 
and remained in place for 24-h. Participants kept diaries of wake and sleep periods, 
which were used to calculate sleep and waking times. Only participants with a 
minimum of 20 measurements during the day and a minimum of 7 measurements 
during the night period were included in the analysis [13, 181]. Additionally, any 
participants with data lacking for more than two consecutive hourly intervals were 
excluded (see Appendix E) [13, 73, 181]. All participants provided written informed 
consent and ethical approval was obtained from the Clinical Research Ethics 
Committee Cork.  
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6.4 Statistical Analysis 
Cosinor Analysis 
The single-component cosinor model, which was first developed by Halberg [112, 
113], uses a single cosine function as a model for physiological processes that have 
a circadian rhythm. This can be extended to a multiple-component model in the 
context of BP:  
         ∑   
 
      (
   
  
    )      , i = 1,2…,n (28) 
where BP(t) is BP as a function of time (t), M is the MESOR, the average value over 
the period, A is the amplitude for each cosine term (half the difference between the 
highest and lowest values, or the distance between the MESOR and the highest 
(lowest) value), τ is the period or duration of one cycle corresponding to each 
cosine term, ϕ is the acrophase (a measure of the time of the overall high values 
recurring in each cycle for each cosine term), e is the error term and n represents 
the number of cosine curves (n=1 represents the case of the single-component 
cosinor model).  
The fixed-effects multiple-component model in equation (28) can be incorporated 
into a random-effects model. The mixed-effects model [87, 88] is a well-recognised 
tool in the analysis of longitudinal data that allows both population (fixed-effects) 
and subject-specific (random-effects) trajectories to be obtained which makes it 
useful for the analysis of ABPM data. It is assumed the random-effects have mean 
zero and an unstructured variance-covariance matrix. The individual level residuals 
(e) have mean zero and variance-covariance matrix Σe. As individual ABPM readings 
taken close in time are likely to be correlated, a model with an independent 
residual correlation structure may not be appropriate. We compared this to a 
model with a first-order autoregressive AR(1) structure and examined a plot of the 
ACF to detect violations of the assumption of independence. We determined the 
appropriate number of cosine terms by graphically comparing subject-specific 
predicted BP fits to the data (while increasing the number of terms) and formally by 
comparing models with different number of cosines using a LRT [88, 183]. Based on 
a LRT we univariately tested the inclusion of each term as a random-effect. If a 
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significant improvement was obtained, the term was included as a random-effect in 
the final model. The appropriate variance and residual function structures were 
also identified using a LRT in addition with the ACF plot.  
The parameters for our final model were estimated using REML as this method 
produces unbiased estimates unlike ML estimation [93]. Subject-specific 
trajectories were based on empirical Bayes estimates of the random-effects [88].  
Cosinor Derivatives and Morning Surge 
To obtain an estimate of the maximum morning surge we first estimate BP(t) for 
each individual from our random-effects model and then obtain its first derivative, 
BP(t)ʹ. This will give the rate of change or slope at each time of the day. Next, by 
limiting our analysis between 02:00 to 12.00 we can obtain the maximum slope and 
corresponding time during this period by numeric estimation for each individual 
which corresponds to their maximum morning slope or surge. As participants kept 
diary entries, we know their waking times. The earliest waking time is 05:00 but we 
broadened our period of interest further back to 02:00 in the unlikely event that an 
individual’s maximum surge occurred just before waking. As the shape of the data is 
not overly complex over this period, assuming only one local maximum for this time 
is a reasonable assumption.  
Cosinor Bootstrap and Simulations 
Bootstrap estimation was performed in order to get an unbiased estimate of the 
standard error for the morning slope. A total of 1000 bootstrap datasets were 
created by randomly resampling from the original dataset with replacement. The 
bootstrap estimates were examined and determined to follow a normal distribution 
from which a standard error could be obtained. Results from the analysis were used 
to obtain bias corrected 95% CI for the slopes.  
Additionally, to obtain an estimate of the between-individual variance in maximum 
slopes we ran 1000 simulations based on our final model. From this we obtained an 
estimate of the distribution of the slopes. This is similar to exploring the distribution 
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of the individual slopes from our final model but should result in a more precise 
estimate of between-person variation.  
Functional Principle Component Analysis 
The aim of FPCA is to find a combination of a few functions which capture the 
largest proportions of variation in the data. As a method of validation we compared 
model fits from the final multiple-component cosinor model to a model arising from 
FPCA. The purpose of this was to determine if the cosinor model was capable of 
capturing fluctuations in BP as well as the FPCA which is less restricted and can 
provide a flexible fit. 
We implemented a FPCA which can be seen as an analogous to multivariate PCA 
where we can identify the main types of variation in patterns as a function of time 
as opposed to discrete measures [129, 130]. Instead of eigenvectors we obtain 
eigenfunctions which are associated with each eigenvalue and represent the FPCs 
which describe the different variations in the data.  
To begin with, the mean curve was obtained through a method developed by Yao et 
al. which first ignores the hierarchical structure of the data and then fits a smooth 
curve to the pooled data [134]. This estimate of the mean curve is then used to 
obtain the covariance matrix of the deviations from the mean for each pair of time-
points. This covariance matrix is smoothed using a bivariate smoother and the main 
diagonal is removed to normalise data. This smoothed covariance matrix is then 
decomposed into a linear combination of orthogonal (uncorrelated) eigenfunctions 
and eigenvalues i.e. into its principal components and scores [133]. The first 
principal component captures the most variation, the 2nd captures the second-
most variation and so forth. Therefore, a linear combination of a few efficient 
functions can account for a high proportion of the variance. In our analysis, 10 B-
spline basis functions were used to estimate the mean function, and for the 
bivariate smoothing of the covariance function. The number of FPCs to include was 
then determined by visual inspection of a scree plot. In the context of random-
effects models these FPCs can be seen as patterns of within-subject variation 
remaining after the mean fit.  
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The weights that define the optimal fit to each function are the principle 
component scores. These can be used to obtain individual curves by multiplying the 
weights by the functions. Zero scores for an individual would result in their 
trajectory following the mean pattern. The scores would usually be estimated 
through numerical integration but with sparse data, as in the case of ABPM 
(compared to high sampling frequency data e.g. every second, that is often 
associated with functional data [131]), the approximation is sometimes deemed 
inadequate and in this case the scores were estimated by the principal component 
analysis through conditional expectation (PACE) method [133, 134]. Using this 
method the scores are estimated for each individual using their repeated measures 
while borrowing strength from the cohort with sample estimates of the mean 
function, covariance, eigenvalues and eigenfunctions [133, 134].  
As a final step the random-effects of the multiple-component cosinor model were 
correlated with the individual FPC scores from the FPCA. This allowed us to 
determine if the cosinor model and their parameters were capturing the main 
components of 24h BP obtained through FPCA which was a more elaborate, flexible 
and data driven approach. If they correlated well it would help advocate the use of 
our model.  
In a separate analysis and final method of validation we compared model fits from 
the final multiple-component cosinor model to a spline model. The purpose of this 
was to determine if the cosinor model was capable of capturing fluctuations in BP 
as well as a cubic spline model which is less restricted and can provide a flexible fit. 
We implemented a random-effects model cubic spline model with four knots at 
18:00, 24:00, 04:00 and 08:00 allowing all terms to be random similar to our cosinor 
model. It was agreed that allowing four knots gave sufficient flexibility in the curve 
to capture BP pattern. Model fits were visually compared to the cosinor model. 
Target Organ Damage  
Finally, after the model has been compared to FPCA and as a method to illustrate 
the approach outlined we run the final model separately on those with and without 
evidence of microalbuminuria. Subject-specific curves are obtained and plotted for 
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each group. In addition, mean curves for both groups, over the 24h period are 
overlaid on the same plot giving a graphical comparison. We also obtain and 
compare first derivative curves in both groups.  
Software 
All analysis including bootstrapping and simulations were implemented in R [187]. 
Although the model can be rewritten in a linear form [196], when n (number of 
cosine terms) is greater than 1 it is easier to obtain estimates of the parameters 
directly from the non-linear model as opposed to calculating them post-hoc using 
trigonometry with the linear model. For this reason the nonlinear mixed-effects 
model was solved using the nlme command in the nlme R-package [188]. Initial 
starting values were obtained from a model incorporating fixed effects only. FPCA 
was utilised using the refund R-package [197]. A shiny app was also built in R using 
the shiny R-package [198] to illustrate different model fits that can be obtained 
from our final random-effects model using simulated data based on the model. 
 
6.5 Results 
The study questionnaire and physical examination was completed by 2047 
participants (response rate: 67%). ABPM was completed by 1207 participants 
(response rate: 58%), of whom 886 had a minimum of 20 day and 7 night 
measurements and no data missing for more than two consecutive hourly intervals. 
Their main clinical characteristics are presented in Table 6-1.  
Figure 6-1 is a graphical representation of ABPM for four individuals. Included are 
subject-specific fits from a random-effects cosinor model with varying number of 
cosine terms; single, two and three-component models (n=1,2,3). It can be seen 
that the single component model offers a very simplistic curve that struggles to 
capture the shape of the data. There is a large improvement observed however 
with both the two and three-component models where large fluctuations are 
accounted for more than in the restricted single model. When visually comparing all 
the two and three-component model fits, there was little difference between them. 
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For this reason and to obtain the most parsimonious model we identified the two-
component as a satisfactory model to describe ABPM.  
The final two-component SBP cosinor model parameters estimates are presented in 
Table 6-2. Initially all the parameters were included as fixed-effects. A significant 
improvement in fit was observed when additionally including each term individually 
as a random-effect, based on a LRT (all p<0.001). As a consequence we included all 
parameters as random-effects. The MESOR or average BP over 24h was 124 mmHg. 
The values of the parameters for the first and second cosine curves are presented 
separately. As expected, the first cosine with period 24h is the dominant curve with 
amplitude of 13.2 mmHg while the second cosine curve with period 12h has 
amplitude 5.6 mmHg. Similarly, the phase shift of the first cosine is larger than the 
second one which are both measured from 12:00 in units of 30mins, 5.3 (2.6h) 
compared to 1.0 (0.5h), which corresponds to a time of approximately 14:18 and 
12:30 respectively. Exploring the random-effects covariance matrix suggests that 
there is a moderate positive correlation between the two amplitudes (r=0.51) and 
the two phase shifts (r=0.44). However, there is a weak correlation between the 
amplitudes and their corresponding phase shifts (-0.01 and -0.16). As some 
correlations were quite low we considered reducing the size of the covariance 
matrix by removing weak correlation terms but as Harrell et al. suggest removing 
separate terms in this way provides very little gains in terms of precision and power 
[199]. As a result the covariance structure was not altered. The variation between-
individuals in the first cosine amplitude was greater compared to the second (SD, 
6.1 mmHg vs 2.8 mmHg). However in contrast, there was less variation in the phase 
shift of the first cosine compared to the second (9mins vs 18mins). The within-
subject SD () was 11.9 mmHg. Examining the ACF plot indicated that the inclusion 
of an AR1 residual structure adequately accounted for the auto-correlation in the 
data. Incorporating an AR1 structure resulted in a significant improvement in fit 
(ρ=0.22, p<0.001). 
After applying the final two-component cosinor model to the data and obtaining 
the random-effects coefficients, derivatives of the function were calculated. Figure 
6-2 presents ABPM readings for three individuals with their fitted subject-specific 
140 
 
trajectories and corresponding first derivative curves. This represents the rate of 
change or slope at each time point during the day. By focusing on the morning 
period we can obtain the magnitude and location (time) of the maximum surge. The 
estimate of the maximum slope obtained from the derivatives from our final model 
was 2.857 mmHg/30min, Table 6-3. Also presented in Table 6-3 is the bias 
corrected bootstrap distribution estimates from which a standard error for the 
estimate of average maximum slope could be obtained (SE=0.0012), resulting in 
95% CI: 2.855-2.858 mmHg/30min. The simulation results allowed us to quantify 
the between-individual SD in maximum slopes which was 1.01. The distribution of 
the maximum slopes from the simulations is presented in Figure 6-3. Further 
histograms of the slopes from the original model and the bootstrap estimates were 
also obtained which provided evidence of a normal distribution (see Appendix F).  
As a separate analysis we compared a two-component model to a spline model as 
outlined previously. Model fits and derivative plots from a random-effects cubic 
spline model indicated a similar pattern giving further justification of the use of 
two-component cosinor model (see Appendix F).  
B-splines were explored in FPCA. From a visual inspection of the scree plot, three 
principle components were retained (see Appendix F). Results indicated that the 
first three FPCs which accounted for 76.3% (FPC1), 9.2% (FPC2) and 6.8% (FPC3) 
accounted for 92.3% of total variation in the data. To help visualise and interpret 
the individual FPCs, Figure 6-4 illustrates the mean curve along with the effects to 
the pattern when a small amount of the component is added and subtracted from 
the mean. It is evident that the first component which accounts for the majority of 
the variance in the data represents a relatively constant shift in the mean. 
Individuals with positive scores on the second component have a slightly higher BP 
during the day and a lower BP at night indicating a large peak-to-tough value, those 
who score negatively have a slightly lower value during the day and higher value at 
night indicating a small peak-to-trough. It can be argued that this component is 
capturing dippers and non-dippers. Individuals with positive scores on the third 
component are associated with an earlier dip at night and a large morning rise, 
those with a low value seem to be shifted to the right and have a slightly less 
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pronounced morning rise. A larger version of Figure 6-4 can be found in the 
appendix with the first six FPCs included (see Appendix F). The correlation matrix 
presented in Figure 6-5 shows strong correlations between the FPC scores and the 
individual random-effects from the two-component cosinor model. It 
demonstrates, as expected that the first principle component score summarizes the 
MESOR (mean curve). The second principle component score has a strong 
correlation with both amplitudes especially the first one (r=0.9). Similarly the third 
principle component score has a strong correlation with both phases especially the 
first one (r=0.9). A similar correlation matrix including all the FPC scores is included 
in Appendix F. 
The model was applied separately to those with and without evidence of 
microalbuminuria. A graphical comparison of the mean curves and their associated 
first-derivatives are presented in Figure 6-6. It can be seen that, on the average 
over 24h, those with microalbuminuria had higher SBP but the patterns were 
similar. As a result, the overall pattern in the rate of change over time is broadly 
similar in both groups. Although significantly lower in those with microalbuminuria, 
the difference in the maximum surge reached in the morning period between both 
groups was small, (2.6 vs 2.3 mm Hg/30mins, p<0.01). The time of the maximum 
surge reached in the morning was 08:24 and 08:39 for those with and without 
microalbuminuria respectively. At the point of their maximum first derivative or 
surge, a difference of 9 mmHg in average SBP was observed between those with 
and without microalbuminuria (129 vs 120 mmHg, p<0.01).  
In addition, we have created a simple shiny app to illustrate different fits our model 
can provide to the data. We have simulated data based on our model and fits and 
derivatives are shown to different simulated individuals. The link to the app is 
https://user632.shinyapps.io/App_Double_Cosinor/  
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6.6 Discussion 
In this study we have demonstrated that extending the traditional single cosinor to 
a two-component cosinor in a random-effects model results in a substantial 
improvement in fit. From our findings, the evidence suggested that the two-
component model offered similar fits to that of a three-component model and a 
spline model. In addition, using FPCA we have demonstrated that the main 
components of variation in the data correlate extremely well with the parameters 
from our model. By obtaining model derivatives we have demonstrated a novel 
approach to quantify rate of change of BP throughout the day. This is the first 
demonstration of the cosinor model to obtain a measure of morning surge. The use 
of FPCA on ABPM data also offers a novel method to quantify BPV.  
Considering the traditional single cosinor model has been the most commonly used 
approach for the longitudinal analysis of ABPM, further research in an attempt to 
extend the model seemed warranted. There has been much criticism of the single 
cosinor method [121, 122, 142] but we have illustrated that the inclusion of just 
one additional cosine term gives the model substantial flexibility which helps 
alleviate many of the concerns raised. The main criticism has focused on the 
unrealistic assumption that diurnal BP follows a simple symmetrical pattern. Unlike 
the single model, multiple-component models, while retaining the periodic 
property, can capture local minimum and maximum points as evident in this study. 
It has been stated that shapes closely approximating a single cosine curve are 
uncommon which is not under question [122]. We realise that a two-component 
model does not offer a perfect fit but is much more flexible than a single model and 
in order to compromise for a parsimonious model and interpretable terms, it offers 
a good alternative to other methods with fewer parameters and a similar fit (e.g. 
three-component cosinor).  
The use of FPCA enabled us to obtain the main patterns of variation in the data and 
determine how much each component contributed to the total variation in the 
data. This offers a novel method to describe variation within BP, that to our 
knowledge, has not been used before on ABPM data. The use of functional data 
analysis allows flexible fits to be obtained without the need to pre-specify a model. 
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Although similar, this is not the same as a traditional random-effects model. FPCA 
will be inherently more flexible. For example, if we consider a two-component 
cosinor random-effects model – it would assume a mean and two cosine terms with 
two different periods, FPCA however will try to estimate the “optimal” functions 
that explain the variability in the dataset. However, if the mean, a one-period 
cosine and two-period cosine are close to optimal then the rest of FPCA and the 
model fitting will be similar: random-effects will be used to estimate the subject-
specific coefficients for each of these functions. The fact that the random-effects 
from our model correlated well with the FPC scores help justify the use of our 
model. To elaborate, the two-component model correlates well with the optimal fit 
obtained through FPCA. Our finding that the first FPC correlates exactly with the 
mean value is not surprising where other studies have found in practise, the first 
FPC is essentially a mean shift [132, 200]. Not only do our values correlate, visually 
examining the effects of the scores on the mean pattern illustrate that the main 
components refer to a mean shift, peak-to-tough and a shift left to right which is 
being captured by the parameters of the cosinor model. In fact using FPCA and the 
cosinor model together complement each other well. Sometimes interpreting FPCs 
can be difficult and subjective but when it is used in parallel with a cosinor model 
and results correlate so well it is easier to explain findings. Although not as directly 
interpretable as a single-cosinor model, the two-component model is still more 
intuitive than for example, a spline model. An individual’s amplitude being made up 
of the weighted sum of two cosine amplitudes throughout the day is more intuitive 
than an arbitrary spline coefficient. In addition, the MESOR which is the average 
over 24h represents the most important parameter of BP. 
Of the definitions identified in the recent meta-analysis examining the prognostic 
significance of morning surge, only one used a more advanced technique than 
simply obtaining differences between arbitrary night and day averages [193]. Head 
et al. developed a six parameter double logistic model which is characterised by a 
day and night plateau of variable length, an independent slope for the fall and rise 
over the day and a midpoint for each transition [194, 195].  The double logistic 
model can be used to obtain the rate of rising during the morning period and the 
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power of the morning surge which is the derivative of the curve multiplied by the 
amplitude [201]. However, it has been suggested that the parametric structure of 
the model is very simple and because of the day and night plateaus important BP 
fluctuations may be averaged out [142]. The approach does however offer 
alternative morning BP measures that attempt to incorporate more data in a 
mathematical model than traditional methods and Head et al. have tried to refute 
some of the criticism. They argue that their model is quite flexible and can follow a 
single-component cosinor model, a saw tooth shape in either direction as well as a 
square wave-like shape [143]. There are, however, some limitations. Importantly, 
they stress that the model cannot capture complex fluctuations associated with 
multiple-component cosinor models and can miss short-term peaks. Research 
suggests that more complex patterns such as the ones obtained through our 
approach are not necessarily an advantage as it may be difficult for an investigator 
to obtain a coherent picture from wavy curves [143]. This may be true if the sole 
purpose is to decipher individual model fits. We argue however the main purpose 
of our method is to obtain an estimate of morning slope through derivative 
estimation and this requires capturing the most accurate curve possible while 
simultaneously obtaining interpretable parameters that describe it. Obtaining the 
balance between obtaining complex curves and interpretable parameters is 
difficult. Complex wavy curves will not alter our ability to describe in simple terms 
the rate in change or surge. In addition their analysis has focused on analysing each 
individual ABPM curve one by one which will result in inflated standard errors for 
their estimates unlike our model that incorporates random-effects. 
The use of estimated derivatives in medical research can often offer new, intuitive 
clinical markers [202, 203]. In the context of modelling ABPM, considering the 
emphasis is on exploring curves, the use of derivatives is surprisingly rare. As 
highlighted we have demonstrated that obtaining derivatives from the cosinor 
model offers a novel method of determining morning slope that has not to the best 
of our knowledge been implemented elsewhere. An advantage of this approach is it 
is not restricted to the analysis of morning slope but can be used to obtain critical 
points throughout the day e.g. dip. We have focused our analysis in this study to 
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morning BP due to the substantial literature surrounding its potential prognostic 
significance and the debate surrounding its quantification [23, 45, 46, 193]. 
Morning parameters to date have focused on summary measures, usually the 
difference between a pre-awaking value and post-waking value [193]. The primary 
issue with this approach is that by definition, a morning surge represents a spike or 
rate of increase in BP during this period which is not accurately captured by 
differences between two time points. We propose that our method which 
specifically obtains a rate of change parameter is a better estimate. In fact Parati et 
al. argue that a tangent with the steepest slope to a curve from a model that 
accurately captures morning BP could be the most appropriate estimate of the 
morning rise in BP [142]. Provided the model fits the data well, estimates derived 
from it should be more robust which in turn will lead to more precise inferences 
being made to outcomes. Despite our comprehensive knowledge of BP, obtaining 
new measures and methods to model BP remains a crucial research priority which 
may help advance our understanding of different aspects of BPV including morning 
surge [52, 66]. This may be particularly useful in clinical trials where we may be able 
to provide evidence that a new antihypertensive medication outperforms another 
in a way we would not traditionally be able to detect e.g. their mean values may 
indicate no difference.  In this study, we illustrated how the model can be 
compared in two groups using those with and without evidence of 
microalbuminuria as an example. Although the microalbuminuria group had higher 
SBP, there was little difference in the pattern of the curves. This was similar to 
findings observed in Chapter 5 when we examined the same data using a piecewise 
linear model. Using that approach, we found no evidence to suggest the overall 
shape differed, although the microalbuminuria group had significantly higher SBP. 
In addition, the slope parameter that was obtained for the morning period using 
the piecewise approach (2.21 mmHg/30mins) is similar to the cosinor approach 
(2.86 mmHg/30mins). It must be noted that the cosinor method obtained a 
maximum value while the piecewise approach obtained an average value. A 
comparison of both methods using hard endpoints (cardiovascular events) as 
opposed to a surrogate marker of CVD is recommended in future work.  
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There are a number of limitations to the study. Primarily, we note the model does 
not give the optimal fit to the data (although the parameters correlated well with 
the more flexible FPCA). In fact, it is acknowledged that it is extremely difficult for 
any model to capture all the features of a 24h BP profile simultaneously. Perhaps 
the chosen model should be dependent on the research question posed. For 
instance as highlighted complex models may not be the most intuitive to 
understand directly but if the purpose is to obtain a BP measure (e.g. morning 
surge, dip) from the model post-hoc through additional analyses (derivatives), an 
initial simple model may not necessarily be the best choice. Another limitation of 
the study was that we were not able to include the effect of antihypertensive 
medication in the analysis. Although we knew if a participant was on treatment, we 
had insufficient data on the specific class of antihypertensive medication the 
individual was prescribed which meant drug-class comparisons were not possible.  
In conclusion, we have demonstrated a simple method to obtain a measure of 
morning BP surge using a random-effects multiple-component cosinor where our 
focus was not only at a group level but also the individual level. In addition to the 
ability of the model to obtain estimates for the morning BP, we derived derivatives 
of the circadian curves which allow us to locate and quantify the magnitude of 
other slopes at critical points on the trajectory. The approach offers novel 
alternative methods of quantifying new BP indices that may be useful in the 
exploration of BPV where there remains debate over its prognostic significance. The 
use of FPCA also offers a new alternative approach to quantify BPV. Considering the 
single-component cosinor has been the most common method of analysis for 
ABPM, a recommendation for future studies from the evidence presented in this 
study is to incorporate a second cosine in the context of a random-effects model. 
The method offers a substantial improvement in fit compared to the traditional 
cosinor that is capable of capturing short-term peaks and can be implemented in 
standard statistical software. Future studies should also investigate the clinical 
prognostic significance of the morning surge parameter obtained through the 
analysis outlined in this study.  
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Table 6-1 Baseline Characteristics 
Characteristic Total (n=2047) 
ABPM (sub-sample) 
Total (n=886) 
Age, y 59.8 (5.5) 59.9 (5.5) 
Gender, Male n(%) 1008 (49.2) 401 (45.3) 
BMI, n (%) 
Underweight/normal (<25kg/m
2
) 
Overweight (25-30 kg/m
2
) 
Obese (≥30 kg/m
2
) 
 
447 (21.9) 
925 (45.3) 
668 (32.8) 
 
195 (22.0) 
380 (42.9) 
310 (35.0) 
Office SBP, mm Hg 129.6 (16.9) 134.7 (17.7) 
Office DBP, mm Hg 80.1 (9.8) 83.1 (10.2) 
Hypertension, n (%) 951 (46.5) 528 (59.7) 
Data are mean (SD). BMI:Body mass index, ABPM: Ambulatory blood pressure monitor. Hypertension: ≥140/90 mmHg and/or 
on antihypertensive treatment.  
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Figure 6-1 ABPM readings (circles, thin black line) of four individuals along with 
predicted subject-specific trajectories from a random-effects model as a function 
of time using (i) single cosinor (thick black line) (ii) two-component cosinor (thick 
red line) and (iii) three-component cosinor (thick blue line) models.  
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Table 6-2 Model parameter estimates (SBP) along with corresponding correlations 
and variances 
Parameter Model  
Fixed effects Estimate (SE) 
24h MESOR (mmHg) 124 (0.44)* 
First Cosine (24h period):  
Amplitude (mmHg) 13.2 (0.23)* 
Phase shift (30mins) 5.3 (0.02)* 
Time of phase shift  14:18 
Second Cosine (12h period):  
Amplitude (mmHg) 5.6 (0.14)* 
Phase shift (30mins) 1.0 (0.03)* 
Time of phase shift 12:30 
  
Random-effects  
Σ 
172.3 
0.18   37.0 
-0.03  -0.01   0.1   
0.30   0.51  -0.14  7.8  
-0.03  0.01   0.44  -0.16  0.4    
 11.9 
ρ 0.22 
*P<0.001, Random-effects matrix shown has variances on the diagonal and correlation coefficients on off-diagonals.  
Phase shift measured from 12:00 noon. Time presented in 24h clock. 
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Figure 6-2 ABPM readings of three individuals with fitted subject-specific 
trajectories from a two-component cosinor random-effects model (left panels). 
Their corresponding rate of change curves (first derivatives) are also plotted on 
right panels (red line indicating reference zero mark).  
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Table 6-3 Maximum Morning Surge (mmHg/30mins) 
 Median Mean Variance/CI 
Original model  2.779 2.857 0.994 
Simulations (1000) 2.840 2.840 1.040 
Bias Corrected Bootstrap 2.857 2.857 CI (2.855 - 2.858) 
 
 
 
 
Figure 6-3 Histograms of maximum morning slope by simulations 
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Figure 6-4 FPCA: Each of the first three FPCs as variations about the mean along with the percentage of total variation explained by the 
component. The solid black line represents the mean SBP over the day and the functions obtained by adding and subtracting ± SD of the 
eigenfunctions to the mean. Plus signs indicate addition and minus signs indicate subtraction. 
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Figure 6-5 Scatter plots and the corresponding correlations between the two-component random-effects cosinor model parameters and the 
first three FPC scores from FPCA.   
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Figure 6-6 A two-component cosinor random-effects model implemented separately on those with and without presence of 
microalbuminuria. Subject-specific curves for those with (black lines) and without (light grey lines) evidence of microalbuminuria are also 
displayed. Red (microalbuminuria) and blue (no microalbuminuria) lines represent average curves for both groups. The corresponding first 
derivative curves indicating the rate of change over the day for both groups are also presented.               
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7.1 Introduction  
The use of ABPM provides the ability to classify individuals into different 
hypertension categories that cannot be achieved with a clinic BP reading. The 
reproducibility of these hypertension categories has been examined with 
inconsistent results [204-207]. Of particular interest is nocturnal hypertension 
which is a predictor of CVD and mortality [15, 16, 208]. However, the limited 
reproducibility of night-time BP patterns is recognised [209] and using absolute BP 
categories rather than dipping status may be more reproducible [210]. Yet, of those 
with isolated nocturnal hypertension (defined as nocturnal hypertension without 
daytime hypertension) at baseline only one third retained this pattern after 2 to 4 
years in one small study [211]. This was again examined more recently in a 
community-based sample of adults (n=282) with similar findings where isolated 
nocturnal hypertension had poor reproducibility four weeks apart [212].  
The majority of studies examining changes in ABPM readings between two time-
points have focused on mean values and hypertension categories. Few longitudinal 
studies explore how variability changes between two ABPM readings. McDonald et 
al. found that while mean BP did not change, BPV, measured by day/night/24h SD 
and coefficient of variation, were significantly higher at 10 year follow-up compared 
to baseline in a community cohort of older people (n=83, median age 70 years) 
[213]. The percentage of patients taking antihypertensive medication increased 
from 46% at baseline to 69% at follow-up which may explain no change in mean BP. 
Conversely, in a community sample of 162 individuals aged 55 to 80 years, 
Goldstein et al. found that mean BP increased while day and night variability 
measured by SD decreased over two time-points 5 years apart [214]. Although 
there were no individuals diagnosed with hypertension at baseline, 14 subjects had 
BP with hypertensive levels. At baseline, no participant was on antihypertensive 
medication while there were 14 at follow-up.   
In addition to exploring changes in hypertension categories and variability, we are 
interested in the reproducibility of the overall shape of the BP trajectories. 
Examining changes to variability measures only allows us to quantify changes in 
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fluctuation about the circadian rhythm but does not inform us if the pattern is 
changing. For example, an individual’s BP trajectory may follow a similar pattern 
when measured at a second time-point but the variability about the pattern could 
increase or decrease. The purpose of this study is to outline an approach that can 
be used to comprehensively interrogate the reproducibility of ABPM readings over 
time. Changes in hypertension categories and variability measures are explored 
between two ABPM readings four years apart. In addition, parameters from a two-
component cosinor model at each time-point are compared as a method of 
comparing changes in the shape of the circadian rhythm.  
 
7.2 Methods 
Baseline ABPM was obtained from the Mitchelstown Study, a population based 
study of middle-aged men and women, recruited in Ireland [74]. ABPM 
measurements were performed using the MEDITECH ABPM-05 in 2010 and data 
was stored using the dabl ABPM system (dabl ltd., Ireland). Based on the initial 
ABPM results the sample was divided into 4 groups: normotension, isolated 
nocturnal hypertension, isolated daytime hypertension and day-night hypertension 
[81]. Twenty participants were randomly selected from each group and invited to 
attend for follow-up ABPM measurements in 2014 using the Spacelabs 90217 
monitor. Data was stored using the Spacelabs 92506 Ambulatory BP Report 
Management System software.  
For both time-points, the monitors were programmed to record the BP every 30min 
throughout the 24h period. Participants kept a diary of the times they went to bed 
and got up. Diary times were used to calculate mean daytime and night-time BP. 
Mean 24h BP was calculated as the mean of all the readings throughout the 24h 
period. Use of antihypertensive medication was also recorded at both time-points. 
Night-time BP was categorised by dipping status as follows: 
(1) Dipping pattern: 10 to 20% fall in night-time SBP  
(2) Non-dipping pattern: <10% fall in night-time SBP  
(3)  Extreme dipping pattern: >20% fall in night-time SBP  
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(4)  Reverse dipping pattern: Rise in night-time SBP 
 
BP was also categorised based on the absolute BP levels into four groups: 
(1) Normotension: Daytime BP <135/85mmHg and night-time BP <120/70mmHg 
(2) Isolated daytime hypertension: Daytime BP ≥135/85mmHg and night-time BP 
<120/70mmHg 
(3) Isolated nocturnal hypertension: Daytime BP <135/85mmHg and night-time BP 
≥120/70mmHg 
(4) Sustained day-night hypertension: Daytime BP≥135/85mmHg and night-time BP 
≥120/70mmHg 
 
As indices of short-term BPV, we estimated the SD over 24h, wSD, coefficient of 
variation ((24h BP SD / 24h BP mean)*100) and ARV. The wSD is the mean of day 
and night standard deviation values corrected for the number of hours included in 
each of these two sub-periods. The ARV averages the absolute differences between 
consecutive measurements.  Additional indices of SD, coefficient of variation, and 
ARV were calculated for both the day and night periods. 
 
7.3 Statistical Analysis 
Data are presented as the arithmetic mean (SD). The difference between the two 
ABPM results was assessed using a paired t-test. The reproducibility of night-time 
dipping status and absolute BP patterns were assessed using Cohen’s kappa 
statistic. Agreement between the measurements was plotted using the Bland-
Altman method. The per cent change in variability measures between the two time-
points was calculated as the difference between the measures divided by the initial 
value. Changes of less than 5% were regarded as reproducible [205]. To quantify 
changes in the shape of BP as opposed to variability, a two-component random-
effects cosinor model (see Chapter 6) was utilised on both time-points separately. 
Comparing model parameters between time-points identified differences in the 
shape of the curve. Empirical Bayes estimates were obtained for both time-points 
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for each individual and overlaid on the same plot giving a graphical comparison of 
the curves.  
In addition, to determine how much of the variation in the difference between 
parameters over the two time-points can be attributed to measurement error, a 
simulation was performed: 
(i) A random-effects cosinor model based on the data from the first time-
point (2010) was used to estimate the mean parameter values, the 
variance covariance matrix of the random-effects, and the variance of 
the error term. 
(ii) Subject-specific average curves were determined based on a random 
sample (n=47, same as the original sample size) from the estimated 
parameter coefficient distribution.  
(iii) Observed values at 30min intervals were generated by adding random 
error to the values generated in (ii)  
(iv) Step (iii) was repeated to generate a second dataset  
The two simulated datasets were then analysed separately representing two 
different time-points. As before, the difference between model parameters was 
obtained. However, using the simulated datasets, any differences observed was 
due to measurement error. Thus, by comparing this variation to the variation 
observed between the actual readings taken at the two time-points, we can 
determine what percentage of the total variation is due to measurement error. This 
was repeated for n=1000 participants to examine if sample size effected the 
differences observed. Using the simulated data, a similar approach was used to 
explore how much of the variation in the differences in BPV summary measures 
over time could be attributed to measurement error. All analysis was implemented 
in R.  
7.4 Results 
At baseline, 1207 participants (response rate: 58%) underwent ABPM. At four years 
follow-up 80 participants were invited to attend for repeat ABPM and fifty 
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(response rate: 63%) of these participants consented to participation in the follow 
up study. We excluded three participants from the current analysis due to 
incomplete follow-up ABPM data giving a sample of 47 for this study. The mean 
period of follow up was 3.9 years. Raw SBP data for four individuals over 24h for 
the two time-points is presented in Figure 7-1, plots for all individuals are included 
in the Appendix G. Overall mean BPs were similar in 2010 and 2014, Table 7-1. The 
correlation between age and mean SBP was the same in 2010 and 2014 (r=0.17). 
Agreement between the two time-points for BP is given by the Bland-Altman plots 
in Figure 7-2. The reproducibility of BP profiles categorised by dipping status was 
low at 24% with a kappa statistic of -0.11 (p = 0. 89) while reproducibility based on 
categorisation by absolute BP was fair at 40% with a kappa statistic of 0.21 (p < 
0.005), Table 7-2 and Table 7-3. 
Overall, compared to baseline, BPV at follow-up had reduced, Table 7-4. However, 
only SBP variability, measured by wSD, SD and ARV, over 24h and the night period 
had fallen significantly. The Bland-Altman plots for both 24h SD and ARV are given 
in Figure 7-3, where a large spread is observed. Reproducibility of 24h SD (17%), 
ARV (10%) and wSD (23%) was poor. Parameters from a two-component cosinor 
model were obtained for both time-points, Table 7-5. With the exception of the 
second phase, all cosinor parameters were similar four years later. The variation in 
the difference in MESOR between time-points that could be attributed to 
measurement error based on simulations was low (3%), Table 7-6. Measurement 
error explained 19% and 32% of the variation in the difference in amplitudes, 
between the two-points, for the first and second cosines respectively. However, 
measurement error explained a larger amount of the total variation in the 
differences in the first (62%) and second phase shifts (88%). Repeating the 
simulations based on 1000 participants made little difference to our findings, Table 
7-6. Bland-Altman agreement plots for the various parameters are presented Figure 
7-4 and Figure 7-5. Reproducibility of MESOR (36%), first amplitude (14%), first 
phase shift (51%), second amplitude (21%) and second phase (4%) was poor. A 
separate boxplot of the differences between the parameters is given in Figure 7-6 
showing a relatively even spread in the data. Using the simulated data, 
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measurement error between time-points accounted for 79%, 22% and 41% of the 
total variation in the differences of 24h ARV, SD and wSD respectively. Cosinor 
model fits for six individuals is provided in Figure 7-7 highlighting how the overall 
shape of the trajectory for two ABPM readings can easily be compared by 
overlaying the curves.  
The use of antihypertensive medications increased between 2010 and 2014 from 
42% (n=21) to 61% (n=30). In analysis limited to those not on medication (n=17) the 
kappa statistics were -0.2 (p = 0.9) for dipping status and 0.43 (p <0.001) for 
absolute BP categories. Mean BPs for those not on medication were similar in 2010 
and 2014. Moreover, there was no change in variability measures for individuals 
not on medication. However, for those on medication, variability measured by wSD, 
SD and ARV, over 24h (all SBP) remained significantly reduced while the mean BP 
was similar.  
 
7.5 Discussion 
We have outlined methods to compare two ABPM readings taken at separate 
occasions. No one method can fully capture the reproducibility of a circadian BP 
trajectory but we have explored approaches that can account for the main features 
including the comparison of mean and variability values, hypertension 
categorization and a comparison of the shape of the curves. Our findings 
demonstrate the limited reproducibility of night-time BP profiles with poor 
reproducibility of dipping status and only fair reproducibility of absolute BP 
categories despite overall similar mean BPs. On average, variability measured by 
wSD, SD and ARV (all SBP only) significantly reduced over 4 years but reproducibility 
within the measures was fair.  Finally, parameters from a two-component cosinor 
model which can be used to describe the shape of BP trajectories demonstrated 
that on the average patterns were similar but reproducibility of the parameters was 
poor.  
 
Long-term changes in ABPM variability have rarely been explored. However, our 
findings are similar to Goldstein et al. who reported a reduction in variability over 
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two time-points 5 years apart in a similarly aged sample [214]. This is in contrast to 
McDonald et al. who reported BPV obtained by ABPM increased over a 10 year 
follow-up in an older sample [213]. Changes in mean SBP variability, despite no 
significant change in mean SBP is an interesting finding. There has been significant 
work over the last decade to control mean BP levels, coupled with advancements in 
antihypertensive therapy and perhaps an absence of an increase reflects these 
efforts. Much of the debate regarding BPV focuses on antihypertensive 
medications. While different classes of antihypertensives have similar BP lowering 
effects; significant differences between classes in their effects of BPV have been 
observed. Some studies suggest that calcium channel blockers and diuretics are 
superior to other drugs in reducing BPV and preventing stroke and other vascular 
events compared to other classes [61, 160]. In our study, the use of 
antihypertensive medications increased over the four years between the BP 
measurements. While the effect over time on mean BP was similar irrespective of 
medication use, BPV differed by medication use. Although numbers were small and 
hence, power was limited, we were still able to detect a significant reduction in BPV 
within the group on medication. In contrast, there was no difference in BPV over 
time for those not on medications. An analysis stratified by type of anti-
hypertensive class was not possible and is recognised as a study limitation. 
 
Overall reproducibility was poor on all features of the circadian pattern. BP is a 
continuous risk factor [215]. Thresholds define the levels where investigation and 
treatment do more good than harm [216], and for this reason are important but 
clinicians and public health professionals need to recognise the limitations of 
thresholds and that significant numbers of events occur in those below definitions 
of normal [217].  
 
Using simulations, we were able to obtain the fraction of the total variation in the 
changes between time-points that was attributable to measurement error alone. If 
there was no change in the true readings between the two time-points, the only 
difference observed would be due to random error. Assuming a two-component 
cosinor model is an adequate fit for ABPM, which has been illustrated in Chapter 6, 
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we can estimate this random error. Comparing changes in summary BPV measures 
and model parameters from the two simulated datasets to the changes using the 
actual measured readings allow us to quantify the influence of measurement error 
between time-points. This highlights a benefit of using a random-effects model 
when examining reproducibility where the variance of differences between time-
points can be separated into measurement error and true changes that have 
occurred during the intervening time-period.   
 
The two-component cosinor model we have outlined provides a method that not 
only quantitatively assesses differences in the overall shape of two ABPM readings, 
but also offers a quick graphical comparison that may be useful in clinical practice 
when a clinician is trying to gauge changes in an individual’s underlying circadian 
rhythm. The inclusion of the predicted curves in ABPM reports, in combination with 
the standard output may improve clinical decisions and ultimately, BP control. 
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Figure 7-1 Data from four individuals 2010 vs 2014 
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Table 7-1 BP levels 2010 v 2014 
N =47 2010 2014 p-value 
Daytime systolic  133 129 0.05 
Daytime diastolic 79 77 0.2 
Night-time systolic 117 114 0.1 
Night-time 
diastolic 
66 66 0.9 
Twenty four 
systolic 
127 123 0.05 
Twenty four 
diastolic 
74 73 0.3  
 
 
Figure 7-2 Bland-Altman scatter-plots of agreement of measurements of 24h SBP 
and 24h DBP four years apart. The x-axis represents the mean of the two 
measurements and the y-axis represents the difference between them. The black 
dashed lines represent the mean and limits of agreement. The dashed red lines 
represent the 95%CI for the differences in mean values. 
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Table 7-2 Dipping status 2010 v 2014 
 2014 
2010 Dippers Non-
dippers 
Extreme 
dippers 
Reverse 
dippers 
Total 
Dippers  5 11 5 1 22 
Non-dippers 8 3 2 2 15 
Extreme 
dippers 
2 3 1 0 6 
Reverse dippers 1 1 0 2 4 
Total 15 18 8 5 47 
kappa statistic = -0.11 (p = 0. 89) 
 
Table 7-3 BP categories 2010 v 2014 
 
 
 
 
 
 
 2014 
2010 Isolated 
nocturnal 
hypertensio
n 
Day/night 
hypertensio
n 
Isolated 
daytime 
hypertensio
n 
Normotensio
n 
Total 
Isolated 
nocturnal 
hypertension 
4 1 0 7 12 
Day/night 
hypertension 
2 3 2 4 11 
Isolated 
daytime 
hypertension 
1 6 3 4 14 
Normotension 1 0 0 9 10 
Total 8 10 5 24 47 
kappa statistic = 0.21 (p < 0.005) 
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Table 7-4 Variability Indices 2010 v 2014  
Variability 
Measure 
24-hour (mm Hg) Day (mm Hg) Night (mm Hg) 
2010 2014 2010 2014 2010 2014 
ARV SBP 11.7 (2.5) 10.4 (2.2)** 12.2 (3.1) 11.2 (2.9) 11.1 (3.5) 9.2 (2.9)** 
ARV DBP 7.8 (2.2) 7.5 (1.6) 8.2 (2.5) 8.0 (2.1) 7.1 (2.5) 6.7 (2.2) 
SD SBP 15.9 (4.0) 14.6 (4.1)* 13.0 (3.0) 12.5 (3.7) 12.2 (4.1) 10.1 (3.7)** 
SD DBP 11.3 (3.5) 10.1 (2.7) 8.9 (3.0) 8.8 (2.1) 8.4 (2.7) 7.2 (2.6) 
CV SBP 12.5 (3.1) 12.0 (3.2) 9.8 (2.1) 9.8 (2.8) 10.4 (3.3) 8.8 (2.8) 
CV DBP 15.3 (4.4) 14.1 (4.1) 11.3 (3.5) 11.6 (3.2) 12.8 (4.0) 11.1 (4.0) 
wSD SBP 12.7 (2.7) 11.7 (3.2)* - - - - 
wSD DBP 8.8 (2.4) 8.3 (1.8) - - - - 
Abbreviations: ARV: Average real variability, SD: Standard deviation, wSD: Weighted standard deviation, CV: coefficient of 
variation, SBP: SBP, DBP: Diastolic BP. Data presented as mean(SD). *p<0.05; **p<0.01 represents significance between 2010 
and 2014 for each period of the day 
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Figure 7-3 Bland-Altman scatter-plots of agreement of measurements of 24h SBP 
SD and 24h SBP ARV four years apart. The x-axis represents the mean of the two 
measurements and the y-axis represents the difference between them. The black 
dashed lines represent the mean and limits of agreement. The dashed red lines 
represent the 95%CI for the differences in mean values. 
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Table 7-5 Comparison of SBP parameters from two separate two-component random-effects cosinor models (2010 vs 2014)  
SBP Parameter Model Estimate (SE) 
Year = 2010 
Model Estimate (SE)  
Year = 2014 
24h MESOR (mmHg) 127.1 (1.6) 123.2 (2.0)* 
First Cosine (24h period):   
Amplitude (mmHg) 11.4 (1.3) 9.7 (1.1) 
Phase shift (30mins) 5.0 (0.8) 5.1 (0.1) 
Time of phase shift  14:30 14.33 
Second Cosine (12h period):   
Amplitude (mmHg) 3.6 (0.6) 3.5 (0.7) 
Phase shift (30mins) 0.6 (0.1) 1.6 (0.1)* 
Time of phase shift 12:18 12.48 
 12.7 11.5 
*p<0.05 represents significance between 2010 and 2014, Phase shift measured from 12:00 noon. Time presented in 24h clock. 
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Table 7-6 Comparison of SBP parameters from two separate two-component random-effects cosinor models (2010 vs 2014) 
SBP Parameter Total Variation in Differences Variance due to Measurement Error (% of Total Variance) 
Based on 47 Simulations            Based on 1000 Simulations 
24h MESOR (mmHg) 168.1 5.6 (3.3%) 6.1 (3.6%) 
First Cosine (24h period):    
Amplitude (mmHg) 42.2 8.1 (19.2%) 8.8 (20.9%) 
Phase shift (30mins) 2.1 1.3 (61.9%) 1.1 (52.4%) 
Second Cosine (12h period):    
Amplitude (mmHg) 6.6 2.1 (31.8%) 1.9 (28.8%) 
Phase shift (30mins) 1.7 1.5 (88%) 0.9 (52.9%) 
*p<0.05 represents significance between 2010 and 2014, Phase shift measured from 12:00 noon. Time presented in 24h clock. 
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Figure 7-4 Bland-Altman scatter-plots of agreement of measurements of the first 
and second amplitudes four years apart. The x-axis represents the mean of the 
two measurements and the y-axis represents the difference between them. The 
black dashed lines represent the mean and limits of agreement. The dashed red 
lines represent the 95%CI for the differences in mean values. 
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Figure 7-5 Bland-Altman scatter-plots of agreement of measurements of the first 
and second phase shifts four years apart. The x-axis represents the mean of the 
two measurements and the y-axis represents the difference between them. The 
black dashed lines represent the mean and limits of agreement. The dashed red 
lines represent the 95%CI for the differences in mean values.  
 
 
Figure 7-6 Boxplots of differences between each of the cosinor parameters 
between the two time-points (2010 minus 2014). 
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Figure 7-7 Comparison of fits, 2010 vs 2014, for six individuals using two separate 
two-component random-effects cosinor models. 
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8. DISCUSSION 
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This thesis aimed to explore circadian BP patterns by reviewing current and 
previous approaches for analysing ABPM data and describes novel methodologies 
that offer new measures of BP and may help us to obtain new insights into BP.  The 
recent debate towards the prognostic significance of BPV and how it is quantified 
was the original motivating reason to undertake the analysis. The thesis first 
explores summary measures used to describe fluctuations in circadian patterns and 
then goes beyond this to obtain other indices through more advanced methods. 
This chapter outlines the main findings, and strengths and limitations of the thesis. 
Recommendations for areas of future research and a brief conclusion are also 
outlined. 
8.1 Summary of Main Findings 
In Chapter 3, the systematic review collated data to identify current summary 
measures that are used to quantify BPV and explored their association with the 
presence of TOD, specifically LVH. Four measures were identified; SD, ARV, wSD and 
CV. The meta-analysis suggested there is a weak positive correlation, between all 
measures of BPV and LVMI. Despite recent interest in the subject of BPV the 
systematic review highlighted the lack of good epidemiological studies exploring 
the relationship between BPV and LVH. The fact that there were so few studies 
(n=12) and only data available to perform a meta-analysis of such a weak marker 
(correlation coefficient) is evidence of this. In addition, a third of studies in the 
systematic review did not make adjustment for mean BP in any of their analysis 
which is a major methodological limitation. This is an important issue in the context 
of BPV: the adjustment for mean BP. The significance of mean BP has been well 
documented and is not under question but in order to determine if BPV is an 
additional clinic target it is paramount that any analysis adjusts for average BP. 
In Chapter 4, following on from the systematic review, the measures identified 
were calculated for the Mitchelstown ABPM dataset and their association with 
subclinical TOD, documented by microalbuminuria and ECG LVH, were examined. 
The study found no association between any measure of BPV and LVH. Conversely, 
we found all but one measure (CV) associated with microalbuminuria and remained 
associated after adjustment for age, gender, smoking, BMI, diabetes and anti-
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hypertensive treatment. However, when the models were further adjusted for 
mean BP the association did not persist for all indices.  
 
Piecewise regression which is a simple but underutilised approach in 
epidemiological studies [190], allows separate slopes to be fitted to observations 
representing different periods throughout the day or more specifically periods 
before or after a “critical point”. In Chapter 5, we implemented this technique to 
our data in the context of a mixed-effects model. This allowed us to obtain new 
measures of BP. In particular, the method allowed quantification of the steepest 
rise and fall in BP (along with measures of variation between-individuals for these 
parameters), which occurred just after waking (2.23 mmHg/30min) and 
immediately after falling asleep (-1.93 mmHg/30min) respectively. By definition of 
the model and in the context of the morning period this represents a novel 
measure of the rate of change of BP or morning surge. The within-subject variation 
about an individual’s curve was also estimated (12.3 mmHg) and represents a 
measure similar to that of a SD summary measure. Despite a significant difference 
in mean BP values, we found no evidence that slopes were different within 
different periods of the day in those with and without TOD, suggesting a similar 
circadian pattern in both groups. 
 
Cosinor analysis which uses a single cosine to model a circadian BP cycle has been 
the most common longitudinal method to analyse ABPM data. The method has 
rarely been extended to include more than one cosine term in the context of a 
random-effects model. In Chapter 6, we fitted a two-component cosinor random-
effects model to our data and found that it provided a better fit than a single model 
and a similar fit to a more complex three-component model. Additionally, FPCA was 
performed on the data and it was determined that the first three principle 
components accounted for over 90% of the variation in the data. Not only did this 
offer an alternative method to quantify BPV, it also allowed us to determine if the 
two-component model was comparable to a more complex data driven approach 
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that obtained the optimal functions from the data. Our findings indicated that the 
parameters from the two-component cosinor model were highly correlated with 
the first three components from the FPCA. By obtaining first-order derivatives of 
the two-component cosinor model, we outlined a novel approach in the context of 
BP which can be used to visualise changes over time and, locate and quantify the 
magnitude of slopes at critical points along the circadian rhythm. 
In Chapter 7, approaches to compare two ABPM readings obtained at different 
occasions were outlined. The purpose was to explore changes in variability over 
time and examine the reproducibility of patterns of circadian BP curves that go 
beyond looking at mean values and hypertension categories. To this end, we 
implemented the two-component model from Chapter 6 and compared parameters 
from the two time-points. Results indicated that mean levels of BP were similar four 
years later but SBP variability, measured by wSD, SD and ARV, over 24h and the 
night period had significantly fallen. When examining the variability measures for 
those on medication, wSD, SD and ARV, over 24h (all SBP) remained significantly 
reduced. Interestingly, there was no change in variability measures for individuals 
not on medication. Overall, the reproducibility of patterns was poor based on mean 
levels, variability measures, hypertension categories and cosinor parameters. Based 
on simulations we were also able to determine how much of the total variation in 
the difference between parameters and summary measures was attributable to 
measurement error alone. 
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8.2 Implications of Findings 
 
What summary measure of BPV to use? 
We have demonstrated that quantifying variability is difficult and attempting to do 
this with one summary measure makes the task significantly more challenging. The 
main disadvantage of using summary measures to quantify BPV is the loss of 
information as the statistical power associated with longitudinal data is lost by 
collapsing the data into one value. However, as previously stated, many ABPM 
software programs routinely include estimates of variability measures such as SD 
(dabl ABPM system, dabl LTD, Ireland) in their reports and are important reference 
points considering the ease with which they can be obtained.  
We demonstrated that most but not all summary indices of BPV were associated 
(before adjustment for mean BP) with microalbuminuria (Chapter 4). This reiterates 
the problem of inconsistences among indices which makes understanding and 
collating of findings from studies particularly problematic. It is these inconsistences 
that illustrate how sensitive BPV measurement is and accentuates that each 
measure is in fact capturing different characteristics of variability. However, 
compared to other summary measures, we believe ARV is the most suitable index 
to quantify BPV. To reiterate, this measure is the mean of the absolute differences 
between successive readings which is independent of the mean value [36]. It has 
been argued that it is a more reliable representation of time series variability than 
24h SD which only captures variability about a mean value [33, 36]. wSD has also 
been suggested as a better measure to use than 24h SD as it attempts to remove 
the influence of the day-night difference [33]. To elaborate, the primary reason that 
a number of studies have suggested SD is a poor measure is because it only reflects 
the dispersion of measurements around a single value (mean) and does not account 
for the order in which BP measurements were obtained and the longitudinal 
variation in the circadian data [36]. However, if we are only considering variability 
during a specific period i.e. awake or night period separately as opposed to the 
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whole 24h, the use of SD may not be as problematic as the day-night fall is not 
present.  
What longitudinal model to use? 
Parati et al. argue that rather than simplifying ABPM data into mean summary 
measures, incorporating all the data in more advanced models can lead to more 
robust estimates of clinically relevant parameters such as dipping status and 
morning BP surge [142]. In Chapter 2, a number of approaches to model ABPM data 
were outlined where we focused on the use of a piecewise linear and a cosinor 
model in subsequent chapters. Both a piecewise linear model and the use of 
derivative estimation is not new in medical research but in the context of BP they 
offer a simple but novel approach to analyse its circadian rhythm that help extract 
features from the pattern. As outlined in the thesis, there have been a number of 
modelling approaches applied to 24h BP but the ultimate goal remains the 
development of a physiological model that captures known features of the pattern 
while not over-fitting the data so that we can obtain clinically relevant parameters 
[142]. It is widely acknowledged that achieving this is a difficult task and there is no 
perfect model that captures all the features of the circadian rhythm simultaneously 
[49, 142-144]. Using a mathematical model over simple summary measures allows 
us to obtain a smooth predicted curve over the whole 24h period which removes 
some of the “noise” in the data. Removing noise in data is usually perceived as an 
advantage where we remove measurement error and the impact of any outliers 
and are left with the underlying pattern. In the case of BPV however where we are 
specifically trying to understand and capture fluctuations in BP, perhaps smoothing 
the data in a model that captures the whole 24h period may not be the optimal 
approach. The sudden jumps or spikes that are seen in ABPM data may be a 
response to emotional or psychological stress which can sporadically increase BP 
values and are therefore important to measure [50]. Although these spikes may be 
perceived as noise they may also represent an underlining feature of an individual’s 
natural circadian rhythm. Some individuals may be more prone to abrupt changes 
due to stress or anxiety. Obtaining lower sampling frequency measurements such 
as beat-to-beat measurements may help in this regard but are not feasible in large 
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population based studies. We do however have to reach some compromise and 
perhaps modelling the data in separate segments similar to the piecewise model 
represents a suitable approach. However, graphically comparing circadian curves 
obtained at different time-points may be better achieved using the cosinor method 
which gives a smoother fit where differences in the pattern of the shape can easily 
be seen. We reiterate the point made in Chapter 2 that no model is optimal in 
terms of capturing all features of the curve and choosing one involves making a 
compromise based on what the researcher deems most important for their 
particular research question. Using mathematical models does allow us to obtain an 
almost infinite number of BP indices. Comparing these measures between new anti-
hypertensive medications may allow us to determine if a drug outperforms another 
when there is no significant difference in means values.  
 
Policy and Practice  
With the HSE recently acknowledging the importance of ABPM by approving the 
reimbursement of ABPM in primary care for those with a medical card, obtaining 
values of BPV is now more accessible [22]. In practice, summary measures will 
continue to be the most common method of quantifying BPV due to the ease with 
which they can be calculated coupled with their automatic inclusion in some ABPM 
output reports. A recommendation to improve monitors and their output would be 
the inclusion of the ARV index which could be achieved with minimal effort. There 
have been calls in the most recent ABPM position paper to include all measures of 
BPV in ABPM research reports but many just include SD [13]. However, there are no 
current threshold levels for variability in BP guidelines which makes interpretation 
of BPV measures difficult for clinicians. A long-term goal would be to eventually 
have standardised cut-points for which levels of BPV would be controlled to, similar 
to that of mean BP.  For this to happen however we will need stronger evidence of 
the importance of BPV. As highlighted in the position paper, the current threshold 
values for mean BP levels in the NICE guidelines [17], the JNC 7 guideline [218], and 
the ESH/ESC guidelines for 2003, 2007 and 2013 [13, 18, 219], and the results of 
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outcome studies, such as IDACO [220] and Ohasama [221] have contributed to the 
definition of ABPM consensus values currently being used in practice [13]. A similar 
level of research output is required to obtain conclusive evidence on the prognostic 
significance of BPV before we can begin to arrive at suitable variability thresholds.  
More advanced methods to model BP and measure BPV have been suggested as 
particularly useful in research studies rather than directly used in practice [13, 142]. 
This is where we currently suggest the piecewise and cosinor approaches outlined 
in this thesis should be primarily implemented where they may be particularly 
beneficial in clinical trials. However, we suggest that the inclusion of the cosinor 
approach in an ABPM report could be quite useful when comparing two ABPM 
patterns from the same individual. As outlined in Chapter 7, it offers a quick 
graphical comparison that maybe helpful for a clinician when they are trying to 
gauge changes in an individual’s underlying circadian rhythm. We argue the 
inclusion of the predicted curves in ABPM reports, in combination with the 
standard output may improve clinical decisions and ultimately, BP control. 
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8.3 Strengths and Limitations 
The strengths and limitations of each paper have been discussed in previous 
chapters. In this section a summary is provided with a focus on the thesis as a 
whole.   
The thesis inevitably has a number of limitations. Although the use of ABPM is 
considered the gold standard of BP measurement and is recommended by 
guidelines, the monitors will not always provide accurate readings. Undoubtedly, 
there will be some measurement error from the true BP value especially for 
example, during the night when an individual may be lying on the cuff. In the 
Mitchelstown cohort every effort was made by study nurses to emphasise the 
importance of wearing the monitor correctly. In addition, all monitors were 
recalibrated before the study began as recommended [17]. The physical 
inconvenience of wearing the monitor may introduce selection bias where certain 
groups of individuals do not feel comfortable wearing the device. For example, 
perhaps frailer individuals would be more concerned wearing a monitor than 
stronger individuals. Wood et al. explored reasons for ABPM uptake among 770 
participants of different ethnicities in the United Kingdom [222]. In their qualitative 
analysis, reasons suggested for poor uptake included discomfort, sleep disruption, 
stress and embarrassment, and interruption of activities of daily living. In the 
Mitchelstown study, ABPM was offered to all participants but those with high BP 
were encouraged by the study nurses to wear a monitor. No qualitative data was 
recorded for reasons of not availing of ABPM. Despite a response rate of 58%, the 
ABPM subsample was found to be broadly representative of the full sample based 
on age, gender, BMI and diabetes prevalence (see Appendix E for details). However, 
the prevalence of hypertension (≥140/90 mmHg and/or on antihypertensive 
treatment) was higher in the baseline ABPM subsample (46% vs 59%). This 
introduces a selection bias based on hypertension only where there is a systematic 
difference between the subsample and the main sample. This may affect 
interpretation of the results where caution must be exercised when discussing the 
generalizability of the results to the population. It must be stressed that the only 
difference was that based on hypertension and this does not necessarily affect the 
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validity of the comparisons and inferences made within the study or the study’s 
internal validity [223, 224].  
Although a lot of the work in this thesis involved exploring the shape of circadian BP 
curves, Chapter 3 and 4 directly examined the association between BPV and TOD. A 
statistically significant association between an exposure (BPV measure) and an 
outcome (TOD) is not sufficient to imply causality. Hill’s casual considerations offer 
guidance [225]. He listed nine considerations, none of which are essential, that are 
used in epidemiology to build up evidence for a causal relationship: strength, 
consistency, temporality, dose-response, plausibility, reversibility, coherence, 
analogy and specificity [223]. The strength of the association in this study between 
BPV and TOD was weak and did not persist after adjustment for mean BP. The 
systematic review examining the relationship between BPV and LVMI suggested a 
weak association and also provides evidence of poor consistency among studies. 
Temporality in this study is difficult to ascertain. BPV leading to the development of 
TOD and in turn CVD is the hypothesis made in most of the literature but perhaps 
as argued by Hansen et al., as TOD is a forerunner of cardiovascular complications, 
BPV will inevitably increase [168]. This raises the question of reverse causality with 
increased BPV being a marker of underlying disease rather than being an 
independent predictor.  
Although the precise mechanisms responsible for BPV are not entirely understood 
[50], there are a number of acknowledged factors that influence variations in BP 
which have been postulated as to why BPV may cause the development of TOD, 
and ultimately CVD. Parati et al. [51, 52] argue BPV is primarily modulated by neural 
(increased central sympathetic drive and reduced arterial and cardiopulmonary 
reflexes), humoral (angiotensin II, insulin, bradykinin, nitric oxide) and vascular 
effects (elastic properties of arteries). Variability has been shown to be correlated 
with arterial stiffness and peripheral vascular disease which is a blood circulation 
disorder that causes blood vessels outside of your heart and brain to narrow, block 
or spasm which can lead to CVD [25]. Rothwell et al. suggest that BPV could lead to 
cerebral ischaemia (insufficient blood flow to the brain) which could lead to both 
altered central autonomic control of BP and an increased risk of stroke [25].  
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Reversibility refers to whether an intervention to remove or reduce the exposure 
results in the elimination or reduction of the outcome [223]. We cannot assess this 
from our results. A clinical trial comparing the impact of different antihypertensive 
classes on BPV and ultimately TOD would help to address this. Coherence is also 
difficult to assess based on the evidence in this study. However, experimental data 
from animal models lend support to a causal link. It was previously shown that 
experimental sinoaortic denervation in rats, which increases variability in BP 
without changing mean BP, caused LVH and aortic vasoconstriction [24, 226]. 
Analogy refers to the similarity of the effect of interest to other established cause-
effect relationships that would help support the argument for causality [223]. In our 
case, elevated mean BP has long been established as a causal factor for the 
development of TOD and CVD.  As a result, it could be argued that small or large 
fluctuations in BP may also contribute to CVD but this is speculative. In conclusion, 
a causal relationship between BPV and TOD is difficult to prove based on the 
findings in this study and the literature available at present.  
 
Another limitation of the thesis is the use of TOD as surrogate markers of CVD 
rather than the use of hard endpoints. The reason for this was simply the feasibility 
and time constraints of the thesis where only data from wave one is currently 
collected. Although hard endpoints were recorded in the study (MI, stroke), the 
number of events were small which precluded using them. Data collection for wave 
two is currently on-going but we may need to wait for subsequent waves to have 
adequate number of events to detect an association, if one exists.  
Due to the nature of short-term BPV, we are examining a small time frame, only 
24h. Ideally, we would like participants to continue to wear the monitors for a 
number of days or perhaps obtain separate ABPM recordings taken a few days 
apart to be sure of reliable observations. This would also allow the comprehensive 
analysis of the reproducibility of day-to-day circadian patterns. However, the 
practicalities and feasibility of wearing a monitor for a prolonged period of time in 
this cohort study meant we were unable to obtain more readings.  
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As highlighted in the thesis one of the key aspects of BPV has been the suggestion 
that different classes of antihypertensive medications have different effects in 
terms of increasing or reducing variability. Emerging evidence suggests that those 
receiving either CCBs or diuretics, alone or in addition to other drugs have 
significantly lower variability compared with ACEIs, ARBs or β-blockers alone or in 
combination [61-63, 65, 227]. A limitation of the study was that we were not able 
to include the effect of antihypertensive medication in the analysis. Although we 
knew if a participant was on treatment, we had insufficient data on the specific 
class of antihypertensive medication the individual was prescribed which meant 
drug-class comparisons were not possible. As one of the questions in the study 
questionnaire asked if the participant was taking antihypertensive drugs, it allowed 
analysis to be stratified by those taking and not taking medications. Findings were 
broadly similar across both groups (Chapter 4, 5). It could be the case that there are 
differences between classes but by analysing them all together the effect has been 
diluted. When examining changes to short-term variability over time (Chapter 7), 
evidence suggested that BPV in those on medication significantly reduced while 
there was no change in variability measures for individuals not on medication.  
 
Despite the limitations outlined, the thesis has several strengths. Specifically, it 
addresses a relevant and highly topical area in BP research. To date, two of the 
chapters have been published in peer reviewed scientific journals while a third is 
under review. The work is both warranted and appropriate to increase awareness 
and to help develop a deeper understanding of the mechanisms responsible for 
BPV which are not entirely known. Methods to analyse circadian BP patterns that 
account for the longitudinal nature of the data are sparse and this thesis outlines 
new approaches. The thesis includes the first review to our knowledge that 
quantifies the correlation between BPV and LVMI which identifies a research gap 
where stronger epidemiological studies are needed in the area. To the best of our 
knowledge, the thesis is the first to apply a piecewise linear model and FPCA to 
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diurnal BP over 24h. We have demonstrated that incorporating more cosine terms 
into the cosinor model offers a substantial improvement in fit compared to the 
traditional method of ABPM analysis, the single-component model. One of the main 
strengths of the study lie in the robust community based design and large sample of 
ABPM data recorded. Although the inferences that are made may not be applicable 
across all age groups and populations there are no reasons why the methods 
outlined cannot be used on them to obtain valid estimates of BP. This argument can 
be extended where many of the chapters and methods are not limited to the 
exploration of BP but are flexible enough to be applied to other medical data that 
follows a circadian rhythm.   
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8.4 Future Recommendations for Research  
 
As we have alluded to, it is evident that more evidence from large longitudinal 
studies examining the prognostic significance of short-term BPV is needed before 
suitable variability thresholds can be introduced. There is a need for 
standardisation of indices that we use to define BPV. This has been highlighted by a 
recent systematic review of BPV examining its prognostic value for all-cause 
mortality, cardiovascular mortality, all cardiovascular events, stroke and coronary 
heart disease [191]. Taylor et al. argue that the interpretation and use of 24h BPV in 
clinical practice, as a prognostic indicator of cardiovascular events is hampered by 
insufficient evidence and divergent methodologies [191]. Agreement and 
standardisation of indices may not be fully possible for a number of years until 
there is a plateauing effect in the number of methods used to quantify variability. 
We have however, made the recommendation to use the ARV index as the primary 
summary measure of BPV. Rather than using different indices, if all future studies 
included this measure it would make collating results easier. Indeed this thesis has 
developed yet further methods to explore circadian patters but as Dolan et al. 
argue each new measure helps to bring about new insights and is required to 
advance our understanding of BP [66]. We are still however, searching for the 
optimal measure to quantify variability over a short-period; this is as much a 
mathematical problem as it is clinical. This as the thesis has shown, is not easily 
achieved.  
In the context of the single-component cosinor model which has been the most 
common method of analysis for ABPM, a recommendation for future studies from 
the evidence presented in this thesis is to incorporate a second cosine in the 
context of a random-effects model. The method offers a substantial improvement 
in fit compared to the traditional cosinor that is capable of capturing short-term 
peaks and can be implemented in standard statistical software. 
In Chapter 7, we found that short-term BPV measured at two occasions, four years 
apart, decreased in a small sample. Few longitudinal studies explore how variability 
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changes between two ABPM readings. In those that have, inconsistent findings 
were reported [213, 214]. More research into how short-term variability changes 
over time is warranted and further studies exploring the reproducibility of ABPM 
patterns is needed. It must be remembered that the emphasis in this thesis has 
solely been on short-term patterns and not long-term variability which represents 
how much BP fluctuates between visits (months or years).  
The prognostic significance of visit-to-visit BPV seems to be more transparent than 
in the case of short-term BPV. The most recent meta-analysis of 77,299 patients 
suggests that visit-to-visit SD was significantly predictive of all-cause mortality, 
cardiovascular mortality and stroke, after adjustment for mean BP [26]. As there is 
usually less data-points when analysing long-term compared to short-term data 
there is less opportunity to apply more advanced techniques. Studies have primarily 
used SD as a measure of variability. This has helped in collating data from studies, 
although it may not be the best measure of BPV. However, the issues associated 
with measuring short-term BPV may not be as evident for long-term BPV. The 
primary reason is that long-term variability does not have a cyclic component to it 
and there is no dipping effect like ABPM. Long-term variability usually refers to 
fluctuations in clinic BP values which have no night component. In this case, the use 
of SD as a measure of variation may be adequate. Another recommendation would 
be to investigate the association between short-term BPV and the development of 
long-term BPV which there is no data to the best of our knowledge. Perhaps long-
term BPV is the cumulative aggregate of short-term BPV but we will not know the 
answer to this until large longitudinal studies are conducted. Perhaps obtaining 
multiple ABPM readings over the course of a short period e.g. one month, may yield 
the same information and benefits of running a long-term study over a couple of 
years which would save on time and reduce financial costs.  
In context of the work presented in this thesis and following on from the limitation 
of examining surrogate markers, the most obvious recommendation is to explore 
the methods presented in the thesis with long-term follow up data that have hard 
endpoints e.g. cardiovascular events. The second wave of data collection is 
currently on-going for the Mitchelstown cohort. However, in order to have 
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adequate number of events to detect an association, if one exists; data from 
subsequent waves will probably have to be obtained.  
The benefit of our findings may lie in the analysis of clinical trial data, particularly in 
the analysis of chronotherapy effects. The methods offer estimates of BP at 
important times of the day that define a rate of change. This could be applied after 
the ingestion of different antihypertensive drugs to identify which medication 
produced the quickest fall in BP levels. Debate is on-going into the benefits of night-
time administration of antihypertensive medication compared to daytime 
administration but there has been substantial evidence in its favour [67-70]. The 
rationale behind the argument for this seems both plausible and reasonable. That 
is, administering medication at night will help pre-empt the magnitude of the 
morning surge by reducing BP during the night so that on waking, the surge is 
beginning at a lower value and thus not reaching as high a peak. When medication 
is ingested at night there should also be a larger reduction in night-time BP which 
has been highlighted as a stronger predictor of outcome than 24h mean. The latest 
on-going Treatment in Morning versus Evening (TIME) trial with 10,200 patients 
followed for 5 years is anticipated to provide definitive evidence of whether or not 
there is a benefit to administering antihypertensive medications in the evening to 
provide better protection against major adverse cardiovascular events [228, 229]. 
The methods outlined in this thesis are not restricted to the analysis of BP but can 
be applied to the many other physiological processes that follow a circadian rhythm 
such as cortisol, heart rate etc. In this regard it would be interesting to know if the 
methods, especially the more advanced approaches could be of use in analysing 
and answering questions in other medical fields. Indeed, it could be the case that 
the methods outlined could be more suited to important aspects of a particular 
circadian process other than BP. For purposes of dissemination of methods and 
particularly to act as a source for other researchers who are interested in extending 
on the work in the thesis, sample R code has been included in Appendix H. This may 
also be useful for researchers in other fields’ aside from BP. Relevant R packages 
utilised are also included along with the version of R used. The run time for the non-
linear model is also presented 
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8.5 Conclusion 
This thesis has demonstrated different approaches to explore circadian BP patterns 
over a 24h period. Results indicated that most summary measures of BPV were 
associated with microalbuminuria but the association did not persist after 
adjustment for mean BP. There was no association between BPV and LVH. Where 
more advanced models were used incorporating all the data, the rate of increase or 
fall throughout different periods over 24h remained the same between those with 
and without TOD. A novel method to quantify morning surge was also presented 
which may be useful in future studies. FPCA may also be a novel method to 
determine major components of variations in 24h BP. BPV quantification, its 
predictive value and potential as a therapeutic target will remain controversial until 
more studies are conducted and an agreement on how best to accurately quantify 
BPV has been reached. The thesis, which had a large methods and statistical 
component, illustrated novel techniques that can be implemented with standard 
software and whose application may also be useful for analysing other medical 
datasets that follows a circadian process.  
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Appendix A Supplementary material (Chapter 2) 
 
Polynomial Regression 
Briefly, a 6th order polynomial was applied to the dataset and measures of 
variability were obtained from subject-specific predictions. As one measure of 
variability the sum squared of the differences between the observed and subject-
specific profiles was calculated which reflected a participant’s individual BP 
variation across the 24h period. This is a similar measure to that calculated by Sega 
et al. except we used the variation about the individual curve rather than the mean 
[29]. Maximum, minimum and number of minutes spent above certain 
hypertensive guidelines were also calculated as measures of variability. The 
association between the extracted BPV measures and the presence of TOD was 
assessed using logistic regression with adjustment for age, sex, smoking status, 
BMI, diabetes and antihypertensive treatment. Additional models adjusted for 
mean clinic BP. 
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Figure 9-1 Population Level Effects for polynomial regression (Chapter 2) 
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Figure 9-2 Population Level Group Average (95 % CI) Linear Mixed Effects Model (Age, Sex, BMI Adjusted) (Chapter 2) 
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Figure 9-3 Subject-Specific Variation (function of Time only) 
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Table 9-1 Association between parameters extracted from polynomial regression 
model and microalbuminuria (logistic regression). 
Characteristic (SBP) Value (SD) 
Microalbuminuria (10.6%)  
Model 1 
OR (CI%) per hour or per 
10mmHg 
Model 2 
OR (CI%) per hour or per 
10mmHg 
Max Morning, mm Hg 
Time 
133 (13.0) 
11.54pm 
(18min) 
1.53 (1.30-1.81)* 
0.85 (0.59-1.24) 
0.24 (0.03-1.83) 
0.80 (0.55-1.15) 
Minimum, mm Hg 
Time  
108 (12.7) 
4.51am 
(11min) 
1.60 (1.35-1.90)* 
1.08 (0.59-0.97) 
2.74 (0.90-8.33) 
0.82 (0.45-1.49) 
Hours ≥ 130 mm Hg (24 
h)† 
8.4 h (7.9h) 1.07 (1.04-1.10)* 0.98 (0.91-1.04) 
Hours ≥ 135 mm Hg 
(Day)† 
5.2 h (6.4h) 1.06 (1.02-1.10)* 0.95 (0.89-1.01) 
Hours ≥ 120 mm Hg 
(Night)† 
2.5 h (3.1h) 1.14 (1.07-1.21)* 0.96 (0.85-1.09) 
Variability About Curve 123 (58.1) 1.05 (1.02-1.08)* 1.01 (0.97-1.05) 
†European Society of Hypertension ABPM Guidelines: 24 h ≥130/80 mmHg; Day (awake) ≥135/85 mmHg; Night (sleep) ≥120/70 
mmHg. *p-value <0.01. Model 1 adjusted for age, sex, smoking, BMI, diabetes, anti-hypertensive medication. Model 2 adjusted for 
age, sex, smoking, BMI, diabetes, anti-hypertensive medication, 24h SBP 
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Appendix B Supplementary material (Chapter 3) - search 
terms and search strategy for systematic review 
 
EMBASE search strategy  
#1. exp  abpm variability/ 
#2. exp  abp variability/ 
#3. exp  ambulatory bp variability/ 
#4. exp  ambulatory blood pressure variability/ 
#5. exp  ambulatory blood pressure monitor variability/ 
#6. exp  ambulatory blood pressure monitoring variability/ 
#7. exp  24hour BP variability/ 
#8. exp  24-hour blood pressure variability/ 
#9. exp  24h blood pressure variability/ 
#10. exp  24h bp variability/ 
#11. exp  24 hour ambulatory blood pressure variability/ 
#12. exp  24 hour ambulatory bp variability/ 
#13. exp  24 hour ambulatory blood pressure monitor variability/ 
#14. exp  24 hour ambulatory blood pressure monitoring variability/ 
#15. exp  short term bp variability/ 
#16. exp  short term abpm variability/ 
#17. exp  short term blood pressure variability/ 
#18. exp  short term abp variability/ 
#19. exp  24 hour abpm variability/ 
#20. exp  24 hour abp variability/ 
#21. exp  24h abp variability/ 
#22. exp  24-hour abp variability/ 
#23. exp  24-hour abpm variability/ 
#24. exp  24-hour ambulatory blood pressure monitoring variability/ 
#25. exp  24-hour ambulatory blood monitoring variability/ 
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#26. exp  bp variability/ 
#27. exp  blood pressure variability/ 
#28.  (#1 or  #2 or  #3 or  #4 or  #5 or  #6 or  #7 or  #8 or  #9 or  #10 or  #11 or  #12 
or  #13 or  #14 or  #15 or  #16 or  #17 or  #18 or  #19 or  #20 or  #21 or  #22 or  #23 
or  #24 or  #25 or  #26 or  #27 ) 
#29. left ventricular hypertrophy: ab,ti 
#30. left ventricular hyperthrophy: ab,ti 
#31. left ventricular hypertrophy: ab,ti 
#32. left ventricular hypertrophic: ab,ti 
#33. left ventricular mass: ab,ti 
#34. left ventricular mass index: ab,ti 
#35. target organ damage: ab,ti 
#36. organ damage: ab,ti 
#37. target-organ damage: ab,ti 
#38. (#29 or  #30 or  #31 or  #32 or  #33 or  #34 or  #35 or  #36 or  #37 ) 
#39. (#28 and #38) 
#40.#39[Limit: humans & article] 
PubMed search strategy  
#1. abpm variability [all]  
#2. abp variability [all] 
#3. ambulatory bp variability [all] 
#4. ambulatory blood pressure variability [all] 
#5. ambulatory blood pressure monitor variability [all] 
#6. ambulatory blood pressure monitoring variability [all] 
#7. 24hour BP variability [all] 
#8. 24-hour blood pressure variability [all] 
#9. 24h blood pressure variability [all] 
#10. 24h bp variability [all] 
#11. 24 hour ambulatory blood pressure variability [all] 
#12. 24 hour ambulatory bp variability [all] 
#13. 24 hour ambulatory blood pressure monitor variability [all] 
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#14. 24 hour ambulatory blood pressure monitoring variability [all] 
#15. short term bp variability [all] 
#16. short term abpm variability [all] 
#17. short term blood pressure variability [all] 
#18. short term abp variability [all] 
#19. 24 hour abpm variability [all] 
#20. 24 hour abp variability [all] 
#21. 24h abp variability [all] 
#22. 24-hour abp variability [all] 
#23. 24-hour abpm variability [all] 
#24. 24-hour ambulatory blood pressure monitoring variability [all] 
#25. 24-hour ambulatory blood monitoring variability [all] 
#26. bp variability [all] 
#27. blood pressure variability [all] 
#28.  (#1 or  #2 or  #3 or  #4 or  #5 or  #6 or  #7 or  #8 or  #9 or  #10 or  #11 or  #12 
or  #13 or  #14 or  #15 or  #16 or  #17 or  #18 or  #19 or  #20 or  #21 or  #22 or  #23 
or  #24 or  #25 or  #26 or  #27 ) 
#29. left ventricular hypertrophy [all] 
#30. left ventricular hyperthrophy [all] 
#31. left ventricular hypertrophy [all] 
#32. left ventricular hypertrophic [all] 
#33. left ventricular mass [all] 
#34. left ventricular mass index [all] 
#35. target organ damage [all] 
#36. organ damage [all] 
#37. target-organ damage [all] 
#38. (#29 or  #30 or  #31 or  #32 or  #33 or  #34 or  #35 or  #36 or  #37 ) 
#39. (#28 and #38) 
#40. #39[Limit: humans & adults]
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PRISMA checklist (Systematic review checklist for Chapter 3) 
Section/topic  # Checklist item  
Reported on page # (see 
pdf version appendix ) 
TITLE   
Title  1 Identify the report as a systematic review, meta-analysis, or both.  Title page (p1) 
ABSTRACT   
Structured 
summary  
2 Provide a structured summary including, as applicable: background; objectives; data 
sources; study eligibility criteria, participants, and interventions; study appraisal and 
synthesis methods; results; limitations; conclusions and implications of key findings; 
systematic review registration number.  
Abstract (p2) 
INTRODUCTION   
Rationale  3 Describe the rationale for the review in the context of what is already known.  Introduction (p3,4) 
Objectives  4 Provide an explicit statement of questions being addressed with reference to 
participants, interventions, comparisons, outcomes, and study design (PICOS).  
Introduction (p4) 
METHODS   
Protocol and 
registration  
5 Indicate if a review protocol exists, if and where it can be accessed (e.g., Web 
address), and, if available, provide registration information including registration 
number.  
NA 
Eligibility criteria  6 Specify study characteristics (e.g., PICOS, length of follow-up) and report 
characteristics (e.g., years considered, language, publication status) used as criteria 
for eligibility, giving rationale.  
Methods – Types of studies, 
Study populations, predictor 
variables, outcomes (p5) 
Information 
sources  
7 Describe all information sources (e.g., databases with dates of coverage, contact with 
study authors to identify additional studies) in the search and date last searched.  
Methods – search methods for 
identification of studies (p5,6) 
Search  8 Present full electronic search strategy for at least one database, including any limits 
used, such that it could be repeated.  
Methods – search methods for 
identification of studies (p5,6) 
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Study selection  9 State the process for selecting studies (i.e., screening, eligibility, included in 
systematic review, and, if applicable, included in the meta-analysis).  
Methods – search methods for 
identification of studies, data 
extraction (p5,6) 
Data collection 
process  
10 Describe method of data extraction from reports (e.g., piloted forms, independently, in 
duplicate) and any processes for obtaining and confirming data from investigators.  
Methods –data extraction (p6) 
Data items  11 List and define all variables for which data were sought (e.g., PICOS, funding 
sources) and any assumptions and simplifications made.  
Methods –data extraction (p6) 
Risk of bias in 
individual studies  
12 Describe methods used for assessing risk of bias of individual studies (including 
specification of whether this was done at the study or outcome level), and how this 
information is to be used in any data synthesis.  
Methods— search methods for 
identification of studies (p6), 
Quality assessment (Table 4) 
Summary 
measures  
13 State the principal summary measures (e.g., risk ratio, difference in means).  Methods—Statistical analysis 
(p6) Correlation Coefficient 
Synthesis of results  14 Describe the methods of handling data and combining results of studies, if done, 
including measures of consistency (e.g., I
2
) for each meta-analysis.  
Methods—Statistical analysis 
(p6)  
 
Page 1 of 2  
Section/topic  # Checklist item  Reported on page #  
Risk of bias across 
studies  
15 Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., 
publication bias, selective reporting within studies).  
Methods—Statistical 
analysis (p6)  
Additional analyses  16 Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-
regression), if done, indicating which were pre-specified.  
Methods—Statistical 
analysis (p6)  
RESULTS   
Study selection  17 Give numbers of studies screened, assessed for eligibility, and included in the review, 
with reasons for exclusions at each stage, ideally with a flow diagram.  
Results (p7) & Flowchart 
(Figure 1) 
Study 
characteristics  
18 For each study, present characteristics for which data were extracted (e.g., study size, 
PICOS, follow-up period) and provide the citations.  
Results (p7) & Table 1,3 
Risk of bias within 
studies  
19 Present data on risk of bias of each study and, if available, any outcome level 
assessment (see item 12).  
Results (p8) & Quality 
assessment (Table 4) 
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Results of individual 
studies  
20 For all outcomes considered (benefits or harms), present, for each study: (a) simple 
summary data for each intervention group (b) effect estimates and confidence intervals, 
ideally with a forest plot.  
Results (p7), Table 1,3 & 
Forest Plot (Figure 2) 
Synthesis of results  21 Present results of each meta-analysis done, including confidence intervals and 
measures of consistency.  
Results (p7) & Forest Plot 
(Figure 2) 
Risk of bias across 
studies  
22 Present results of any assessment of risk of bias across studies (see Item 15).  Results- Meta-analysis 
(p8,9) 
Additional analysis  23 Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-
regression [see Item 16]).  
Results- Meta-analysis 
(p8,9) & Forest Plot (Figure 
2) 
DISCUSSION   
Summary of 
evidence  
24 Summarize the main findings including the strength of evidence for each main outcome; 
consider their relevance to key groups (e.g., healthcare providers, users, and policy 
makers).  
Discussion (p9) 
Limitations  25 Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level 
(e.g., incomplete retrieval of identified research, reporting bias).  
Discussion (p9,10, 11, 12) 
Conclusions  26 Provide a general interpretation of the results in the context of other evidence, and 
implications for future research.  
Discussion (p9,10, 11, 12) 
FUNDING   
Funding  27 Describe sources of funding for the systematic review and other support (e.g., supply of 
data); role of funders for the systematic review.  
Title page (p1) & Conflict of 
Interest (p12) 
 
From:  Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS 
Med 6(6): e1000097. doi:10.1371/journal.pmed1000097  
For more information, visit: www.prisma-statement.org.  
Page 2 of 2 
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Table 9-2 Baseline Characteristics by anti-hypertensive treatment  
  Untreated (n=757) Treated (n=377) 
Characteristic Total 
(n=1134) 
Men 
(n=362) 
Female 
(n=395) 
Men 
(n=165) 
Female 
(n=212) 
Age, y 60.2 (5.5) 59.5 (5.6) 59.5 (5.5) 61.6 (5.1) 61.9 (5.3) 
BMI, n (%) 
  Underweight/normal 
  Overweight 
  Obese 
 
230 (20.3) 
498 (44.0) 
405 (35.7) 
 
56 (15.5) 
187 (51.8) 
118 (32.7) 
 
130 (32.9) 
171 (43.3) 
94 (23.8) 
 
8 (4.9) 
65 (39.4) 
92 (55.7) 
 
36 (17.0) 
75 (35.4) 
101 (47.6) 
Smoking, n (%) 
   Never 
   Former 
   Current 
 
564 (51.9) 
355 (32.7) 
168 (15.4) 
 
133 (38.8) 
142 (41.4) 
68 (19.8) 
 
241 (63.3) 
86 (22.6) 
54 (14.2) 
 
70 (43.2) 
71 (43.8) 
21 (13.0) 
 
120 (59.7) 
56 (27.9) 
25 (12.4) 
Diabetes, n (%) 103 (9.3) 34 (9.6) 14 (3.6) 31 (19.1) 24 (11.4) 
Hypertension, n (%) 487 (43.0) 140 (38.7) 148 (37.6) 92 (55.8) 107 (50.5) 
LVH, n (%) 75 (6.6) 34 (4.5) 15 (3.8) 21 (12.7) 20 (9.4) 
Microalbuminuria, n 
(%) 
128 (11.4) 73 (9.7) 32 (8.2) 24 (14.6) 31 (14.8) 
ABPM measurements 
  24-h SBP, mm Hg 
  24-h DBP, mm Hg 
  Awake SBP, mm Hg 
  Awake DBP, mm Hg 
  Sleep SBP, mm Hg 
  Sleep DBP, mm Hg 
 
124.1 (13.3) 
71.8 (8.3) 
131.4 (14.1) 
77.4 (9.0) 
112.3 (14.0) 
62.8 (8.3) 
 
126.0 (12.6) 
74.4 (8.4) 
133.5 (13.4) 
80.1 (9.0) 
112.9 (13.4) 
64.6 (8.7) 
 
119.9 (13.7) 
69.6 (7.6) 
127.2 (14.8) 
75.3 (8.5) 
108.5 (13.5) 
60.6 (13.5) 
 
128.0 (12.4) 
74.3 (8.6) 
134.8 (12.6) 
79.3 (9.3) 
117.1 (14.3) 
66.0 (9.2) 
 
125.8 (12.7) 
69.5 (7.4) 
132.9 (13.3) 
74.9 (8.3) 
115.0 (13.9) 
61.3 (7.2) 
Data are mean (SD). ARV: Average real variability, SBP: Systolic Blood pressure, DBP: Diastolic blood pressure, BMI:Body mass 
index, LVH: Left ventricular hypertrophy, ABPM: Ambulatory blood pressure monitor. Microalbuminuria: albumin:creatinine 
ratio ≥ 1.1 mg/mmol 
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Table 9-3 Variability Indices and Dip by White-Coat Hypertension  
Variability 
Measure 
24-hour (mm Hg) Day (mm Hg) Night (mm Hg) 
No (n=986) Yes (n=147) No Yes No Yes 
ARV SBP 11.4 (2.6) 11.1 (2.0) 11.9 (3.2) 11.5 (2.7) 10.6 (3.3) 10.6 (2.6) 
ARV DBP 7.8 (1.8) 7.3 (1.4) ** 8.2 (2.4) 7.6 (2.2) ** 7.3 (2.2) 6.9 (1.8) * 
SD SBP 15.9 (4.0) 15.4 (3.0) 12.9 (3.6) 13.0 (3.0) 11.2 (3.6) 10.7 (2.7) 
SD DBP 11.5 (2.8) 10.9 (2.4) * 9.0 (2.8) 8.6 (2.5) 8.1 (2.4) 7.6 (2.0) * 
CV SBP 12.8 (2.9) 12.8 (2.8) 9.7 (2.4) 10.1 (2.4) 10.0 (3.0) 9.8 (2.5) 
CV DBP 16.1 (3.8) 15.6 (3.4) 11.6 (3.7) 11.5 (3.5) 12.9 (3.8) 12.5 (3.5) 
wSD SBP 12.3 (3.0) 12.2 (2.2) - - - - 
wSD DBP 8.7 (2.1) 8.2 (1.7) - - - - 
Dip SBP 14.4 (7.0) 14.2 (6.8) * - - - - 
Dip DBP 18.7 (7.7) 18.2 (7.2) - - - - 
Data are mean (SD). ARV: Average real variability, SD: Standard deviation, wSD: Weighted standard deviation, CV: coefficient 
of variation, SBP: Systolic Blood pressure, DBP: Diastolic blood pressure, *p<0.05; represents significance between those with 
and without white-coat hypertension during each period of the day 
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ROC curves for microalbuminuria (Chapter 4 supplementary material) 
  
ARV awake ROC curve. M1: Age, Sex, 24-h mean BP, ARV awake, Smoking, Diabetic, 
bmi, anti-hypertensive; M2: Age, Sex, 24-h mean BP, Smoking, Diabetic, bmi, anti-
hypertensive (p-value=0.56) 
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wSD ROC curve. M1: Age, Sex, 24-h mean BP, wSD, Smoking, Diabetic, bmi, anti-
hypertensive; M2: Age, Sex, 24-h mean BP, Smoking, Diabetic, bmi, anti-
hypertensive (p-value=0.73) 
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SD awake ROC curve. M1: Age, Sex, 24-h mean BP, SD awake, Smoking, Diabetic, 
bmi, anti-hypertensive; M2: Age, Sex, 24-h mean BP, Smoking, Diabetic, bmi, anti-
hypertensive (p-value=0.25) 
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24-h mean BP ROC curve. M1: 24-h mean BP, clinic BP; M2: clinic BP (p-value=0.01) 
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24h mean BP ROC curve. M1: Age, Sex, 24-h mean BP, clinic BP, Smoking, Diabetic, 
bmi, anti-hypertensive; M2: Age, Sex, clinic BP, Smoking, Diabetic, bmi, anti-
hypertensive (p-value=0.13) 
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Appendix D Supplementary material (Chapter 5) 
 
Figure 9-4 VPC (visual predictive check) plot. Black lines represent median of observed data with 90% interquantile range of 
observations.  Red line is predicted mean along with 90% prediction interval.  
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Figure 9-5 Predicted average (95% CI) piecewise linear trajectory of those with/without presence of microalbuminuria adjusted for 
age, sex, BMI and including an interaction of the spline terms with microalbuminuria using a linear mixed-effects model (Model 3). 
Each linear spline represents the rate of BP increase or decrease (slope) for that time period which is referred to in Table 5-2. 
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Appendix E Supplementary material (Missing Data) 
(References for this appendix are at the end of the section.) 
Although some studies have monitors set to collect data less frequently at night 
compared to daytime, sometimes every 30mins during the day and every hour at 
night, our study had the advantage that data was collected at the same sampling 
frequency, 30mins throughout 24h. Earlier ESH guidelines recommended a 
minimum of 14 measurements during the day and a minimum of 7 measurements 
during the night as the satisfactory number of data points for analysis [1-3]. 
However the more recent guidelines from the current position paper on ABPM say 
that stricter criteria should be used especially for research purposes [3, 4]. 
Specifically they recommend only participants with a minimum of 20 
measurements during the day and a minimum of 7 measurements during the night 
period should be retained. Additionally, any participants with data lacking for more 
than two consecutive hourly intervals should be excluded [3, 4]. Additionally, when 
examining day and night values they recommended fixed time periods to identify 
these periods but we had the advantage of having diary entries of actual bed and 
rising times.  
Unfortunately we had no available data that was collected on the reasons why 
there may be missing data in our study. However, common reasons for missing 
ABPM values include the patient disconnecting the device, suspension of a reading 
by use of the cancelation button, turning the monitor off, dead batteries, 
movement artefact, or kinks in the tubing [5]. Many of these reasons may lead to 
an occasional or sporadic missed reading but multiple missing data may suggest 
there is something else at fault such as a monitor malfunctioning and ignoring data 
from such a monitor seems appropriate. Another issue perhaps is that a certain 
group of individuals may have increased level of missing data. One study examining 
the influence of patient characteristics on the success of ABPM recording found 
that those with diabetes and elevated BMI were associated with less complete 
ABPM session results [6]. In relation to our study we explored differences between 
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those with and without the minimum measurements criteria, see Table 9-4. Similar 
to the Fravel et al. study we found that those with higher BMI were more likely to 
have missing data. However there was no significant difference in the prevalence of 
diabetes. BP was slightly lower in those with missing data but importantly there was 
no significant difference between groups based on hypertension classification 
(≥140/90 mmHg and/or on antihypertensive treatment). There was no difference in 
gender but the missing group were marginally older (59.9 vs 60.7 years, p=0.01). 
The difference in BMI may be explained by the practicality of wearing the monitor. 
Perhaps those with a higher BMI were given a standard size cuff resulting in the 
device either being too restricted and returning an error or it was too painful to 
wear and the participant had to remove it. Without any evidence however we are 
only speculating and the difference between groups was not that large (1.3 kg/m2). 
Importantly from Table 9-4, the ABPM subsample was broadly representative of the 
full sample as prevalence rates were similar. However, those on ABPM had a higher 
prevalence of hypertension. ABPM was offered to all patients but those with high 
BP were encouraged to wear a monitor. This may affect the generalizability of the 
results but will not affect the estimates from our models for this study sample. It 
must be noted that even in the ABPM sample that met the criteria, there was still 
some missing data points. In terms of mixed-effects models, the approach is only 
valid when the incomplete dataset is MAR or MCAR [7-8]. In any real-life dataset 
missing data will never be completely MCAR, MAR or missing not at random 
(MNAR) but rather a combination of each. An assumption has to be made and in 
the case of our work we believe MAR is a reasonable assumption. As we have 
adhered to the most recent ABPM guidelines and feel our remaining ABPM sample 
is representative of the full sample it is reasonable to analysis those with the 
appropriate number of readings as set out by the guidelines. In addition there have 
been studies illustrating that methods that deal with missing data such as multiple 
imputation in mixed-effects models are not necessary and can result in unstable 
estimates and misleading inferences [7,9-10].  
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Table 9-4 Table of demographics comparing full sample to ABPM sample 
  ABPM Subsample (n=1207) 
Characteristic Full Sample 
(n=2047) 
ABPM ‡ 
 (n=886) 
ABPM Missing  
 (n=321) 
Age, y 59.8 (5.5) 59.9 (5.5) 60.7 (5.6)* 
Gender, Male n(%) 1008 (49.2) 401 (45.3) 163 (50.8) 
BMI (kg/m
2
) 28.6 (4.7) 28.6 (4.6) 29.9 (5.3)* 
Office SBP, mm Hg 129.6 (16.9) 134.7 (17.7) 131.7 (17.1)* 
Office DBP, mm Hg 80.1 (9.8) 83.1 (10.2) 80.7 (10.2)* 
Hypertension, n (%) 951 (46.5) 528 (59.7) 182 (56.7) 
Diabetes n (%) 174 (8.7) 81 (9.3) 34 (10.9) 
Data are mean (SD) unless otherwise stated. BMI: Body mass index, ABPM: Ambulatory blood pressure monitor. 
Hypertension: ≥140/90 mmHg and/or on antihypertensive treatment. Diabetes: based on hbA1c greter than 6.5% and doctor 
diagnosed. ‡ABPM group based on minimum 20 valid awake and minimum 7 valid asleep and ≥2 valid daytime and 1 valid 
night-time measurement per h. *p-value<0.05, where p-value is comparing two ABPM groups.  
 
References for Appendix E: 
[1] O’Brien E, Coats A, Owens P, et al. Use and interpretation of ambulatory blood 
pressure monitoring: recommendations of the British Hypertension Society. BMJ 
2000; 320: 1128.  
[2] Fagard RH, Staessen JA, Thijs L. Optimal definition of daytime and night-time 
blood pressure. Blood Pressure Monitoring. 1997;2(6):315-21. 
[3] O'Brien E, Parati G, Stergiou G. Ambulatory blood pressure measurements: 
What is the International Consensus? Hypertension. 2013;62:988–94. 
[4] O'Brien E, Parati G, Stergiou G, Asmar R, Beilin L, Bilo G, et al. European Society 
of Hypertension position paper on ambulatory blood pressure monitoring. Journal 
of Hypertension. 2013;31(9):1731-68. 
[5] Flynn JT, Daniels SR, Hayman LL, Maahs DM, McCrindle BW, Mitsnefes M, 
Zachariah JP, Urbina EM; American Heart Association Atherosclerosis, Hypertension 
and Obesity in Youth Committee of the Council on Cardiovascular Disease in the 
Young. Update: ambulatoryblood pressure monitoring in children and adolescents: 
a scientific statement from the American Heart Association. Hypertension. 2014; 
63:1116–1135. 
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patient characteristics on success of ambulatory blood pressure monitoring. 
Pharmacotherapy 2008; 28: 1341–47. 
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Clin Epidemiol 2013;66:1022  
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Annual Review of Clinical Psychology. 2010;6:79-107. 
[9] Little, RJA and Rubin, DB. Statistical analysis with missing data 2nd ed. Wiley, 
New York, NY, 2002 
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et al. Multiple imputation of missing repeated outcome measurements did not add 
to linear mixed-effects models. J Clin Epidemiol, 65 (2012), pp. 686–695   
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Appendix F Supplementary material (Chapter 6) 
 
Figure 9-6 ABPM readings of three individuals with fitted subject-specific 
trajectories from a two-component cosinor mixed-effects model (five parameters) 
and spline model (six parameters - cubic spline with four knots at 18:00, 24:00, 
04:00 and 08:00) (left panels). Their corresponding rate of change curves (first 
derivatives) are also plotted (right panels). The plots indicated an extremely 
similar pattern thus giving further justification of the two-component cosinor 
model. 
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Figure 9-7 Histograms of maximum morning slope by different methods.  
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Figure 9-8 Scree plot with eigenvalues and the eight principle components which 
make up 99% of the variation.  
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Figure 9-9 FPCA: Each of the six three FPC as variations about the mean along with the percentage of total variation explained by the 
component. The solid black line represents the mean SBP over the day. The “+” curves illustrate what happens when a small amount of the 
component is added to the mean and the “-” curves illustrate the effect of subtracting the component. 
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Figure 9-10 Scatter plots and the corresponding correlations between all the two-component cosinor random-effects model parameters and 
the principle component scores from FPCA. Eight FPCs contribute to 99% of the total variance in the data. 
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ARV Sampling Frequency  
(References at the end of the section) 
Using the simulated data based on the two-component randon-effects cosinor 
model in Chapter 6, ARV values were explored with respect to their sampling 
frequency. ARV was calculated from the simulated data (1) every 10mins and (2) 
every 30mins. Results indicated a substantial difference between the values taken 
at 10min and 30min intervals (p=0.02), see Figure 9-11 and Figure 9-12. The results 
are not surprising but the sampling frequency is not always referred to when ARV is 
mentioned in the literature, even those who developed ARV [1] failed to highlight it 
with only some attempting to adjust for the time interval [2,3]. We believe 
highlighting the findings is worthwhile. Zakopoulos et al. have however, suggested 
and advocated the use of the time rate of BP varation measure which is similar to 
ARV but is independent of the time intervals between measurements [4]. The 
measure was additionally obtained and included in Chapter 3 when summary 
measures were examined. We found the results were similar to the ARV value. 
Future studies using ARV should consider accounting for time between readings 
and determine the time rate of variation index. It must also be noted that although 
possible, in practise however, measurements taken every 10mins are unrealistic. 
The inconvience casued to the participant may result in them becoming iritated 
with the device and in turn lead to misleading values.  
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Figure 9-11 Simulated ARV values taken every 10mins and every 30mins. 
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Figure 9-12 Simulated data for one individual with readings taken 1) every 30min 
and 2) every 10mins. 
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Appendix H Sample R Code 
 
 
######################################################################## 
####Sample R code ################ 
######################################################################## 
R>version 
               _                            
platform       x86_64-w64-mingw32           
arch           x86_64                       
os             mingw32                      
system         x86_64, mingw32              
status                                      
major          3                            
minor          3.1                          
year           2016                         
month          06                           
day            21                           
svn rev        70800                        
language       R                            
version.string R version 3.3.1 (2016-06-21) 
nickname       Bug in Your Hair   
############################################################# 
 
######################################################################## 
####Sample code: Chapter 5: Exploring diurnal variation using piecewise linear################ 
####splines: an example using blood pressure################################## 
######################################################################## 
 
rm(list = ls()) #clear 
 
library(foreign)   #imports stata file 
library(nlme) 
library(multcomp) 
 
getwd() 
setwd("C:/Users/JM") 
w1 <- read.dta("w1.dta") 
w1<-w1[order(w1$id, w1$newtime),] 
 
####newtime 0-47 represents 24h clock 
####newsleep represents subject-specific sleep time 
####newwawke represents subject-specific wake time 
 
####create individual splines with restriction BP on the average is cyclical #### 
####create 5 splines - t12pm,t6pm,tsleep,t4am,twake 
w1$t12pm<-ifelse(w1$newtime<=12, w1$newtime, 12) 
w1$t6pm <- ifelse(w1$newtime<=12, 0, ifelse((w1$newtime>12) & (w1$newtime<=w1$newsleep), 
(w1$newtime-12), (w1$newsleep-12)))   
w1$tsleep<-ifelse(w1$newtime<=w1$newsleep, 0, ifelse((w1$newtime>w1$newsleep) & (w1$newtime<=32), 
(w1$newtime-w1$newsleep), (32-(w1$newsleep))))    
w1$t4am<- ifelse(w1$newtime<=32 ,0, ifelse((w1$newtime>32) & (w1$newtime<=w1$newwake), 
(w1$newtime-32), (w1$newwake-32)))    
w1$twake<-ifelse(w1$newtime<=w1$newwake, 0, ifelse((w1$newtime>w1$newwake) & (w1$newtime<=47), 
(w1$newtime-w1$newwake), (47-(w1$newwake))))    
 
####code introducing restriction ensuring pattern is periodic 
w1$s2time<-w1$newsleep-12 
w1$s3time<-32-w1$newsleep 
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w1$s4time<-w1$newwake-32 
w1$s5time<-47-w1$newwake 
 
#final splines - s2,s3,s4,s5 
w1$s2<-w1$t6pm-((w1$s2time/12)*w1$t12pm) 
w1$s3<-w1$tsleep-((w1$s3time/12)*w1$t12pm) 
w1$s4<-w1$t4am-((w1$s4time/12)*w1$t12pm) 
w1$s5<-w1$twake-((w1$s5time/12)*w1$t12pm) 
######################################################### 
 
 
####Unadjusted Model 1 #### 
m1r<- lme(sbp~ s2 + s3 + s4 + s5 ,  
          random = ~ s2 + s3 + s4 + s5 | id ,method="REML", 
          data=w1,control = lmeControl(msMaxIter=1000,opt = "optim",msVerbose=T), 
          na.action="na.omit",correlation = corAR1(form=~1|id))    
summary(mr1) 
####variance-covariance matrix - random effects  
getVarCov(m1r) 
####need to go back to work out s1 estimate using linear combinations using glht command 
####s1 refers to first spline rewritten 
summary(glht(m1r, linfct = c("(s2*10+s3*10+s4*8+s5*7)/-12=0")))   #0.0158 se=0.037 
 
 
######################################################################## 
######################################################################## 
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############################################################################ 
####Sample code: Chapter 6: Morning surge in blood pressure using a random-effects ###### 
####multiple-component cosinor model ########################################### 
############################################################################ 
rm(list = ls()) #clear 
 
library(foreign)   #creates stata file 
library(lme4) 
library(nlme) 
library(survey)  
library(gmodels) 
library(dplyr) 
library(ggplot2) 
library(multcomp) 
library(mgcv) 
library(lmerTest) 
library(splines) 
library(ares)   #only works with R2.13.2, lspline i.e. mkspline 
library(car) 
library(lme4) 
library(RLRsim) 
#library(MASS)      #ldahist, multiple histograms 
library(Hmisc) 
library(corrplot) 
library(reshape) 
library(reshape2) 
library(zoo) 
library(broom) 
library(lmtest) 
library(doBy)   #tabstat stata 
 
getwd() 
a1 <- read.dta("dataset.dta") 
 
 
###2-component cosinor nonlinear method### 
##system.time=2530 =42minutes run time 
cos1qq<-nlme(sbp~m + am1*cos((2*pi*newtime/48)+ph1) + am2*cos((4*pi*newtime/48)+ph2),             
             data=a1, 
             fixed=m+am1+ph1+am2+ph2~1, 
             random =m+am1+ph1+am2+ph2~1| Study_ID, 
             start=c(m=124,am1=13.3,ph1=5.29,am2=4.2,ph2=0.87), 
             control=nlmeControl(pnlsMaxIter=1000,pnlsTol=0.008,maxIter = 1000,msVerbose = TRUE), 
             na.action="na.omit",correlation = corAR1(form=~1|Study_ID))   
#saveRDS(cos1qq, "cos1qq.rds")     
cos1qq <- readRDS("cos1qq.rds 
summary(cos1qq) 
 
 
 
 
####2 component cosinor#### 
#cos cos2 sin sin2 
fm2 <- lme(sbp ~ cos(2*pi*newtime/48) + sin(2*pi*newtime/48) + cos(4*pi*newtime/48) + 
sin(4*pi*newtime/48),  
           random = ~ cos(2*pi*newtime/48) + sin(2*pi*newtime/48)+cos(4*pi*newtime/48) + 
sin(4*pi*newtime/48) | Study_ID,method="ML", 
           data=a1,control = lmeControl(msMaxIter=1000,opt = "optim",msVerbose=T), 
           na.action="na.omit",correlation = corAR1(form=~1|Study_ID)) 
#saveRDS(fm2, "fm2.rds")     
fm2 <- readRDS("fm2.rds")   
summary(fm2) 
anova(fm1,fm2)   #same models 
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####plot different fits- single,2 & 3 component - comparison#### 
somePDFPath = "some.pdf" 
pdf(file=somePDFPath)   
par(mar=c(5,4,1.5,1.5)+0.1)  #remove title space 
par(las=1)    #y axis labels horizontal 
par(mfrow = c(2,2))   #change depending how many per page 
#par(mar = c(4,4.5,1.5,1.5) + 0.1) 
 
for (i in unique(a1$Study_ID)) {   
   
  plot(a1[a1$Study_ID==i, "newtime"], a1[a1$Study_ID==i, "sbp"],bty="l", 
       #col=a1[a1$Study_ID==i, "visitno"], 
       xaxt = "n", 
       #xlim = range(a$bphour2), ylim = range(a$sbp), # base the axes on full data range 
       ylim=c(80,180), 
       # main = paste("Plot of", i), 
       xlab="Time (24-h clock)", ylab="SBP (mmHg)",font.main = 1,cex.lab=1.5,cex.axis = 1.5)   
  lines(a1[a1$Study_ID==i , "sbp"]~a1[a1$Study_ID==i , "newtime"], lwd=1)   
  lines(a1[a1$Study_ID==i , "fitted_sub1"]~a1[a1$Study_ID==i , "newtime"], lwd=3) 
  lines(a1[a1$Study_ID==i , "fitted_sub2"]~a1[a1$Study_ID==i , "newtime"], lwd=3,col="red") 
  lines(a1[a1$Study_ID==i , "fitted_sub3"]~a1[a1$Study_ID==i , "newtime"], lwd=3,col="blue") 
 axis(1, at=c(0,12,23,35,47), labels=c("12.00", "18.00", "00.00", "06.00", "12.00"),cex.axis = 1.5) 
} 
dev.off() 
 
####derivatives, simulation & obtain max slope#### 
a1<-a1 %>% group_by(Study_ID) %>% mutate(derivative2 = c(NA,diff(fitted_sub2) / diff(newtime))) %>% 
  ungroup()  %>% 
  as.data.frame() 
 
####prediction every minute#### 
z<-expand.grid(newtime=seq(0,47,by=1),Study_ID=unique(a1$Study_ID))   #prediction of lme for every minute 
of day 
z<-expand.grid(newtime=seq(0,47,by=1/30),Study_ID=unique(a1$Study_ID))   #prediction of lme for every 
minute of day 
z$pred <- predict(fm2, newdata=z,level=1) 
z$pred <- predict(cos1qq, newdata=z,level=1) 
z<-z %>% group_by(Study_ID) %>% mutate(derivative = c(NA,diff(pred) / diff(newtime))) %>% 
  ungroup()  %>% 
  as.data.frame() 
detach(package:plyr) 
z<-z %>% group_by(Study_ID) %>% mutate(derivative = c(NA,diff(pred) )) %>% 
  ungroup()  %>% 
  as.data.frame() 
 
#manually getting derivative 
library(mosaic) 
D(124.32941 + 6.58314*cos(2*pi*t/P) + 10.35877*sin(2*pi*t/P) ~ t, P=48) # default values for parameters. 
 
 
##################################################################### 
####correct identification of max slope derivative #### 
#coefficients 
bc<-coef(fm2) 
bc<-cbind(Study_ID = rownames(bc), bc)  
colnames(bc)[2] <- "b0" 
colnames(bc)[3] <- "b1" 
colnames(bc)[4] <- "b2" 
colnames(bc)[5] <- "b3" 
colnames(bc)[6] <- "b4" 
 
###one person 
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t<-rep(28:47) 
n<-function(t,p=48){ 
  bc$b0[bc$Study_ID=="LHC0005"]  + bc$b1[bc$Study_ID=="LHC0005"]*cos(2*pi*t/p) + 
bc$b2[bc$Study_ID=="LHC0005"]*sin(2*pi*t/p) + 
    + bc$b3[bc$Study_ID=="LHC0005"]*cos(4*pi*t/p) + bc$b4[bc$Study_ID=="LHC0005"]*sin(4*pi*t/p) 
} 
max(grad(n, t)) 
 
 
##loop works 
t<-seq(28,47,by=1/30) 
for(row in 1:nrow(bc)){ 
  n<-function(t,p=48){ 
    bc$b0[row]  + bc$b1[row]*cos(2*pi*t/p) + bc$b2[row]*sin(2*pi*t/p) + bc$b3[row]*cos(4*pi*t/p) + 
bc$b4[row]*sin(4*pi*t/p) 
  } 
  bc$newvar[row] <-max(grad(n, t)) 
} 
summary(bc$newvar) 
 
################################## 
################################## 
 
 
 
###########################################################################################
#########Chapter 6: FPCA Work###################### 
################################################################################## 
 
library(refund) 
library(refund.shiny) 
 
load("BPM.Rdata") 
 
## Expand grid for all observations from 0 to 47 time points  
res <- merge( 
  expand.grid(newtime=unique(BPM$newtime), Study_ID=unique(BPM$Study_ID)), 
  BPM, all=TRUE) 
BPM=res[order(res$Study_ID),] 
BPM$Study_ID<-as.character(BPM$Study_ID) 
 
y=NULL 
for(i in 1:length(unique(BPM$Study_ID))){ 
  y[[i]]=t(BPM$sbp[which(BPM$Study_ID==unique(BPM$Study_ID)[i])])} 
names(y)<-sprintf(unique(BPM$Study_ID),1:length(y)) 
y=t(sapply(y, '[', 1:max(sapply(y, length)))) 
 
 
n = dim(y)[1] 
s = seq(1, 48, length = dim(y)[2]) 
 
## do FPCA on the observed functions 
fpca.sys = fpca.sc(y) 
fpca.sys 
 
par(las=1)    #y axis labels horizontal 
par(mfrow = c(1,3))  
par(mfrow = c(1,4))  
par(mfrow = c(2,3))  
par(mar=c(5,5,1.5,1.5)+0.1)  #remove title space 
 
 
## plot FPCA effects for the first basis function 
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plot(s, fpca.sys$mu, type = 'l', ylim = c(90, 160), ylab = "", bty="l", 
     pch = 19, lwd = 2, xaxt = "n",cex.lab=1.5,xlab="Time (24-h clock)",  
     main = paste("1st PC for SBP (", 100*round(fpca.sys$evalues[1]/sum(fpca.sys$evalues),3), "%)", sep = "" ), 
     cex.axis = 1.5) 
axis(1, at=c(0,12,23,35,47), labels=c("12.00", "18.00", "00.00", "06.00", "12.00"),cex.axis = 1.5) 
title(ylab = "SBP (mmHg)", cex.lab = 1.5, line = 3) 
points(s, fpca.sys$mu - sqrt(fpca.sys$evalues[1]) * fpca.sys$efunctions[,1], pch = "+") 
points(s, fpca.sys$mu + sqrt(fpca.sys$evalues[1]) * fpca.sys$efunctions[,1], pch = "-") 
 
## plot FPCA effects for the second basis function 
plot(s, fpca.sys$mu, type = 'l', ylim = c(90, 160), ylab = "",  
     xaxt = "n",cex.lab=1.5,xlab="Time (24-h clock)", bty="l", pch = 19, lwd = 2, cex.axis = 1.5, 
     main = paste("2nd PC for SBP (", 100*round(fpca.sys$evalues[2]/sum(fpca.sys$evalues),3), "%)", sep = "" )) 
axis(1, at=c(0,12,23,35,47), labels=c("12.00", "18.00", "00.00", "06.00", "12.00"),cex.axis = 1.5) 
title(ylab = "SBP (mmHg)", cex.lab = 1.5, line = 3) 
points(s, fpca.sys$mu - sqrt(fpca.sys$evalues[2]) * fpca.sys$efunctions[,2], pch = "+") 
points(s, fpca.sys$mu + sqrt(fpca.sys$evalues[2]) * fpca.sys$efunctions[,2], pch = "-") 
 
 
## plot FPCA effects for the 3rd basis function 
plot(s, fpca.sys$mu, type = 'l', ylim = c(90, 160), ylab = "",  
     xaxt = "n",cex.lab=1.5,xlab="Time (24-h clock)", bty="l", pch = 19, lwd = 2, cex.axis = 1.5, 
     main = paste("3rd PC for SBP (", 100*round(fpca.sys$evalues[3]/sum(fpca.sys$evalues),3), "%)", sep = "" )) 
axis(1, at=c(0,12,23,35,47), labels=c("12.00", "18.00", "00.00", "06.00", "12.00"),cex.axis = 1.5) 
title(ylab = "SBP (mmHg)", cex.lab = 1.5, line = 3) 
points(s, fpca.sys$mu - sqrt(fpca.sys$evalues[3]) * fpca.sys$efunctions[,3], pch = "+") 
points(s, fpca.sys$mu + sqrt(fpca.sys$evalues[3]) * fpca.sys$efunctions[,3], pch = "-") 
 
 
## plot FPCA effects for the 4th basis function 
plot(s, fpca.sys$mu, type = 'l', ylim = c(90, 160), ylab = "",  
     xaxt = "n",cex.lab=1.5,xlab="Time (24-h clock)", bty="l", pch = 19, lwd = 2, cex.axis = 1.5, 
     main = paste("4th PC for SBP (", 100*round(fpca.sys$evalues[4]/sum(fpca.sys$evalues),3), "%)", sep = "" )) 
axis(1, at=c(0,12,23,35,47), labels=c("12.00", "18.00", "00.00", "06.00", "12.00"),cex.axis = 1.5) 
title(ylab = "SBP (mmHg)", cex.lab = 1.5, line = 3) 
points(s, fpca.sys$mu - sqrt(fpca.sys$evalues[4]) * fpca.sys$efunctions[,4], pch = "+") 
points(s, fpca.sys$mu + sqrt(fpca.sys$evalues[4]) * fpca.sys$efunctions[,4], pch = "-") 
 
 
## plot FPCA effects for the 5th basis function 
plot(s, fpca.sys$mu, type = 'l', ylim = c(90, 160), ylab = "",  
     xaxt = "n",cex.lab=1.5,xlab="Time (24-h clock)", bty="l", pch = 19, lwd = 2, cex.axis = 1.5, 
     main = paste("5th PC for SBP (", 100*round(fpca.sys$evalues[5]/sum(fpca.sys$evalues),3), "%)", sep = "" )) 
axis(1, at=c(0,12,23,35,47), labels=c("12.00", "18.00", "00.00", "06.00", "12.00"),cex.axis = 1.5) 
title(ylab = "SBP (mmHg)", cex.lab = 1.5, line = 3) 
points(s, fpca.sys$mu - sqrt(fpca.sys$evalues[5]) * fpca.sys$efunctions[,5], pch = "+") 
points(s, fpca.sys$mu + sqrt(fpca.sys$evalues[5]) * fpca.sys$efunctions[,5], pch = "-") 
 
 
## plot FPCA effects for the 6th basis function 
plot(s, fpca.sys$mu, type = 'l', ylim = c(90, 160), ylab = "",  
     xaxt = "n",cex.lab=1.5,xlab="Time (24-h clock)", bty="l", pch = 19, lwd = 2, cex.axis = 1.5, 
     main = paste("6th PC for SBP (", 100*round(fpca.sys$evalues[6]/sum(fpca.sys$evalues),3), "%)", sep = "" )) 
axis(1, at=c(0,12,23,35,47), labels=c("12.00", "18.00", "00.00", "06.00", "12.00"),cex.axis = 1.5) 
title(ylab = "SBP (mmHg)", cex.lab = 1.5, line = 3) 
points(s, fpca.sys$mu - sqrt(fpca.sys$evalues[6]) * fpca.sys$efunctions[,6], pch = "+") 
points(s, fpca.sys$mu + sqrt(fpca.sys$evalues[6]) * fpca.sys$efunctions[,6], pch = "-") 
 
 
#scree plot 
par(mar=c(5,5,1.5,1.5)+0.1)  #remove title space 
par(mfrow = c(1,1))  
dd<-data.frame(y=fpca.sys$evalues,x=1:8) 
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plot(dd$x, dd$y, type = 'l',   ylab = "", 
     cex.lab=1.5,xlab="Principle Component", bty="l", pch = 21,cex=2,lwd = 2, cex.axis = 1.5) 
title(ylab = "Eigenvalue", cex.lab = 1.5, line = 3) 
points(dd$x, dd$y, pch = 21,cex=2,bg="white",lwd = 2) 
 
 
## Curve reconstruction for different values of k 
plot(y[800,], pch=19, ylab = "mmHg", xlab="Timepoint", main= "Curve reconstruction for subject 800 with K 
expansions") 
lines(fpca.sys$mu+(fpca.sys$scores[800,1]*fpca.sys$efunctions[,1]+fpca.sys$scores[800,2]), col="blue") 
lines(fpca.sys$mu+(fpca.sys$scores[800,1]*fpca.sys$efunctions[,1]+fpca.sys$scores[800,2]*fpca.sys$efunctions
[,2] 
                   +fpca.sys$scores[800,3]*fpca.sys$efunctions[,3]+fpca.sys$scores[800,4]),col="green") 
lines(fpca.sys$mu+(fpca.sys$scores[800,1]*fpca.sys$efunctions[,1]+fpca.sys$scores[800,2]*fpca.sys$efunctions
[,2] 
+fpca.sys$scores[800,3]*fpca.sys$efunctions[,3]+fpca.sys$scores[800,4]*fpca.sys$efunctions[,4]+fpca.sys$scor
es[800,5]*fpca.sys$efunctions[,5]+fpca.sys$scores[800,6]*fpca.sys$efunctions[,6]+fpca.sys$scores[800,7]*fpca.
sys$efunctions[,7]+fpca.sys$scores[800,8]*fpca.sys$efunctions[,8]), col="red") 
legend("topright",legend=(c("k=2","K=4","k=8")),col=c("blue","green","red"),lty=1,bty="n",xpd=NA, seg.len = 2) 
 
plot_shiny(fpca.sys) 
 
 
####COMPARE FPCA to COSINOR#### 
uy<-data.frame(fpca.sys$scores)   #extract individuals scores 
uy$Study_ID<-unique(BPM$Study_ID) 
colnames(uy) = c("PC Score 1","PC Score 2","PC Score 3", "PC Score 4", "PC Score 5", 
                 "PC Score 6", "PC Score 7", "PC Score 8" ,"Study_ID")  
uy 
 
#bring in cosinor 2-component values 
a<-ranef(cos1qq) 
colnames(a) = c("MESOR","Amplitude 1","Phase 1", "Amplitude 2", "Phase 2")  
a<-cbind(Study_ID = rownames(a), a)  
a 
names(a) 
aw<-merge(a,uy,by= "Study_ID") 
names(aw) 
aw<-select(aw,-Study_ID) 
 
 
 
 
#correlation plot 
pairs(aw) 
panel.cor <- function(x, y, digits=1, prefix="", cex.cor, ...) 
{ 
  usr <- par("usr"); on.exit(par(usr)) 
  par(usr = c(0, 1, 0, 1)) 
  r <- abs(cor(x, y)) 
  txt <- format(c(r, 0.123456789), digits=digits)[1] 
  txt <- paste(prefix, txt, sep="") 
  if(missing(cex.cor)) cex.cor <- 0.8/strwidth(txt) 
  text(0.5, 0.5, txt, cex = 2) 
       #, cex = cex.cor * r)   #remove size proportional to correlation 
} 
pairs(aw, upper.panel=panel.cor, pch=20,cex.labels=2) 
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Appendix I Research output, dissemination and training 
Table 9-5 Peer reviewed publication from PhD  
Year Peer reviewed journal 
2016 
(Under 
Review) 
Madden JM, Li X, Tilling K, Kearney PM, Fitzgerald AP. Exploring Diurnal 
Variation Using Piecewise Linear Splines: An Example Using Blood 
Pressure. (Under review - Emerging Themes in Epidemiology) 
2015 Madden JM, O'Flynn AM, Fitzgerald AP, Kearney PM. Correlation 
between short-term blood pressure variability and left-ventricular 
mass index: a meta-analysis. Hypertens Res. 2015 39, 171–177; 
doi:10.1038/hr.126 
2015 Madden JM, O'Flynn AM, Dolan E, Fitzgerald AP, Kearney PM. Short-
term blood pressure variability over 24h and target organ damage in 
middle-aged men and women. J Hum Hypertens 2015 doi: 
10.1038/jhh.2015.18 
 
Table 9-6 Other research output during PhD 
Year Peer reviewed journal 
2015 O'Flynn AM, Madden JM, Russell AJ, Curtin RJ, Kearney PM. Isolated 
nocturnal hypertension and subclinical target organ damage: a 
systematic review of the literature. Hypertens Res. 2015 Apr 2. doi: 
10.1038/hr.2015.43.   
2015 O'Flynn AM, McHugh SM, Madden JM, Harrington JM, Perry IJ, Kearney 
PM. 'Applying the Ideal Cardiovascular Health Metrics to Couples: A 
Cross-Sectional Study in Primary Care'. Clinical Cardiology, 2015 
2013 Harrington, J., Fitzgerald, A. P., Kearney, P. M., McCarthy, V. J., 
Madden, J., Browne, G., Dolan, E. & Perry, I. J. DASH Diet Score and 
Distribution of Blood Pressure in Middle-Aged Men and Women. Am J 
Hypertens 2013 Aug 6. 
2013 Buckley, C. M., Madden, J., Balanda, K., Barron, S., Fahy, L., Harrington, 
J., Perry, I. J. & Kearney, P. M. Pre-diabetes in adults 45 years and over 
in Ireland: the Survey of Lifestyle, Attitudes and Nutrition in Ireland 
2007. Diabet Med. 2013 May 10. doi: 10.1111/dme.12226 
2013 Curtin, M., Madden, J., Staines, A. & Perry, I. J. Determinants of 
vulnerability in early childhood development in Ireland: a cross-
sectional study BMJ Open 2013;3:e002387 
2013 Balanda KP, Buckley CM, Barron SJ, Fahy LE, Madden JM, et al. (2013) 
Prevalence of Diabetes in the Republic of Ireland: Results from the 
National Health Survey (SLAN) 2007. PLoS ONE 8(10): e78406. 
doi:10.1371/journal.pone.0078406 
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2013 McKenna, G., Madden, J., Manton, S. & Cronin, M. Survey of Oral 
Health Behaviors of Patients Receiving Methadone Therapy at a Drug 
Rehabilitation Centre. Journal of Theory and Practice of Dental Public 
Health, 2013; Vol 1 No. 3. Pg 6-13 
2013 Hayes, M., Burke, F. M., McKenna, G., Madden, J. & Cronin, M. An 
analysis of the attitudes of dental patients attending general dental 
practice in Galway. Journal of The Irish Dental Association, 2013; 59 
(4): 179-182. 
 
 
Table 9-7 Conference Presentations during PhD 
Year Title Conference 
2016 Blood Pressure Variability over 24 
hours using Mixed-effects Models 
SPHeRE Network 2nd Annual 
Conference, RCSI, Dublin, Ireland, 
February 29th, 2016 
2015 Short-Term Blood Pressure 
Variability over 24-h Using Mixed-
effects Models 
International Biometric Society, Eastern 
North America Region, Miami, USA 
March 15-18, 2015 
2015 Short-term Blood Pressure 
Variability over 24 hours and 
Target Organ Damage in Middle-
Aged Men and Women 
Conference on Applied Statistics in 
Ireland, UCC, Cork, Ireland, May 11-
13th, 2015 
2015 Short-term Blood Pressure 
Variability over 24 hours and 
Target Organ Damage in Middle-
Aged Men and Women 
SPHeRE Network 1st Annual 
Conference, RCSI, Dublin, Ireland, 
January 9th, 2015 
2013 Intensity of Physical Activity and 
Obesity in an Irish Cohort Using 
GENEActiv Accelerometers.  
3rd International Conference on 
Ambulatory Monitoring of Physical 
Activity and Movement Amherst, 
Massachusetts, USA June 17-19, 2013 
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Table 9-8 Training & workshops attend during PhD 
Year Course 
2016 HRB-Trials Methodology Research Network: Statistical Considerations 
in Clinical Trial Design, UCC 
2015 European Society of Hypertension Summer School, Vienna 
2014 Newcastle R Course (1 week), Colin Gillespie 
2014 Advanced programming in R: Royal Statistics Society RSS Colin Gillespie  
2014 Multilevel Modeling using Stata, SPHeRE PhD programme, George 
Leckie 
2014 An Introduction to Cochrane Systematic Reviews, Cochrane 
Collaboration, UCC 
2013 Introduction to Propensity Score Methods with R, Predictive Modeling 
with R and the caret Package, User R Conference, Albacete, Spain 
2012 Analysis of Repeated Measures, Centre for Multilevel Modeling, Bristol 
2012 PG7016 Systematic reviews for the health sciences, UCC 
 
Table 9-9 Placements Completed 
Year Supervisor Award 
Summer 
2013 
Dr. John Newell Biostatistics Unit in the HRB Clinical Research Facility, 
NUI Galway 
Summer 
2015 
Prof Kate Tilling School of Social and Community Medicine, University 
of Bristol 
 
Table 9-10 Awards 
Year Award 
2014 Travel Bursary: College of Medicine and Health, UCC 
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